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I. ABSTRACT 
To promote survival and proliferation cancer cells re-programme their metabolism, 
altering both uptake and utilisation of extracellular nutrients. To examine 
correspondences between nutrient supply and viability, in order to identify targetable 
requirements, I individually depleted amino acid nutrients from diploid Human 
Mammary Epithelial (HME) isogenic cells expressing commonly activated 
oncogenes. Cystine deprivation was found to induce massive-oxidative stress 
associated-cell death of HME cells expressing an activated epidermal growth factor 
receptor (EGFR). Cell death occurred via an iron-dependent mode, known as 
ferroptosis associated with increased generation of reactive oxygen species and lipid 
peroxidation. Pharmacological inhibition of EGFR or mitogen-activated protein 
kinase/extracellular regulated kinase (MAPK/ERK) signalling was found to block 
ferroptosis and ROS production and was associated with increased expression of 
glutathione peroxidase 4 (GPX4). Suppression of GPX4 expression in wild-type or 
gefitinib-treated HME-EGFR cells was sufficient to sensitise cells to ferroptosis. 
Importantly, MAPK signals were also important in suppressing cell-cell contact and 
communication that was found to provide an essential line of defence against 
ferroptosis induction and spread. In this way, microscopic observation of ferroptosis 
in wild-type HME cells identified a cell death spread phenotype that is consistent with 
necrosis phenotypes observed in ischemic models. Inhibition of ROS generation and 
lipid peroxidation effectively blocked the progression of necrosis indicating that 
counteracting lipid peroxidation might be beneficial for degenerative conditions 
where lipid peroxidation is evident. Additional therapeutic application of my findings 
was modelled using non-small lung cancer cell (NSCLC) lines with overactive ERK 
signalling. These cells were found to be sensitive to ferroptosis following deprivation 
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of cystine in vitro as well as in vivo where in systemic deprivation of cystine was 
achieved in xenografted mice following administration of a cystine-degrading 
enzyme. Taken together, my results show that the presence of common oncogenic 
mutations can render cells sensitive to the depletion of a specific nutrient, and further 
suggest potentially novel anti-cancer therapies based on the inability of some MAPK-
driven cancer cells to overcome oxidative stress following nutrient depletion, as well 
as therapies to limit the spreading phenotype of ferroptosis in cells associated with 
other diseases such as Alzheimer’s Disease, or that occur in normal cells in 
response to ischemic reperfusion and acute kidney injuries. 
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1. CHAPTER 1: GENERAL INTRODUCTION 
1.1 Targeting the vulnerabilities of cancer cells.  
During tumour development cancer cells obtain genetic and epigenetic 
characteristics that provide them with an evolutionary proliferative and survival 
advantage over their normal counterparts. These advantages are often called the 
hallmarks of cancer because they endow abilities such as evading cell death, 
unlimited proliferative capacity, constitutive mitogenic signals and induction of 
tumour angiogenesis to ensure adequate supply of oxygen and nutrients (Hanahan 
and Weinberg, 2000, 2011). However, these advantages can come at a cost 
because they can endow cancer cells with particular and often unanticipated 
vulnerabilities. It is thought that by systematically identifying such vulnerabilities 
novel cancer therapies might be developed (De Raedt et al., 2011). Currently, most 
cancer therapies instead rely on chemotherapeutic agents that target the rapid cell 
division of cancer cells (Chabner and Roberts, 2005). However, single agent 
treatment is often insufficient to prolong long-term survival and patients frequently 
undergo relapse of disease (Brognard et al., 2001; Li et al., 2008). Moreover, it is 
now recognised that tumours often consist of multiple clones of malignant cells with 
different characteristics that can influence responses to treatment (Swanton, 2012). 
Finally, the large doses of chemotherapeutic agents used are often accompanied 
with significant toxicity to normal cells leading to alopecia, diarrhoea and cardiac 
damage (Pearce et al., 2017). Therefore, there is clinical demand for multi-agent 
treatments that simultaneously or sequentially exploit cancer cell vulnerabilities to 
provide patient benefit.  
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1.1.1 Oncogene addiction and synthetic lethality. 
Illustrations of how such novel therapeutic strategies might be developed are 
through the identifications of both oncogene addiction and synthetic lethal genetic 
relationships between cancer-causing and normal genes (Hartwell et al., 1997). 
Tumour cells that are oncogene-addicted display continual dependence on the 
presence of an oncogene. For example, melanoma cells typically express mutant 
BRAF in more than 60% of patient cases from early stages of melanoma 
development (Davies et al., 2002) and recent development of BRAF inhibitors such 
as vemurafenib (Tsai et al., 2008), which specifically targets BRAF with a V600E 
mutation (Joseph et al., 2010), have shown good clinical results (Chapman et al., 
2011). However, despite initial promising results using targeted BRAF inhibitors 
resistance was found to develop in approximately half of the patients (Sosman et al., 
2012). In the majority of the cases tumours established alternative compensatory 
mechanisms that induced activation of MAPK pathway (Paraiso et al., 2010) 
highlighting the underlying addiction of these tumours to hyperactivation of this 
pathway. To effectively target the development of resistance in patients, combined 
treatment with inhibitors of MEK have been used instead of vemurafenib 
monotherapy (Long et al., 2014).   
Another example of oncogene addiction is found in pancreatic ductal 
adenocarcinomas (PDAC) where 90% of tumours bear KRAS mutations leading to 
constitutive mitogenic signalling (Smit et al., 1988) and continued dependence upon 
KRAS during tumour development (Collins et al., 2012). The important role of KRAS 
and the other homologs in pancreatic and a variety of other cancers has been 
extensively studied with the hope of developing agents that could specifically target 
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and block mutant KRAS inhibiting its activity and kill KRAS-mutant tumour cells. 
However, little progress has been achieved despite multiple attempts, primarily due 
to the lack of good inhibitor binding pockets in RAS proteins and the very high affinity 
of KRAS for guanine nucleotides (McCormick, 2015). The failure to produce an 
effective inhibitor has attributed the characterisation “undruggable” to the RAS 
proteins (Cox et al., 2014). Efforts have since focused on “synthetic lethality” screens 
to identify features of malignancy that the presence of activating RAS mutation 
confers on cancer cells and could be exploited therapeutically (Downward, 2015).  
“Synthetic lethality” describes the relationship between two genes whose 
concomitant loss or inhibition together but not individually impairs cell survival 
(Dobzhansky, 1946; Lucchesi, 1968). In malignancies such relationships can be 
challenged by pharmacologically inhibiting a normal gene product which works 
together with a mutated cancer gene and that promotes cell survival/proliferation of 
mutant cells (Rehman et al., 2010). An example of such a relationship with clinical 
relevance is found in familial breast cancer between poly adenosine diphosphate 
(ADP)-ribose polymerase (PARP), and mutations in the BReast CAncer susceptibility 
genes (BRCA) BRCA1 and BRCA2 (Bryant et al., 2005). Tumours bearing mutations 
in either BRCA1 or BRCA2 lack the ability to repair DNA damage via homologous 
recombination and are sensitive to inhibition of PARP because these tumours are 
dependent upon base-excision repair mechanisms for genomic integrity (Bryant et 
al., 2005; Farmer et al., 2005). This synthetic lethality relationship could be 
expanded to other alterations that generate phenotypes similar to BRCA gene loss of 
function, a feature termed “BRCAness” (Lord and Ashworth, 2016; McCabe et al., 
2006). Synthetic lethal relationships can be identified by both genetic and drug-
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based screening platforms and can provide novel insights into the essential 
requirements of cancer cells (Barbie et al., 2009; Possik et al., 2014; Scholl et al., 
2009). 
To conclude there is an increasing interest in identifying cancer cell 
vulnerabilities, particularly with respect to pancreatic and other cancers where 
treatment options are limited, and patient survival is poor (De Raedt et al., 2011; 
Huhn et al., 2013). It is hoped that knowledge of such vulnerabilities could ultimately 
be used in the design of novel therapeutics that are used either alone, or in 
combination with existing treatments, to improve patient survival. Insight into the 
functional consequences of oncogenic transformation could provide new directions in 
the search for such targetable dependencies.  
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1.2 The role of EGFR signalling and its downstream RAS-RAF-MEK-ERK MAPK 
kinase and PI3K-AKT pathways in cancer. 
The EGFR protein belongs to the family of receptor tyrosine kinases (RTK), 
signalling molecules that are activated through ligand interaction and transduce 
signals to downstream intracellular targets (Schlessinger, 2000). The interaction of 
EGFR with its corresponding ligand epidermal growth factor (EGF) or transforming 
growth factor alpha (TGF-α) promotes receptor dimerization and subsequent 
phosphorylation on the receptor intracellular domains (Schlessinger and Ullrich, 
1992). Phosphorylation of the intracellular part of the EGFR protein occurs in a 
conserved domain within the C-terminus of the protein, and is recognised by proteins 
with a conserved domain called Src homology 2 (SH2) domains (Moran et al., 1990). 
Such SH2 domains are required for interaction of the EGFR protein with adaptor 
proteins that aid in downstream signal transduction through activation of downstream 
effector proteins (Pawson and Schlessinger, 1993). In this way proliferative signals 
from EGFR initiate multiple signalling cascades with the most notable examples 
being the MAPK and PI3K-AKT pathways (Raymond et al., 2000).   
Hyperactivation of EGFR signalling has been reported in several cancers, and 
particularly in non-small cell lung cancers (NSCLCs) where 20% of the cases have a 
mutation or amplification of the gene leading to higher downstream activation levels 
(Shigematsu et al., 2005). The most common mutations found in NSCLCs on the 
EGFR gene are a deletion of exon 19 and a single mutation in exon 21 that leads to 
substitution of leucine to arginine at codon 858 (L858R), (Shigematsu and Gazdar, 
2006). In both of these cases the receptor is constitutively activated independently of 
EGF binding (Greulich et al., 2005). Effective inhibition of EGFR mediated-signalling 
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in NSCLC requires inhibition of the two downstream pathways of MAPK and AKT 
suggesting their central role in EGFR-driven oncogenesis (Ono et al., 2004). 
1.2.2 RAS-RAF-MEK-ERK MAPK pathway. 
The mitogen-activated protein kinases (MAPK) are crucial regulatory 
elements of eukaryotic cells responding to a variety of extracellular stimuli such as 
growth factors, hormones and cytokines (Krishna and Narang, 2008). There are four 
distinct MAPK pathways (ERK1/2, P38α/β/γ/δ, JNK1/2/3, and ERK5), each one 
comprising of a unique kinase cascade involving 3 different kinases (Roberts and 
Der, 2007). The most well-studied MAPK signalling pathway is the ERK1/2 MAPK 
pathway, due to its critical role in many types of cancer and functions in cell growth, 
proliferation, survival, differentiation and motility (Yoon and Seger, 2006).  
Activation of the EGFR following ligand interaction leads to a cascade of 
phosphorylation of the elements involved in this pathway. Phosphorylated tyrosine 
residues on EGFR allow interaction with the SH2 domain of GRB2, an adaptor 
protein (Lowenstein et al., 1992) responsible for recruitment and activation of SOS, a 
protein with guanosine exchange factor (GEF) function for RAS, in the plasma 
membrane (Egan et al., 1993). RAS proteins are small GTPases, proteins with an 
ability to bind and hydrolyse GTP, which catalyse activation of downstream proteins 
when binding GTP, but are in an inactive confirmation when binding GDP (Bourne et 
al., 1991). RAS proteins are lipidated and associated with the plasma membrane 
(Seabra, 1998). Recruitment of SOS to the plasma membrane following interaction 
with the EGFR-GRB2 complex brings it in close proximity with RAS proteins to 
promote nucleotide exchange of GDP to GTP allowing activation of its downstream 
targets (Egan et al., 1993). Therefore, mitogenic stimuli through the EGFR pathway 
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lead to activation of RAS and its downstream effectors (Buday and Downward, 
1993).   
The family of RAS genes in mammalians is comprised of three highly 
homologous genes termed HRAS, KRAS and NRAS (Lowy and Willumsen, 1993). 
RAS genes were initially identified as viral oncogenes found in Rat Sarcoma tumours 
that could induce oncogenic transformation (Noda et al., 1985). These viral 
oncogenes originated from mutated genes obtained by viruses from hosts (Barbacid, 
1987). The molecular function of RAS proteins is characterised as a signalling switch 
that controls the transduction of external stimuli to activation of cellular functions. 
Alterations and aberrant activity of RAS signalling is often associated with oncogenic 
transformation, highlighting the central role of these proteins and their connected 
pathways in oncogenesis (Downward, 2003) 
The best characterised effectors of RAS are proteins of the RAF family of 
serine/threonine protein kinases that consists of three members, ARAF, BRAF and 
CRAF (Wellbrock et al., 2004)  (Shaw and Cantley, 2006). Members of the RAF 
family interact directly with the active GTP-bound form of RAS through a RAS-
binding domain (RBD) located in their N-terminal regulatory domain (Vojtek et al., 
1993). RAF kinases are responsible for the phosphorylation and activation of the 
dual specificity MAPK/ERK kinases 1/2 (MEK1/2), which are found downstream in 
this signalling cascade (Kyriakis and Avruch, 2001). MEK1/2 are responsible for 
activation of the extracellular signal-regulated kinases (ERK) ERK1/2 (Crews et al., 
1992). The ERK1/2 kinases have a very wide variety of substrates found in both the 
cytoplasm and the cell nucleus where the protein translocates to following activation 
(Pouyssegur et al., 2002). Notable examples include transcription factors, such as 
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ELK1 and MYC, enhancing the gene expression of the downstream target genes, as 
well as downstream kinases like p90 ribosomal protein S6 kinase (RSK) and MAPK-
interacting serine/threonine kinase (MNK) (Yoon and Seger, 2006) .  
Oncogenic mutations within RAS genes tend to cluster in particular codons 
and render it in a conformation that is constitutively active (Bos, 1989). The overall 
incidence of these mutations in cancer is considered to be around 20%, with certain 
tumour types demonstrating higher mutation incidence, indicative of oncogenic 
dependence on these genes (Bos, 1989). The most striking example is found in 
PDACs where mutations on the KRAS gene are present in more than 90% of cases 
(Smit et al., 1988). High levels of incidence are also commonly reported in colon, 
thyroid and lung cancers, as well as in myeloid leukemias (Lowy and Willumsen, 
1993).  
Hyperactivation of MAPK signalling is not solely dependent on RAS 
mutations. For example, RAS mutations account for only 15% of melanoma tumours, 
whereas mutation within the downstream BRAF gene is recorded in 66% of these 
tumours (Bos, 1989; Davies et al., 2002). The majority of BRAF mutations are 
located within the kinase domain of the protein, with the substitution of valine in 
codon 600 for glutamic acid (V600E) accounting for 80% of cases (Davies et al., 
2002).  Activation of the MAPK pathway is highly elevated in the presence of BRAF 
activating mutations independently of RAS activity, and is sufficient to promote 
oncogenesis (Wan et al., 2004). Inhibition of oncogenic BRAF activity can inhibit 
tumour growth, suggesting the addiction of these cancer cells to the constitutively 
active BRAF. Effective Inhibitors of BRAF have been developed and employed in the 
clinic, demonstrating significant anti-tumour responses, at least initially (Chapman et 
  
37 
al., 2011). However, in many patients resistance quickly develops as cancer cells 
establish alternative signalling pathways to induce MAPK activation (Nazarian et al., 
2010; Paraiso et al., 2010) .  
1.2.3 PI3K/AKT signalling  
 Aside from downstream activation of the MAPK pathway, EGFR can also 
induce activation of phosphatidylinositol 3-kinases (PI3Ks) and their downstream 
pathways. Activation of the PI3K-AKT pathway can promote several cellular 
processes, including cell survival, cell growth, proliferation, migration, and 
metabolism (reviewed in (Cantley, 2002; Luo et al., 2003)). Class I PI3Ks are lipid 
kinases that phosphorylate phosphatidyinositol-4,5-bisphosphate (PIP2) to 
phosphatidylinositol-3,4,5-trisphosphate (PIP3), a lipid that acts to recruit proteins 
bearing pleckstrin-homology (PH) domains to the plasma membrane. PI3Ks have 
crucial roles in oncogenesis and are found mutationally activated in some cancers 
(Zhao and Vogt, 2008a). PI3Ks members of class Ia consist of two subunits, a 
regulatory known as p85 and a catalytic subunit termed p110 (Yuan and Cantley, 
2008). The regulatory p85 subunit contains an SH2 domain that binds to 
phosphorylated tyrosine residues within the C-terminus of EGFR, and then forces a 
conformational change within the p110 subunit to render it catalytically active 
(Carpenter et al., 1993). The function of PI3K proteins is counteracted by the 
tumours suppressor phosphatase and tensin homolog deleted on chromosome ten 
(PTEN), that dephosphorylates phosphatidylinositol-3,4,5-trisphosphate to 
phosphatidyinositol-4,5-bisphosphate (Myers et al., 1998), and by SH2 domain-
containing inositol 5'-phosphatase (SHIP) which removes the 5’ phosphate of PIP3 to 
yield phosphatidyinositol-3,4-bisphosphate (Damen et al., 1996).   
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PIP3 is responsible for activation of protein kinase beta (PKB), also known as 
AKT due to homology to the viral oncogene v-AKT, and is recognised as the main 
downstream kinase effector of the PI3K pathway (Lawlor and Alessi, 2001). AKT is 
brought to the plasma membrane through interaction of its PH domain with PIP3, 
and is phosphorylated by phosphoinositide-dependent kinase-1 (PDK1) on threonine 
308 (Alessi et al., 1997). PDK1 recruitment to the cell membrane is similar to that of 
AKT, and regulated by PIP3 interaction with its PH domain (Currie et al., 1999). A 
second phosphorylation on serine 473, thought to be catalysed mainly by mTORC2, 
stabilises AKT in its active form and allows dissociation from the plasma membrane 
(Sarbassov et al., 2005). Cell growth is promoted by AKT by phosphorylation and 
inactivation of TSC2, which has the effect of enhancing mTORC1 activity (Manning 
et al., 2002) and stimulating cell growth. Cell survival is supported by a role of AKT in 
stimulating the NF-κB pathway (Ozes et al., 1999), in facilitating the ability of MDM2 
to ubiquitinylate p53 and mark it for downregulation (Trotman and Pandolfi, 2003), or 
preventing apoptosis by phosphorylating Bad and the proapoptotic transcriptional 
factor FOXO (Datta et al., 1999). Cell cycle progression is stimulated by AKT through 
its ability to phosphorylate and inhibit Glycogen synthase kinase-3 (GSK3) to 
eventually negatively regulate cyclin accumulation and progression to the S phase 
(Diehl et al., 1998).  
Activation of the PI3K pathway can be additionally controlled by other factors. 
Other RTK proteins such as the insulin receptor (InR) induce activation of PI3K 
through interaction with the adaptor proteins insulin receptor substrate (IRS1/2) 
(Shepherd et al., 1998). Other receptors rely on tyrosine phosphorylated scaffold 
proteins such as CD19 in B cells. Active RAS facilitates PI3K activity via direct 
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binding to the Ras-binding domain within the p110 catalytic subunit 
(Rodriguezviciana et al., 1994).  Mutations or deletions that inhibit the PTEN gene 
are associated with higher levels of PIP3, ultimately resulting in the generation of 
signals that are similar to active RTK signalling induced by growth factors (Stambolic 
et al., 1998). Such alterations are found in many human tumours and are often 
associated with poor outcomes and aggressive tumour phenotypes (Keniry and 
Parsons, 2008; Saal et al., 2007; Steck et al., 1997).  Several cancers, including  
breast, ovarian, colorectal and hepatocellular cancers often accumulate mutations or 
amplifications in PIK3CA, the gene that codes for the p110α catalytic subunit (Bader 
et al., 2006). Some of these mutations confer a gain of function by either affecting 
the ability of p85 to inhibit p110 function or conferring constitutive kinase activity to 
p110 (Bader et al., 2006). For example, PIK3CA with mutations in exon 9 lead to a 
p110α protein that is no longer inhibited by p85 interaction.  On the other hand, exon 
20 mutations which results in substitution of histidine 1047 to arginine (H1047R) 
leads to a constitutively active p110α protein which leads to elevated levels of PIP3 
(Zhao and Vogt, 2008b). 
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1.3 Cancer cells adapt their metabolism to their nutritional microenvironment. 
One of the newly-appreciated hallmarks of cancer is the capacity that tumour 
cells have to re-programme their metabolism to support their biosynthetic and 
survival requirements (Hanahan and Weinberg, 2011). All eukaryotic cells require 
nutrients for homeostasis and growth. This applies particularly to rapidly-dividing 
neoplastic cells, and forces them to adapt their metabolism in order to fuel their 
growth and survival (Heiden et al., 2009; Vander Heiden, 2013). Additionally, it is 
thought that tumours are characterised by altered requirements for various nutrients 
in order to meet their increased biosynthetic needs (Hsu and Sabatini, 2008).  It is 
hoped that by understanding the mechanisms responsible for such metabolic 
differences between normal and cancer cells novel therapeutics targeting cancer 
metabolism can be developed (Habrook and Lyssiotis, 2017; Vander Heiden, 2013).  
1.3.1 Pancreatic cancer provides examples of metabolic adaptations  
One such example of a tumour demonstrating metabolic adaptation is found 
in pancreatic ductal adenocarcinoma (PDAC) (Poursaitidis and Lamb, 2017). PDAC 
is characterised by a pronounced desmoplastic reaction, generating a stromal 
component that can account for the majority of the tumour mass (Provenzano et al., 
2012). The surrounding stroma consists of pancreatic stellate cells (PSCs), immune 
cells and endothelial cells embedded in collagen, hyaluronan and other extracellular 
matrix (ECM) proteins. PSCs are fibroblast-like cells found in the healthy pancreas 
as well as PDAC lesions, and have an important role in the stromal desmoplastic 
reaction found in PDAC (Feig et al., 2012). Under physiological conditions, PSCs 
regulate the turnover of the ECM through regulation of expression and degradation 
of matrix-associated proteins such metalloproteases (Apte and Wilson, 2012). In 
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PDAC lesions PSCs are found in large numbers and in an activated state, in which 
they produce excessive quantities of stromal components (Haber et al., 1999). 
Accumulation of ECM components, generates excessive interstitial fluid pressure 
that is responsible for the collapse of the local vasculature (Jacobetz et al., 2013). 
Lack of developed blood vessels in PDAC tumours, is responsible for limiting the 
supply of both nutrients and oxygen to PDAC cancer cells (Feig et al., 2012). These 
adverse conditions force the metabolic adaptation of the PDAC cells, allowing them 
to grow and proliferate in a nutritionally poor microenvironment.   
Although the extent of these metabolic adaptations is not completely 
understood, there are several mechanisms that have been characterised providing 
these cells with an evolutionary advantage.  One such feature of pancreatic cancer 
cells within PDAC tumours is their high rate of macropinocytosis, a process through 
which cells engulf and degrade extracellular proteins in order to generate nutrients 
they lack (Commisso et al., 2013; Kamphorst et al., 2015). One recent report 
highlights the significance of PSC-generated collagen which PDAC cells can utilise 
through macropinocytosis, as a supply of required amino acids, particularly proline 
(Olivares et al., 2017). PDAC cells and PSCs are thought to establish a bilateral 
signalling network regulating each other’s properties, promoting the survival of the 
former (Tape et al., 2016). In conditions of nutrient scarcity PDAC cells also promote 
autophagy in neighbouring PSCs, which then excrete the nutrient amino acid 
alanine. PDAC cells are then able to import and utilise alanine for biosynthetic needs 
(Sousa et al., 2016).  
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1.4 Cancer cells have increased requirement for glucose. 
Elevated requirement of cancer cells for glucose was first observed by Otto 
Warburg, and recorded in a series of studies that were published beginning in the 
1930’s (Warburg, 1930). In these studies, Warburg demonstrated that cancer cells 
growing in the presence of oxygen produce their energy mainly through high levels 
of glycolysis followed by lactic acid production, rather than by the relative lower 
levels of glycolysis followed by oxidation of pyruvate that takes place in normal cells 
growing under similar conditions (Warburg, 1930, 1956a, b). Why cancer cells 
preferentially utilise glycolysis and lactic acid fermentation is likely because this 
produces metabolic intermediates useful for biosynthesis and critical for proliferation 
(Ward and Thompson, 2012). The lower adenosine triphosphate (ATP) yield from 
this process is thought to be compensated for by increased glucose uptake and 
utilization. 
The reprogramming of cell metabolism results from both the presence of 
activating mutations in oncogenes, and by the loss-of-function of tumour suppressor 
genes (Hsu and Sabatini, 2008). Major oncogenic signalling pathways are also 
responsible for altering the function of mitochondria in a manner that supports 
anabolic processes (Ward and Thompson, 2012). For example, constitutive 
activation of the PI3K/AKT pathway is known to facilitate the Warburg effect in cells 
by promoting aerobic glycolysis (Elstrom et al., 2004). Moreover, enhanced glucose 
uptake and glycolysis are also observed in cancer cells bearing activating mutations 
in the RAS-MAPK pathway (Ying et al., 2012). Pharmacological inhibition of 
glycolysis and of glucose uptake is demonstrating promising results as novel forms 
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of cancer therapy, which, in combination with existing agents, may improve patient 
survival (Zhao et al., 2013). 
1.5 Selective requirements for nutrient amino acids 
In addition to an increased requirement for glucose, cancer cells in a variety of 
human malignancies have increased steady state levels of most amino acid nutrients 
compared to their untransformed counterparts in normal tissue (Hirayama et al., 
2009; Kami et al., 2013). In this way, cancer cells may demonstrate an increased 
general requirement for nutrient amino acids. However amino acid needs may be 
more selective in some situations. For example, analysis of conditioned media from 
pancreatic cancer cell lines has revealed that some amino acids are preferentially 
taken up in favour of others (Wang and Permert, 2002). Thus, it is possible that 
restriction of certain nutrients might selectively compromise the viability of PDAC and 
other cancer cells. 
1.5.1 Sensing plenitude and limitation of amino acid nutrients.  
In order to understand the requirements of cancer cells for certain amino 
acids it is important to know how cells more generally sense their presence or 
absence, and how they then respond to such changes. Nutrient amino acids are 
required for essential cell processes but can also act as signalling molecules (Efeyan 
et al., 2015). This aspect is manifest in cells by development of mechanisms that 
allow them to sense the availability of amino acids, and thereby regulate their growth 
and metabolism accordingly (Lamb, 2012). In the absence of amino acid nutrients 
cells inhibit anabolic processes such as protein synthesis (Klionsky, 2007), and 
promote catabolic processes like autophagy as adaptive measures until amino acid 
levels are restored (Pain, 1994). 
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In mammalian cells amino acids signal through Mechanistic Target Of 
Rapamycin Complex 1 (mTORC1) to induce activation of S6 kinases (S6K1 and 
S6K2) as well as dissociation of the eukaryotic initiation factor 4E (eIF4E)-binding 
protein-1 (4E-BP1) from eIF4E through phosphorylation (Hara et al., 1998). TOR 
was first described in yeast as the target molecule of the immunosuppressant 
rapamycin (Heitman et al., 1991). TOR can form two different complexes, termed 
mTORC1 and mTORC2, and that, in mammalian cells, control distinct cell functions 
(Saxton and Sabatini, 2017). The mTORC1 complex comprises of mTOR, Raptor 
and mLST8 whereas the mTORC2 complex comprises of mTOR, Rictor, SIN1 and 
mLST8 (Jacinto et al., 2006; Kim et al., 2002; Kim et al., 2003; Loewith et al., 2002; 
Sarbassov et al., 2004; Wullschleger et al., 2006). 
Although the exact mechanism through which amino acids regulate mTORC1 
activation is unclear, several aspects are known. mTORC1 is recruited to the 
lysosomal surface for activation through interaction with the Rag GTPases (Sancak 
et al., 2010; Sancak et al., 2008). There are four Rag-family GTPases, RagA, RagB, 
RagC and RagD with functional similarity between RagA and RagB, and between 
RagC and RagD. These GTPases form heterodimers consisting of RagA with either 
RagC or RagD, or of RagB with either RagC or RagD (Kim et al., 2008; Sancak et 
al., 2008). These heterodimers are tethered to lysosomes by binding to Ragulator, a 
pentameric complex that consists of p18, p14, MP1, C7orf59 and HBXIP proteins 
(Bar-Peled et al., 2012; Sancak et al., 2010). The GTP loading status of the Rag 
GTPases has been implicated in the binding of mTORC1 and its subsequent 
activation. (Bar-Peled et al., 2013; Bar-Peled et al., 2012; Petit et al., 2013; Tsun et 
al., 2013). 
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Another requirement for activation of mTORC1 is the presence of the small 
GTPase Ras homolog enriched in brain (Rheb) in its GTP loaded form (Inoki et al., 
2003). Rheb is under negative regulation by the GTPase-activating protein (GAP) 
activity of the tuberous sclerosis complex (TSC1-2) that is comprised of TSC1, TSC2 
and the recently described TBC1D7 (Dibble et al., 2012). The TSC complex acts as 
a GAP for Rheb to promote the hydrolysis of GTP and render Rheb inactive (Zhang 
et al., 2003). The protein kinase AKT, stimulated by insulin and other growth factors, 
is thought to play a role in maintaining Rheb activation through an ability to 
phosphorylate and in some way inactivate TSC1-2 (Inoki et al., 2002; Manning et al., 
2002).  
mTORC1 activation controls cell growth through activation of several 
eukaryotic translation initiation factors and initiation of cap dependent protein 
translation. eIF4E can directly bind to the 5’ cap structure on eukaryotic mRNAs and 
recruit the eIF4F complex to initiate translation (Gingras et al., 1999). Active 
mTORC1 directly phosphorylates 4EBP1 leading to its dissociation from eIF4E, and 
also further contributes to translation through activation of eukaryotic translation 
initiation factors eIF4A and eIF4B via activation of S6K (Zoncu et al., 2011).  
Aside from inducing mRNA translation mechanisms within the cell, mTORC1 
actively inhibits scavenging processes that cells only require when starved of 
nutrients. Autophagy (also termed macroautophagy) is such a scavenging 
mechanism allowing optimal utilisation and recycling of nutrients. Autophagy is a 
multi-step regulated process through which cells recycle their own proteins and 
organelles through lysosomal degradation (Rabinowitz and White, 2010). Autophagy 
is also important for homeostatic recycling of defective organelles or misfolded 
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proteins, and can also provide missing nutrients to nutrient-starved cells (Mizushima 
and Komatsu, 2011). The autophagic process involves the formation of the 
autophagosome, a membranous structure incorporating the cell components 
targeted for degradation. Autophagosomes fuse with lysosomes to allow proteolysis 
of targeted proteins/organelles. Under nutrient replete conditions mTORC1 inhibits 
autophagy through phosphorylation of autophagy-related protein 13 (ATG13) and 
Unc-51-like kinase (ULK1), two proteins essential for the formation of the 
autophagosome (Hosokawa et al., 2009). However, withdrawal of amino acids 
inhibits mTORC1 and induces activation of autophagy (Ravikumar et al., 2004). 
Restoration of amino acids by autophagic flux reinstates mTORC1 activity and 
terminates any further autophagy (Yu et al., 2010).  
It is apparent that regulation of mTORC1 signalling is crucial for cell 
homeostasis. Therefore, it is not surprising that mTORC1 is commonly found 
deregulated in many cancers through constitutive activation of key signalling 
pathways such as the Ras-MAPK and/or the PI3K pathways (Menon and Manning, 
2008). Such deregulated mTORC1 signalling can uncouple cells from the 
requirement of mitogenic stimuli to promote growth and proliferation of malignant 
cells (Menon and Manning, 2008). 
General control non-derepressable 2 (GCN2, EIF2AK4) is a serine/threonine 
kinase responsible in eukaryotic cells for the phosphorylation of eIF2α, a subunit of 
the eukaryotic initiation factor 2 (eIF2) (Hinnebusch, 2005). eIF2 is responsible for 
transferring the first methionine charged tRNA to the ribosome and initiate mRNA 
translation (Sonenberg and Hinnebusch, 2009). GCN2, along with three other 
kinases (haem-regulated eIF2α kinase (HRI, EIF2AK1), protein kinase R (PKR, 
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EIF2AK2) and PKR-like endoplasmic reticulum kinase (PERK, EIF2AK3)), interpret 
different signals and induce the activation of the integrated stress response (ISR) 
pathway, that involves several distinct cellular responses (Baird and Wek, 2012). All 
these kinases sense different stimuli; nutrient amino acid deprivation by GCN2, 
endoplasmic reticulum (ER) stress by PERK, deprivation of heme by HRI and viral 
infection through PKR (Baird and Wek, 2012). Despite their unique regulation from 
different factors they share a conserved kinase domain, and, collectively, they 
converge on phosphorylation of Ser51 on eIF2α. Phosphorylation of eIF2α blocks 
the GEF activity of eIF2B leading to inhibition of eIF2 function, and ultimately 
blocking the initiation of general mRNA translation (Hinnebusch, 2005). At the same 
time p-eIF2α promotes the translation of activating transcription factor 4 (ATF4), a 
transcription factor responsible for regulating gene expression in response to stress 
(Harding et al., 2003).  
The mechanism of GCN2 activation during periods of amino acid starvation 
has been well-studied (Hinnebusch, 2005). GCN2 contains a domain homologous to 
histidyl-tRNA synthetases, and binding uncharged tRNA molecules induces 
activation of the kinase (Wek et al., 1989). Thus, tRNA binding causes GCN2 
autophosphorylation which then forces a conformational change to the protein 
transforming it to an active state that allows binding and phosphorylation of eIF2α 
(Baird and Wek, 2012). This mechanism can be influenced by mTORC1 because 
pharmacological inhibition of this kinase under amino acid replete conditions induces 
activation of GCN2 (Wengrod et al., 2015). However, GCN2 activation imposes 
inhibition of mTORC1 through both ATF-driven and -independent pathways (Averous 
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et al., 2016; Ye et al., 2015). Thus, there is evidence of significant crosstalk between 
the mTORC1 and GCN2 amino acid-sensing pathways.  
The pathways of mTORC1 and GCN2 activation are tightly regulated, and 
both provide cells with the ability to regulate processes that control amino acid 
utilisation in the face of nutrient scarcity(Lamb, 2012; Yan and Lamb, 2012). Cells 
can inhibit their metabolic activity and growth through inhibition of mTORC1 and limit 
protein synthesis via activation of GCN2, minimising nutrient utilisation until their 
nutrient sources are replenished (Carroll et al., 2015; Gonzalez and Hall, 2017) 
Failure to regulate these pathways could be catastrophic for cells. For example, 
melanoma cancer cells having hyperactive Ras-MAPK pathway activation maintain 
high levels of mTORC1 signalling even in the absence of the essential amino acid 
leucine. As a consequence, this constant activation of mTORC1 fails to inhibit cell 
growth and activate autophagy and results in widespread apoptosis of the cells 
(Sheen et al., 2011). 
1.5.2 Asparagine restriction in acute lymphoblastic leukemias.  
The clinical relevance of nutrient restriction is well described in Acute 
lymphoblastic leukemias (ALLs). The malignant cells of ALL do not express 
asparagine synthase, an enzyme required for asparagine synthesis, and ALL cells 
rely on the provision of exogenous asparagine for their survival (Broome, 1968). 
Clinically this reliance can be exploited by administration of a formulation of 
asparaginase to lower circulating asparagine levels which induces selective 
apoptosis of the malignant cells (Holleman et al., 2003; Tallal et al., 1970). Whether 
a similar approach can be applied to solid tumours, such as PDAC, remains to be 
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determined. Conceivably, such an approach requires identification of particular 
amino acids key to malignant cell survival in each case.  
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1.5.3 Glutamine addiction and anaplerosis. 
Many cancer cell lines display a dependence upon glutamine, despite it being 
a non-essential amino acid that some cells have the capacity to synthesise (Lacey 
and Wilmore, 1990). Glutamine is the most abundant amino acid found in plasma, 
and, in cells, it is used for protein synthesis, as a precursor for biosynthetic 
molecules and as an energy source for adenosine triphosphate (ATP) generation 
(Bergstrom et al., 1974). As a precursor for biosynthetic molecules, glutamine acts 
as a nitrogen donor by providing amine groups for the synthesis of other non-
essential amino acids (NEAA) and nucleotides. As an energy source for ATP, 
glutamine provides carbon molecules through incorporation of its metabolites into the 
tricarboxylic acid (TCA) cycle via a process known as anaplerosis (Hensley et al., 
2013). 
Glutamine is imported into cancer cells mainly via the Slc1a5 [ASCT2] 
transporter (Bode et al., 1995; Collins et al., 1998). Elevated protein levels of ASCT2 
have been reported in a wide range of cancers, possibly reflecting the increased 
need of many malignant cells for glutamine (Fuchs and Bode, 2005; Hassanein et 
al., 2013). ASCT2 expression is upregulated by the c-Myc oncogene (Gao et al., 
2009; Wise et al., 2008) whose own expression is upregulated/deregulated in many 
cancers (Dallafavera et al., 1982; Schwab et al., 1983).  
Glutamine uptake by ASCT2 can also be controlled by the abundance of 
glucose due to the role of both nutrients in glycosylation (Wellen et al., 2010). 
Glycosylation is a post-translational modification essential for the correct localisation 
and function of some membrane proteins (Kornfeld and Kornfeld, 1985; Ohtsubo and 
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Marth, 2006). Glucose and glutamine converge on the hexosamine biosynthesis 
pathway that controls the synthesis of glucosamine, a critical building block used for 
protein glycosylation (Hanover, 2001). Due to the role of glycosylation in the 
localisation of the glutamine transporter itself the availability of glucose and thereby 
glucosamine can inhibit the uptake of glutamine (Wellen et al., 2010). 
The initial reaction in the catabolism of glutamine is the deamination of 
glutamine to glutamate (Figure 1). Enzymes like glutamine-fructose-6-phosphate 
aminotransferase (GFPT) 1 and 2 are amidotransferases that transfer the amide 
group from glutamine to glucose and generate glucosamine (Broschat et al., 2002; 
Slawson et al., 2010). Alternatively, glutaminases such as those encoded by the 
GLS1 and GLS2 genes catalyse glutaminolysis whereby glutamine is converted to 
glutamate and ammonia (Mates et al., 2013). Interestingly, GLS1 up-regulation is 
often found in rapidly dividing cells, unlike the p53-driven expression of GLS2 which 
is correlated with enhancing the redox potential of normal quiescent cells (Hensley et 
al., 2013).  
Glutamate is used itself for the synthesis of glutathione (GSH), which is the 
most prevalent antioxidant within cells (Lu, 2013). Alternatively, it can be further 
catabolised by either glutamate dehydrogenase (GLUD1 or GDH), or alanine and 
aspartate transaminases to generate α-ketoglutarate (α-KG), a component of the 
TCA cycle (Shashidharan et al., 1994). Under nutrient replete conditions, 
transaminase enzymes transfer the amine group from glutamate on to newly 
synthesised NEAAs like serine, glycine, alanine, and aspartate (Yang et al., 2009). 
However, when cells experience nutrient stress, glutamate is directly deaminated by 
GLUD1 to quickly provide α-KG that is shuttled into the TCA cycle (Yang et al., 
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2009). Incorporation of α-KG into the TCA cycle can also be exploited for ATP 
production through oxidative phosphorylation (Reitzer et al., 1979). Additionally, it 
provides the carbon skeleton to replenish the intramitochondrial pool of oxaloacetate 
(OAA) to counterbalance the negative equilibrium of other components such as 
citrate, being used for biosynthetic purposes (DeBerardinis et al., 2007). Aside from 
a source of energy and carbon, α-KG is also a substrate of dioxygenases that play 
an important role in epigenetic regulation of gene expression (Son et al., 2013). 
Requirement for glutamine can also be predicated by the presence of 
activated oncogenes. Activating mutations in KRAS increase the requirement of the 
malignant cells in PDAC for glutamine (Son et al., 2013). In these cells mutant KRAS 
suppresses expression of GLUD1 leaving the mitochondrial aspartate transaminase 
GOT2 free to transfer the amine group of glutamate to oxaloacetate and convert it to 
aspartate. This is then transferred to the cytosol to be converted back to OAA by the 
cytosolic homolog of aspartate transaminase GOT1, whose transcription is 
enhanced by mutant KRAS (Son et al., 2013). Subsequently, OAA is reduced to 
malate by malate dehydrogenase (MDH1) while oxidising reduced nicotinamide 
adenine dinucleotide (NADH) to oxidised (NAD+). The last step in this pathway 
involves the conversion of malate by the malic enzyme (ME) to produce pyruvate 
and reduce oxidised nicotinamide adenine dinucleotide phosphate (NADP+) to 
reduced (NADPH). This pathway of glutamate usage is important for pancreatic 
cancer cells because they depend on it to generate NADPH and maintain their redox 
capacity. PDAC cells cannot make NADPH by the oxidative pentose phosphate 
pathway because it is downregulated (Ying et al., 2012), a feature that makes them 
vulnerable to changes in the availability of glutamine.  
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It is clear that glutamine has diverse roles as a nutrient, and that targeting the 
supply of this amino acid could be exploited therapeutically to inhibit the growth and 
oncogenicity of addicted cells. An example of such targeting is inhibition of GLS with 
small molecules that can inhibit cancer cell growth in a variety of in-vivo and in-vitro 
models (Robinson et al., 2007; Wang et al., 2010). The potencies of these inhibitors 
can be maximised and their side effects minimised when they are used in 
conjunction with reactive oxygen species (ROS)-inducing molecules such as 
Dihydroartemisinin (DHA) (Wang et al., 2016), inhibitors of NADPH:quinone 
oxidoreductase 1 (NQO1) (Chakrabarti et al., 2015) and chemotherapeutic agents 
(Chen et al., 2016). 
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Figure 1.1 Glutamine utilisation pathways.   
Glutamine (Gln) uptake in epithelial and cancer cells lines is mainly facilitated via Slc1a5 
(ASCT2). Glutamine inside cells is then converted to glutamate (Glu) by acting as an amine 
donor like in glucosamine (GlcN) production via the HBP or by enzymatic degradation from 
the glutaminase enzymes GLS1 and GLS2.  The derived Glu can be used for GSH 
production or, when energy is required, glutamate can be converted to α-ketoglutarate (α-
KG) by GLUD1 and used as an anaplerotic source for the TCA cycle. Activating KRAS 
mutations inhibit the function of GLUD1 and glutamate is converted to aspartate (Asp) via 
GOT2 inside the mitochondria. Asp can exit the mitochondria and generate cytoplasmic 
oxaloacetic acid (OAA) via the function of GOT1, a cytoplasmic transaminase that is 
upregulated by the oncogenic signalling of KRAS. Cytoplasmic OAA can be converted to 
malate by malate dehydrogenase (MDH1) and then to pyruvate by the malic enzyme (ME1), 
a step that generates NADPH and is required to maintain the cellular redox balance. 
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1.5.4 The requirement of cancer and immune cells for arginine and nitric oxide. 
Arginine is a positively charged non-essential amino acid, and yet many 
cancer cells appear to be sensitive to its depletion. Sensitivity to depletion of arginine 
is often correlated with reduced expression of the enzymes involved in the 
biosynthesis of this amino acid (Patil et al., 2016). Arginine is synthesised from its 
precursor citrulline by argininosuccinate synthase (ASS) and argininosuccinate lyase 
(ASL) (Albaugh et al., 2017). ASS has been shown to be downregulated in a variety 
of tumours including melanoma (Feun et al., 2012), lymphoma (Delage et al., 2012) 
mesothelioma (Szlosarek et al., 2006) and pancreatic cancer (Bowles et al., 2008). 
In contrast, downregulation of ASL has been reported thus far only in glioblastoma 
(Syed et al., 2013).  
Sensitivity to arginine depletion has been explored also as an anti-cancer 
therapy. Engineered enzymes like human arginase and arginine deiminase (ADI) 
from mycoplasma can lower systemic levels of arginine and inhibit malignant cell 
growth in various tumour models, including pancreatic, melanoma, small cell lung 
cancer and hepatocellular carcinoma (Phillips et al., 2013). Both enzymes have the 
potential to reduce serum levels of arginine, with ADI being more effective than 
arginase (Patil et al., 2016). Arginine loss can induce either cycle arrest, followed by 
apoptosis, or in other settings a strong autophagic response that can lead to 
autophagic cell death (Wang et al., 2014). However, these approaches have 
caveats, because resistance can quickly be developed. The most common 
resistance mechanism involves upregulation of ASS expression, restoring innate 
arginine biosynthesis (Tsai et al., 2009). A further resistance mechanism involves 
induction of an immunogenic response where antibodies are developed against the 
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enzymes, and in particular ADI because of its derivation from mycoplasma, that 
inhibit their activity (Szlosarek et al., 2013).  
The importance of arginine is associated with its special role in the generation 
of nitric oxide (NO) (Fukumura et al., 2006). NO is generated by nitric-oxide synthase 
(NOS) enzymes during oxidation of the guanidine nitrogen of arginine to convert it to 
citrulline (Fukumura et al., 2006). Citrulline can subsequently be recycled by ASS 
and ASL to regenerate the intracellular pool of arginine. The released NO is 
important in angiogenesis, and loss of arginine has demonstrated inhibitory effects 
on VEGF-induced vascularisation of tumours (Fukumura et al., 2001; Thomas et al., 
2002).  
Arginine deprivation however is a double-edged sword as it can act both to 
suppress tumour growth in arginine-dependent tumours but in other cases can 
provide promote tumour survival . In animal models of breast cancer, lower levels of 
arginine in the tumour microenvironment, correlate with higher levels of malignant 
cell growth which can be reversed by re-supplementation (Cao et al., 2016). This 
phenomenon was attributed to the role of arginine and NO in promoting anti-
tumoural innate immune responses within the tumour microenvironment (Kirk et al., 
1992). T-cells and macrophages require arginine for activation and can target cancer 
cells (Bronte and Zanovello, 2005). In addition, immunosuppressive myeloid-derived 
suppressor cells (MDSCs) also produce high levels of arginase as an adaptive 
mechanism to reduce local levels of arginine in the tumour microenvironment and 
block immune responses (Cao et al., 2016)  
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1.5.5 Serine requirements in cancer.  
Serine is a non-essential amino acid with a significant role in one-carbon 
metabolism, a biosynthetic process that takes carbon molecules from serine and 
glycine and redirects them into pathways such as the folate and methionine 
biosynthesis pathways (Yang and Vousden, 2016). Despite the capacity of cells to 
de-novo synthesise serine, rapidly proliferating cells preferably utilise dietary serine 
for one-carbon metabolism (Jain et al., 2012; Maddocks et al., 2013). Serine is 
particularly useful as a one-carbon donor to the folate pathway because of 
ubiquitous expression of serine hydroxymethyltransferase1 (SHMT1) an enzyme that 
transfers a -hydroxymethyl group to tetrahydrofolate (THF), converting serine to 
glycine (Yang and Vousden, 2016). 
Cells have two main mechanisms to generate serine (Figure 1.2). The first is 
termed the serine synthesis pathway (SSP). This pathway branches from glycolysis 
at the point were 3-glycerolphosphate (3PG) is generated (Yang and Vousden, 
2016). In the first step of the SSP pathway 3PG is converted to 3-
phosphohydroxypyruvate (3PHP), a serine precursor, by phosphoglycerate 
dehydrogenase (PHGDH). This reaction results in the reduction of oxidised 
nicotinamide adenine dinucleotide (NAD+) to its reduced form NADH. Subsequently, 
3PHP is transaminated into phosphoserine by phosphoserine aminotransferase 1 
(PSAT1) with a concomitant conversion of glutamate to α-KG. Finally, phosphoserine 
is dephosphorylated to serine by phosphoserine phosphatase (PSPH) (Yang and 
Vousden, 2016). The second pathway for serine generation occurs through the 
bilateral action of the enzyme SHMT1. This enzyme can catalyse a reverse reaction 
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transferring the hydroxymethyl group from folate back to glycine to convert it to 
serine. However, this second pathway is not favoured because it exhausts the 
availability of one carbon units (Labuschagne et al., 2014). 
Cancer cells defective in p53 function appear to be dependent upon provision 
of exogenous serine, likely because of the importance of this amino acid in 
generating the antioxidant GSH. Mechanistically, deprivation of serine has been 
shown to inhibit pyruvate kinase m2 (PKM2), allowing accumulation of 3PG due to 
the blockade of glycolysis (Chaneton et al., 2012). Accumulated 3PG is then 
converted by SSP pathway to serine, replenishing intracellular levels of serine 
(Chaneton et al., 2012). The reduction in glycolysis due to blockade of PKM2 
however leads to a decrease in ATP levels (Mazurek, 2011). However, cells can 
counterbalance ATP depletion by activation of oxidative phosphorylation which in 
turn leads to higher levels of ROS. Increased ROS in turn requires an increase in 
GSH synthesis to maintain redox balance (Chaneton et al., 2012). This is provided 
by glycine, generated from exogenous serine for GSH as well as nucleotide 
synthesis (Maddocks et al., 2013). Thus, deprivation of serine results in lower levels 
of GSH and nucleotides which activates p53 in order to arrest cycle progression and 
inhibit cell growth in a p21-dependent manner (Deng et al., 1995; Linke et al., 1996). 
Loss of p53 or downstream p21 expression is associated with failure to induce this 
protective metabolic adaptation. Cells do not arrest, and as result they use up the 
derived glycine in anabolic processes like nucleotide synthesis instead of GSH 
synthesis (Maddocks et al., 2013). As a result, viability of p53 null cells is 
compromised due to a high burden of ROS and inability to adapt to the new 
conditions. 
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Despite the fact that glycine and not serine is the metabolite used in the 
above biosynthetic pathways, exogenous glycine alone cannot protect the viability of 
these cells (Labuschagne et al., 2014). This appears due to the role of serine in 
generating one carbon units for the folate pathway (Tibbetts and Appling, 2010). 
Supplementing cells growing in serine-free media with formate, an alternative one 
carbon donor, allows utilisation of exogenous glycine in biosynthetic pathways for 
nucleotide synthesis (Labuschagne et al., 2014). Serine addiction has recently been 
exploited in a therapeutic model whereby serine and glycine-free diets have been 
shown to impair the growth of p53null xenograft tumours in mice (Maddocks et al., 
2017). However, in contrast serine and glycine-free diets do not inhibit KRAS-driven 
pancreatic tumours in a mouse model. This appears due to higher levels of serine 
synthesis within these tumours (Maddocks et al., 2017). High levels of serine 
synthesis have also been observed in human tumours, including breast cancers 
negative for oestrogen receptor (ER-) (Possemato et al., 2011), melanoma with 
chromosome 1p amplifications (Locasale et al., 2011) and pancreatic cancers with 
loss of liver kinase B1 (LKB1) (Kottakis et al., 2016) where enzymes within the SSP 
have been shown to be overexpressed. In these models, downregulation of the SSP 
enzymes have been shown to compromise malignant cell viability, demonstrating the 
dependence of some malignant cells on de novo serine synthesis (Possemato et al., 
2011). Overall, the varied responses to serine depletion indicates that the 
requirement for exogenous serine, or for serine biosynthesis, is both oncogene- and 
cell-dependent.  
Therapeutically, serine dependence may be exploitable. An inhibitor of 
PHGDH, the first enzyme in the SSP pathway, has been recently developed (Pacold 
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et al., 2016). This inhibitor has been shown to block the growth of not only tumours 
that rely on de-novo serine synthesis, but also tumours with high serine uptake 
(Pacold et al., 2016). 
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Figure 1.2 Serine uptake and biosynthesis.  
Cells can obtain serine from dietary sources or synthesise it. Serine is fundamental for cell 
survival as it provides one carbon molecules on THF, a component of the folate cycle, and 
generates glycine that cells use for the biosynthesis of nucleotides and GSH.  For serine 
synthesis cells utilise two main pathways: the SSP a pathway that utilises 3-PG generated 
from glycolysis to generate serine and the other one through the bilateral function of SHMT1 
that can generate serine from glycine albeit in the expense of one carbon donors.  
  
62 
1.5.6 Methionine has a fundamental role in epigenetic regulation.  
Methionine is an essential amino acid, and, aside from its role in protein 
synthesis, has additional roles that appear important for cancer cell survival. 
Methionine is the main donor of methyl groups for posttranslational modification of 
proteins and for DNA methylation important for epigenetic regulation of gene 
expression (Mato et al., 2002). These methyl groups are derived from the conversion 
of methionine to S-adenosylmethionine (SAM) by methionine adenosyltransferase 
(MAT) and by the demethylation of SAM into S-adenosylhomocysteine (SAHC) by 
protein and DNA methyltransferases (Yi et al., 2000) (Figure 1.3).  
Within the methionine cycle, SAHC is hydrolysed to homocysteine by S-
adenosylhomocysteine hydrolase (SAHCH) and can then be either used within the 
transulfuration pathway to generate cysteine, or be remethylated back to methionine 
(Toohey, 2006). Re-methylation of homocysteine utilises 5-methyltetrahydrofolate 
(5mTHF) as a one-carbon donor, vitamin B12 as a cofactor and is catalysed by 
methionine synthase (MS) (Toohey, 2006). SAM is also important because it can be 
incorporated into the polyamine synthesis pathway to generate adenosine, spermine 
and spermidine, prior to being recycled back to methionine (Pegg, 2009). 
A feature of some cancer cell lines is that they are auxotrophic for methionine 
(Cavuoto and Fenech, 2012; Cellarier et al., 2003). In normal cells depletion of 
methionine can be rescued by provision of homocysteine, 5mTHF and vitamin B12 
(Kreis et al., 1980; Kreis and Goodenow, 1978). However, cancer cell lines 
auxotrophic for methionine often have lower levels in expression of MS leaving them 
unable to effectively recycle methionine and maintain growth even when 
  
63 
supplemented with homocysteine, 5mTHF and vitamin B12 (Ashe et al., 1974; 
Halpern et al., 1974).  
To induce methionine restriction therapeutically, recombinant enzymes that 
degrade methionine, termed methionases, have been developed. L-methionine-α-
deamino-γ-mercaptomethane-lyase from Pseudomonas putida was the first enzyme 
to be used for this purpose (Tan et al., 1997) , but its use is limited because it 
induces an immunogenic response that inactivates the enzyme (Tan et al., 1998). 
The immunogenicity of methionases has been mitigated with the development of a 
humanised version of this enzyme engineered from cystathionine -lyase that 
selectively degrades methionine (Stone et al., 2012).  
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Figure 1.3 The methionine cycle provides methyl donors, polyamines and cysteine.   
Methionine (Met) metabolism begins with conversion of Met to SAM. SAM can be 
incorporated in the polyamine synthesis pathway or be used by methyltransferase enzymes 
for DNA/protein modifications. Following, transfer of the methyl-group SAM is converted to 
SAHC and then to homocysteine. Homocysteine can be recycled back to methionine through 
the function of MS and the presence of vitamin B12 and a one carbon donor in the form of 
5mTHF. Alternatively, homocysteine can be used for cysteine synthesis through the 
transulfuration pathway. 
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1.5.7 Serine and one carbon metabolism are responsible for recycling of 
methionine. 
An important consideration of amino acid dependency is interconnection of 
the metabolic pathways which generate/use amino acids for cell metabolism. For 
example, cells which show a dependence on serine, exogenous or otherwise, 
appear unable to provide one-carbon intermediates to recycle methionine (Maddocks 
et al., 2016), potentially making these cells susceptible to methionine depletion that 
cannot be rescued by the presence of homocysteine. Serine can participate in 
methionine recycling due to its function as a one carbon donor to the folate pathway 
(Maddocks et al., 2016). Moreover, in PDAC cells with activated KRAS where LKB1 
is lost, increased expression of DNA methyltransferases (DNMT) DNMT1 and 
DNMT3A augments the requirement of these cells for SAM with the consequence 
that expression of the components of the SSP are upregulated as the cell’s 
requirement for serine as a one-carbon donor increases (Kottakis et al., 2016). This 
latter example demonstrates how subversion of the methionine metabolic pathway 
for epigenetic methylation and cancer cell pathogenesis results in co-opting the 
serine metabolic pathway to ensure malignant cell survival. In this way, a synthetic 
lethality requiring different amino acid nutrients might also be envisioned.   
1.5.8 Threonine requirement for mouse embryonic stem cells is associated 
with methionine metabolism and epigenetic regulation.  
Another example of the interconnection between amino acid metabolic 
pathways and nutrient dependence is observed in undifferentiated mouse embryonic 
stem (ES) cells (Wang et al., 2009). These cells are dependent upon threonine for 
viability and proliferation whilst they remain pluripotent because of their requirement 
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for methionine to maintain DNA methylation prior to the beginning of differentiation 
(Shyh-Chang et al., 2013). Mouse ES cells express the enzyme threonine 
dehydrogenase (TDH) which selectively breaks down threonine to generate glycine 
and Acetyl-CoA (Wang et al., 2009). Glycine provides one carbon donors to the 
folate pathway for the regeneration of methionine within the cycle donating methyl 
groups for DNA methylation (Shyh-Chang et al., 2013). Despite that this deficiency 
does not apply to human ES cells as they do not have the TDH enzyme, potentially 
other mechanisms might operate in cancer cells given the extensive range of 
differentiation and aberrant DNA methylation patterns that occur in these. 
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1.5.9 Cysteine requirement of cancer cells and ferroptosis 
Cysteine, together with methionine, are the only two sulphur-containing amino 
acids incorporated into proteins within mammalian cells, where they function as the 
only source of sulphur for biosynthetic purposes (Cooper, 1983). Whereas 
methionine is essential because it can only be obtained through the diet, cysteine is 
considered semi-essential since it can also be synthesised endogenously from 
methionine through the intermediate, homocysteine, in a process known as 
transulfuration (Cooper, 1983). However, in certain circumstances, such as in during  
embryonic development, cysteine becomes essential because of lack of expression 
of transulfuration enzymes such as cystathionine--lyase required for this conversion 
(Sturman et al., 1970). Cysteine is available in two forms; a reduced state with a 
reactive sulfhydryl group (Cys-SH), or an oxidised form, known as cystine, where two 
molecules of cysteine form a disulphide bridge across the sulfhydryl groups (Cys-S-
S-Cys). Within cells cysteine is prevalent due to the reductive environment found 
there, but extracellularly, due to its high reactivity, cysteine is rapidly oxidised to 
cystine (Crawhall and Segal, 1967).  
Several amino acids transporters for cysteine and cystine have been 
described. Cysteine can be imported directly into cells through A, ASC and L 
subfamily amino acid transporter systems as a neutral amino acid (Bannai, 1984). 
However, due to its prevalence extracellularly, cells require mechanisms of uptake of 
the reduced cystine. Cellular take up of cystine is mediated primarily by the 
glutamate-cystine antiporter system Xc-, which is a Na+-independent anionic 
bidirectional transporter that mediates cystine influx and glutamate efflux (Bannai 
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and Kitamura, 1980). Exchange is promoted by high intracellular concentrations of 
glutamate and high extracellular concentrations of cystine (Bannai and Kitamura, 
1980). Glutamate availability can affect uptake of cystine because when 
concentrations of glutamate in the growth media are high, uptake of cystine is 
inhibited (Bannai, 1984; Bannai and Kitamura, 1980). Conversely, when cystine is 
absent from the media, efflux of glutamate is impaired (Bannai and Kitamura, 1980). 
Upon uptake by cells cystine is readily reduced to cysteine by either glutathione, or 
through the thioredoxin–thioredoxin reductase system which generates cysteine for 
the synthesis of glutathione and/or proteins (Figure 1.) (Bannai and Kitamura, 1980; 
Mandal et al., 2010b).  
The majority of intracellular cysteine is utilised for the synthesis of glutathione 
(Meister and Anderson, 1983). Glutathione (L-γ-glutamyl-L-cysteinylglycine, GSH) is 
a tripeptide with a fundamental role in the antioxidant capacity of cells (reviewed in 
(Griffith, 1999; Lu, 2013)). GSH is synthesised in two sequential steps that require 
energy in the form of ATP. The first step in this pathway is formation of γ-
glutamylcysteine through the function of glutamate-cysteine ligase or γ-
glutamylcysteine synthetase (Yan and Meister, 1990). The second step is catalysed 
by GSH synthetase and includes the addition of glycine on to γ-glutamylcysteine to 
form GSH (Oppenheimer et al., 1979). Cysteine is the rate-limiting component for the 
synthesis of GSH (Lu, 1999) and a decrease in the levels of cysteine lowers the 
GSH pool (Griffith, 1999).  
As with cysteine/cystine, glutathione can be found in a reduced (GSH) and an 
oxidised (GSSG) form, the latter comprising two glutathione molecules connected by 
a disulphide bridge between opposing cysteine residues. GSH has the reductive 
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capacity to neutralise a variety of toxic ROS as well as reactive nitrogen species 
(RNS) (Griffith, 1999). Following neutralisation of these free radicals GSH is oxidised 
to GSSG, and can be recycled back to its reduced form through the function of 
glutathione reductase which uses NADPH as a reducing equivalent (Kehrer and 
Lund, 1994). Under physiological conditions the GSH pool is predominantly in its 
reduced form and GSH is generally found in 100-fold greater concentration than 
oxidised GSSG (Akerboom et al., 1982). Accumulation of GSSG due to oxidative 
stress leads to its transport out of cells to avoid disrupting the redox balance within 
cells (Griffith, 1999). Extracellular GSSG and GSH can subsequently be recycled 
through the γ-Glutamyl cycle whereby these peptides are degraded by γ-Glutamyl 
transpeptidase (γ-GT) and the individual amino acids transported back into the cell  
(Meister and Anderson, 1983).  
Glutathione can react with ROS either alone, or via two classes of enzymes: 
glutathione peroxidases (GPXs) and glutathione S-transferases (GSTs). GPX 
enzymes are selenoproteins that contain selenocysteine, a unique amino acid whose 
structure is similar to that of cysteine but contains selenium instead of sulphur in the 
active site of the enzyme (Brigelius-Flohe and Maiorino, 2013; Lu and Holmgren, 
2009). The selenhydryl group (-SeH) of selenocysteine is more nucleophilic than the 
sulfhydryl group of cysteine endowing this class of enzymes with greater reducing 
capability against ROS (Gromer et al., 2003). Glutathione is used in this context to 
recycle GPX enzymes back to their active reduced state. In contrast to GPX 
enzymes, GST enzymes do not contain selenocysteine but catalyse the transfer and 
conjugation of GSH in order to neutralise free radicals or reactive intermediates 
(Sharma et al., 2004).  
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Figure 1.4 Cystine uptake, synthesis of GSH and GSH recycling via the γ-GT cycle.  
Cysteine is not stable and is quickly oxidised to cystine disulphide in the environment. Cells 
have two different mechanisms to mediate uptake of both forms of this amino acid. Cysteine 
is taken up by systems A, ASC and L similarly to most amino acids. Cystine on the other 
hand could only be transferred by the function of the system XC- that functions as an 
antiporter of cystine and glutamine. Once taken up cystine is reduced to cysteine as the 
intracellular reductive environment favours this form. Cysteine can be incorporated in protein 
synthesis but the bulk of it is used in the synthesis of the tripeptide GSH that is the major 
antioxidant found in cells. Neutralisation of ROS by GSH oxidises it to GSSG which is 
secreted by the cells. Cells have the ability to recycle extracellular GSSG via the function of 
γ-GT that breaks down GSH to its comprising amino acids which can then be taken up back 
by the cells.  
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1.5.10 Ferroptosis a novel form of regulated cell death in in response to 
deprivation of cystine.  
Ferroptosis is a recently-characterised iron-dependent regulated form of 
necrotic cell death (Dixon et al., 2012). Ferroptosis occurs upon accumulation of lipid 
peroxides in cellular membranes, and is therefore an oxidative type of cell death 
(Dixon et al., 2012; Yang et al., 2014). This process was first characterised in 
pharmacological screens of small molecules that target cancer cells with activating 
RAS mutations (Dixon et al., 2012). It was found that these compounds, known as 
RAS synthetic lethal molecules (RSL), trigger a non-apoptotic, iron-dependent form 
of cell death (Yagoda et al., 2007; Yang and Stockwell, 2008). Erastin is an RSL 
originally described as an inhibitor of voltage-dependent anion channels (VDAC)  
VDAC2/3 (Yagoda et al., 2007), but which was later found to additionally inhibit the  
Xc- system-mediated uptake of cystine (Dixon et al., 2012). Treatment of cells with 
erastin leads to loss of intracellular glutathione and accumulation of ROS, particularly 
lipid peroxides (Dixon et al., 2012). In this situation iron is likely required to catalyse 
the Fenton reaction which is responsible for the formation of hydroxyl moieties within 
lipid molecules (Doll and Conrad, 2017). The importance of iron and the Fenton 
reaction in the process of ferroptosis is demonstrated by experiments showing that 
chelation of iron blocks the formation of lipid peroxides and induction of cell death 
(Dixon et al., 2012; Yang and Stockwell, 2008).  
In order to effectively detoxify lipid peroxides cells depend upon GPX4, a 
glutathione peroxidase enzyme with selectivity for detoxification of lipid peroxides 
(Brigelius-Flohe and Maiorino, 2013). GPX4 requires glutathione as a cofactor to 
recycle its enzyme active site (Brigelius-Flohe and Maiorino, 2013), and loss of GSH 
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impedes the capacity of GPX4 to neutralise target lipid peroxides leading to their 
accumulation (Yang et al., 2014). A role for GPX4 in ferroptosis was demonstrated 
by genetic knockdown experiments (Friedmann Angeli et al., 2014) and by 
experiments where the novel compound RSL3 was used to inhibit the activity of this 
enzyme (Yang et al., 2014). These experiments showed that such manipulation 
allowed lipid peroxides to accumulate and resulted in ferroptosis, even when cystine 
was present. These data therefore indicate that control of the intracellular levels of 
lipid peroxidation is crucial to the prevention of ferroptotic cell death. 
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Figure 1.5 The mechanism of Ferroptosis.   
Ferroptosis occurs due to accumulation of lipid peroxides in the cell membrane. Inhibitors 
Fer1 and Lip1 have the ability to scavenge lipid peroxides preventing accumulation. GPX4 is 
a selenoprotein with a similar intracellular function to neutralise lipid peroxides and inhibit 
ferroptosis. Lipid peroxides occurs as a by-product of the Fenton reaction that generates 
hydroxyl radicals from hydrogen peroxide and ferrous iron. GSH is synthesised by 
intracellular cysteine and is required for the neutralisation of ROS and lipid peroxides (Lipid 
ROS) through the function of GST and GPX enzymes. Ferroptosis occurs following inhibition 
of GPX4 either by pharmacological inhibition with RSL3 or following depletion of the required 
cofactor GSH that is essential for the recycling of the enzyme. Loss of glutathione occurs 
following deprivation of cystine either due to absence from the extracellular media or 
following inhibition of the system XC- by small molecules such as erastin.  
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Ferroptosis is considered as a regulated type of cell death (RCD), but it still 
differs significantly from other forms of RCD. Unlike ferroptosis, RCDs like apoptosis 
and the newly described necroptosis and pyroptosis are mediated by activation of an 
executioner protein or a protein complex that facilitates the cell death process 
(Fearnhead et al., 2017).  
Apoptosis is the best characterised and most extensively-studied form of cell 
death as it was considered for many years the only form of RCD. Apoptotic cell 
death can be triggered either intrinsically as a response to cellular stress and DNA 
damage or extrinsically following activation of death receptors (Elmore, 2007). The 
apoptotic process is mediated by the function of proteolytic enzymes known as 
caspases. Caspases are cysteine proteases that cleave endogenous proteins and 
are the main mediators of apoptosis (Cohen, 1997). The intrinsic response to 
apoptosis is mediated through the release of cytochrome C from the mitochondria 
which is regulated by the Bcl-2 family of proteins (Green and Reed, 1998; Reed, 
1994). Cytochrome C release promotes the formation of the apoptosome, by 
facilitating the interaction of Apaf-1 with caspase-9 (Cain et al., 1999; Zou et al., 
1999). The apoptosome activates through proteolytic cleavage, caspases 3 and 7, 
the executioner caspases of apoptosis (Cecconi et al., 1998). Caspase activation 
can also be mediated by the extrinsic pathway following activation of death receptors 
tumour necrosis factor receptors TNFR and FAS Nagata (Nagata, 1997). Interaction 
of the death receptors with their corresponding ligands leads to the formation of the 
death-inducing signalling complex (DISC) which includes pro-caspase 8 (Kischkel et 
al., 1995). Self-induced proteolysis of pro-caspase 8 leads to generation of the active 
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caspase 8 which is responsible for further downstream proteolysis of caspase 3 and 
induction of apoptosis (Scaffidi et al., 1998).  
Inhibition of caspase activity inhibits downstream cleavage and blocks 
apoptosis. Such inhibition can be achieved either through pharmacological inhibition 
of caspases by small molecules such as z-VAD-fmk, a pan-caspase inhibitor (Cain et 
al., 1996), or through the involvement of viral proteins(Ray et al., 1992). Inability of 
cells to undergo apoptosis and inhibition promote an alternative pathway of RCD 
known as necroptosis (Vandenabeele et al., 2010).  
Similar to apoptosis, necroptosis occurs following death receptor-ligand 
interaction with downstream activation of receptor-interacting protein kinases 1 and 3 
(RIPK1/3)(Holler et al., 2000; Vercammen et al., 1998; Zhang et al., 2009). Under 
physiological conditions RIPK1 and RIPK3 kinases are proteolytically digested by 
caspase 8 following formation of the DISC complex (Cho et al., 2009). However, in 
the absence of caspase 8 activity, intact RIPK1 and RIPK3 interact inducing auto- 
and cross-phosphorylation of each other promoting formation of the necrosome 
(Declercq et al., 2009). RIPK3 binds and phosphorylates the pseudokinase mixed 
lineage kinase domain-like (MLKL) protein (Sun et al., 2012), which is an essential 
mediator/executioner in the induction of necroptosis (Murphy et al., 2013; Zhao et al., 
2012).MLKL has been shown to oligomerise and translocate in the membrane 
inducing influx of sodium and calcium ions which generate osmotic stress which 
facilitates cell membrane rupture (Cai et al., 2014; Chen et al., 2014). 
Unlike those forms of RCD ferroptosis does not involve the involvement of an 
executioner molecule that promotes the cell death process. Rather than that, the 
death occurs due to the excessive accumulation of lipid peroxidation (Skouta et al., 
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2014; Yang et al., 2014; Yang and Stockwell, 2016). The increased levels of lipid 
peroxides occur as a consequence of reduced anti-oxidant capacity due to loss of 
intracellular cysteine and glutathione or due to impaired capacity of GPX4 to inhibit 
lipid peroxidation (Gaschler and Stockwell, 2017). It is however regulated by the 
presence of certain important proteins like system XC- that controls uptake of cystine, 
and GPX4 that is responsible for removing dangerous lipid peroxides.  Ferroptosis, 
despite recognised as a form of RCD it has been further characterised as by some a 
form of cellular sabotage instead of a cellular suicide (Green and Victor, 2012) . 
Similar to ferroptosis, other forms of RCD have been characterised as that, such as 
mitotic catastrophe where cell division fails due to chromosomal damage or 
segregation (Vakifahmetoglu et al., 2008) or parthanatos where death is induced due 
to overactivation of PARP1 (Andrabi et al., 2008).  
 
1.5.11 Ferroptosis and human disease. 
The generation and accumulation of lipid peroxidation may play a role in 
several aging and neurodegenerative diseases including Alzheimer’s, Parkinson’s 
and Huntington’s diseases as well as motor neuron degeneration (Chen et al., 2015; 
Guiney et al., 2017; Hambright et al., 2017; Yoo et al., 2010). Accumulation of lipid 
peroxides in these diseases suggests that cell degeneration may occur by 
ferroptosis.  Glutamate-induced neurotoxicity (oxytosis) partially involves ferroptosis 
due to inhibition of XC- system by extracellular glutamate, but in contrast to oxytosis, 
ferroptosis is independent of glutamate receptor-mediated calcium influx (Yang and 
Stockwell, 2016). Additionally, recent evidence highlights the importance of 
ferroptosis in disease processes such as ischemia-reperfusion injury (IRI), as 
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demonstrated in murine models of hepatic IRI and acute kidney injury (AKI) 
(Friedmann Angeli et al., 2014; Linkermann et al., 2014). Ferroptosis has also been 
reported to occur in response to liver acetaminophen toxicity, alongside other forms 
of cell death such as necroptosis, due to drug-induced depletion of GSH and 
subsequent GPX4 inhibition (Lorincz et al., 2015). 
Some specific inhibitors of ferroptosis have been developed. These include 
Ferrostatin1 (Fer1) (Dixon et al., 2012) and Liproxstatin1 (Lip1) (Friedmann Angeli et 
al., 2014). Those molecules have the ability to inhibit ferroptosis by acting as free 
radical-trapping antioxidants that can block the oxidation of lipids in the presence of 
iron (Zilka et al., 2017). Despite their antioxidant role these compounds protect 
specifically from ferroptosis as they cannot protect cells from hydrogen peroxide 
oxidative cell death (Dixon et al., 2012).  
Several oncogenes have been found to be involved in mediating sensitivity to 
ferroptosis. The presence of an mutated constitutively active RAS induces activation 
of the downstream RAF-MEK-ERK pathway and sensitises cells to ferroptosis 
following erastin treatment (Yagoda et al., 2007). Moreover, these cells express 
higher levels of transferrin receptor 1 and lower levels of transferrin, leading to an 
increase in the labile iron pool that may also contribute to ferroptosis-sensitivity 
(Yang and Stockwell, 2008). The tumour suppressor p53 has also been found to 
suppress expression of xCT, one of the subunits that comprise system Xc- cystine 
transporter. Loss of p53 function leads to upregulation of the receptor and allows for 
enhanced uptake of cystine (Jiang et al., 2015). A similar upregulation on xCT 
expression is observed through the function of the known redox-controlling gene 
Nuclear factor like 2 (Nrf2) (Fan et al., 2017). 
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The requirement for cystine and the induction of ferroptosis is associated with 
other metabolic requirements and functions. A recent report highlights that 
glutaminolysis may be important for induction of ferroptosis and its inhibition can 
block ferroptosis (Gao et al., 2015). Finally, inhibition of cysteinyl-tRNA synthetase 
(CARS) induces activation of methionine transulfuration enzymes to compensate for 
cystine loss and can be protective against ferroptosis (Hayano et al., 2016). It 
becomes therefore apparent that metabolic networks are interconnected and 
requirements for certain nutrients might also be associated with the presence and 
metabolism of other amino acids. 
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1.6 Work presented in this thesis. 
Those observed differences highlight the need for more systematic analyses 
to elucidate whether amino acid requirements operate oncogene-selectively and to 
identify novel amino acid requirements in different genetic and cellular contexts. So I 
have set out to examine if the presence of a common activated oncogene predicates 
an increased requirement for one or more extracellular amino acid nutrients. In 
chapter 3 I demonstrate that hTERT-HME1 cells with an activating mutation in EGFR 
are particularly dependent on cystine and withdrawal of this amino acid leads to 
ferroptosis. In chapter 4 I elucidate the underlying mechanism through which EGFR-
mediated activation of MAPK pathway regulates the levels of ferroptosis regulator 
GPX4. In the same chapter I demonstrate that an enzymatic approach using a 
modified human enzyme that degrades cystine can induce ferroptosis in both in 
cultured cells as well as in a xenograft model. Finally, in chapter 5 I study the 
necrotic spread observed in hTERT-HME1 cells undergoing ferroptosis as well as 
the involvement of cell adhesion in this spreading process.  
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2. CHAPTER 2: MATERIALS AND METHODS 
2.1 Cell Culture and treatments 
The hTERT-HME cell line (Wild-type) and its isogenic KI cell line counterparts 
(EGFR (delE746-A750), KRAS (G13D), BRAF (V600E), PIK3CA (H1047R)) were a 
kind gift from Prof. Alberto Bardelli (Institute for Cancer Research and Treatment, 
IRCC, Candiolo, Torino, Italy). Cells were grown in Dulbecco's Modified Eagle's 
Medium (DMEM) (Life Technologies, 31966047) with 10% Fetal bovine serum (FBS) 
(Life Technologies), 1% PenStrep (Life Technologies), 20 ng/mL human hEGF 
(Peprotech), 10 μg/ml bovine insulin (Sigma), and 100 μg/ml hydrocortisone (Sigma) 
as described (Di Nicolantonio et al., 2008).  
NSCLC lines, listed in Table 1, were obtained from the University of Liverpool 
Institute of Translational Medicine Authenticated cell line repository, or from 
Professor Michael J. Seckl (Imperial College, London, UK). NSCLC lines were grown 
either in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco) 
supplemented with 10% FBS (Life Technologies), 1% PenStrep (Life Technologies), 
or in DMEM (Gibco) also supplemented with supplemented with 10% FBS (Life 
Technologies), 1% PenStrep (Life Technologies). 
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Table 2.1 Human cell lines used in this thesis. 
 
Table 2.2 List of reagents used in this thesis 
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2.2 Transfection of cultured cells 
2.2.1 siRNA interference 
Lipofectamine 2000 (Invitrogen, ThermoFisher) was used for small interfering RNA  
(siRNA) transfection of HME cells according to the manufacturer’s instruction. 
500,000 cells were plated in 6-well plates and either mock-transfected (where 
lipofectamine was used with no siRNAs), or were transfected with either siCtrl or 
siGenome Smartpool siRNAs (Dharmacon, GE Lifesciences) to GPX1, GPX2, GPX3 
and GPX4 (Table 3) used at a final concentration of 50nM. A day after transfection, 
cells were trypsinised and seeded into a 12-well plate well with 250,000 cells/well, or 
a 96-well plate wells with 25,000 cells per well. 3 days post transfection cells in the 
former were used for immunoblotting, whilst cells in the latter were used in viability 
assays. 
2.2.2 Expression vectors 
For GPX4 overexpression 500.000 HME-EGFR cells were transfected in 3cm dishes 
with 2.5μg/ml (5 of μg in 2ml) of p442-PL1 Flag-Strep-HA-GPX4 , a kind gift from 
Professor Marcus Conrad (Mannes et al., 2011), or control vector using 
Lipofectamine 2000 (Invitrogen, ThermoFisher). 48h after transfection wild-type or 
transfected cells were trypsinised and 20,000 cells/well were re-plated in a 96 well 
format , deprived of cystine for 16h and measure the viability using Cell titre Glo 
2.2.3 Recombinant protein production 
Human glutathione S-transferase alpha isozyme 4-4 (hGSTA4-4) was expressed as 
recombinant proteins using the pET30a(+)-hGSTA4-4 expression vector (Cheng et 
al., 2001) ,a kind gift from Professor Sanjay Awasthi (Department of Medical 
Oncology, Texas Tech University Health Sciences Center, Lubbock, TX 79430, 
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USA) , in BL21 competent E. coli.  Bacterial cultures were incubated with 0.1mM 
Isopropyl β-D-1-thiogalactopyranoside (IPTG, Sigma) to induce protein expression 
for 4h prior to lysis. The overexpressed GSTA4-4 was isolated using agarose beads 
conjugated with glutathione (Sigma) and subsequently eluted using reduced 
glutathione solution (Sigma). Simply blue Safe stain (ThermoFisher) was used to 
determine protein quantity against BSA standards 
 
Table 2.3 Lists of siRNA and plasmids used in this thesis. 
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2.3 Amino acid depletion 
Individual amino acid stocks (Sigma) made at 50X the concentrations used in DMEM 
in water. These stocks were used to generate complete DMEM media (+AA) were all 
amino acids were used, or individual DMEM amino acids were omitted to generate 
single amino acid deficient media. For the initial screen of amino acid sensitivity 
30,000 cells were initially plated per well in a 96-well microtitre plate (NUNC, 
ThermoFisher) in complete DMEM media, that was then switched the following day 
to selectively depleted amino acid media. Cells under these conditions were cultured 
for a further 72 hours.  
2.3.1 Cystine titration 
For the cystine titration experiment cells were plated in triplicate cells at a final 
concentration of 30,000cells/well in a 96-well format (NUNC, ThermoFisher). The 
following day complete synthetic media containing or lacking EGF was serially 
diluted with DMEM lacking cysteine to achieve a range of decreasing cystine 
concentrations. 
2.4 Viability assays 
Viability was assessed using two different assays; one using Calcein AM (Molecular 
Probes, ThermoFisher), or, two, using the CellTitre-Glo assay (Promega). For 
viability measurements using Calcein (only used for the initial screen), cells were 
incubated with 1μM Calcein-AM for 2h followed by fixation with 4% 
paraformaldehyde for 15 mins prior to analysis on a Tecan Genios plate reader using 
an excitation wavelength of 485nm and measuring emission at 535nm. Viability 
measurement using the CellTitre-Glo assay was performed according to the 
manufacturer’s instruction. Briefly, an equal volume of CellTitre-Glo reagent (to the 
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existing cell culture media) was added to the cell culture plate using a multichannel 
pipette. Plates were then vortexed at 1000 rpm for 2 minutes to allow cell lysis, and 
then luminescence was measured using a Tecan Genios plate reader. Cell viability 
of each cell line in test situations were normalised to that of each cell line grown in 
complete DMEM (the control condition). Experiments were performed in triplicate 
and one standard deviation has been used for error bars. 
2.5 Microscopy  
2.5.1 Time-lapse microscopy 
For time lapse microscopy, a Nikon TE-300 microscope equipped with a 10X phase 
contrast (PC) objective and motorised with Sutter filter wheels and a Conix block 
changer, was used. The microscope was encased in a Perspex 37°C incubation 
chamber with an insert for multi-well plates. The incubation chamber was flushed 
with humidified air containing 5% CO2. Green fluorescence was acquired through a 
Nikon B-2A block, and images were collected through a Hamamatsu Orca AG 
camera, using MicroManager software (Edelstein et al., 2010). Conversion of time 
series to an ImageJ readable format was performed using in-house software kindly 
provided by Dr Carlos Rubbi, Department of Molecular and Clinical Cancer Medicine.  
To perform each experiment, cells were plated in a 6-well plate at 500,000 cells per 
well, and then grown for 3 days prior to media switch to cysteine-deprived media. At 
this point Sytox Green nuclear stain (Molecular Probes, ThermoFisher) was added to 
a final concentration of 0.5μM. The plates were then transferred to the microscope 
stage within the incubator and maintained at 37°C with 5% CO2. Individual frames 
were obtained every 5 minutes in phase contrast (PC) and green fluorescence 
channels for detection of nonviable cells. Measurements of Sytox  green-positive 
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cells were performed using ImageJ (Schneider et al., 2012).  An image-analysis 
algorithm to assist with fluorescence measurements was kindly generated by Dr. 
David Mason, Centre for Cell Imaging, Institute for Integrative Biology, University of 
Liverpool, allowing measurements of the rate of cell death spread.  
2.5.2 Immunofluorescence and detection of LAA adducts using confocal 
microscopy. 
For immunofluorescence experiments studying adherens junctions and for the 
detection of LAA adducts cell images were obtained at 63X magnification using a 
confocal laser scanning microscope (Zeiss 3I LSM 800). Confluent wild-type HME 
and HME-EGFR cells were plated in 13mm round glass coverslips. Following 
treatment, cells were fixed with 4% PFA/PBS and permeabilised with 0.2% Triton X-
100/PBS. In order to block unspecific interactions coverslips were incubated in 
Odyssey blocking buffer (LICOR) in PBS (1:1 ratio). Coverslips were incubated with 
primary antibody overnight at 4°C, incubated with labelled secondary goat anti-
Mouse Alexa Fluor 594 antibody (ThermoFisher) for 1 hr at room temperature, and 
mounted using Dako mounting medium (Agilent). 
Lipid peroxidation adducts were detected using the Click-iT lipid peroxidation 
imaging kit as per manufacturer’s instructions (Molecular Probes, ThermoFisher) 
were similarly visualised using a confocal laser scanning microscope (Zeiss 3I LSM 
800). Cumene hydroperoxide (CuOOH, Sigma) was used as a positive control.  
Hoechst 33342 (ThermoFisher) was used as nuclear staining dye. 
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2.5.3 Phase contrast and fluorescence photographs for GJIC scrape loading 
Lucifer Yellow assay 
For single phase contrast and fluorescent images an AMG EVOS FL digital 
inverted microscope was used. Images were obtained at 4x or 20x magnifications. 
Measurement of the total area of fluorescent-positive cells for cell death or for GJIC 
scrape loading assay was performed using ImageJ (Schneider et al., 2012).  
Confluent cultures of wild-type HME cells were treated with the specified 
inhibitors or vehicle DMSO for 30h. Following cell treatment with the vehicle or the 
specified inhibitors cells were washed in Dulbecco’s PBS (DPBS) without calcium 
and transferred to loading solution, which was composed by PBS containing 
0.5mg/mL Lucifer yellow (Sigma), 0.5 mg/mL rhodamine-dextran (Molecular Probes) 
and either DMSO (100μM) or carbenoxolone (CBX, 100μM). For dye loading a 
wound was performed using a pipette tip and the cells were incubated for 15 minutes 
at 37oC. Following incubation, the loading solution was removed, and cells were 
washed in PBS and subsequently fixed in 4% paraformaldehyde (PFA)/PBS. Areas 
close to the wound margin were imaged for green and red fluorescence at 20X 
magnification to demonstrate the infiltration of Lucifer Yellow dye into the monolayer. 
Rhodamine Dextran incorporation was limited in the wound margin as the dye 
cannot pass through gap junctions and was used a loading control for cell wounding. 
2.6 Fluorescence-activated cell sorting (FACS) analysis 
For the detection of intracellular ROS 200,000 cells were plated into 6-well plates 
(Greiner Bio-one). Following 3 days of culture in complete media, the supernatant 
was removed and cell were switched to cysteine deprived media in which they were 
cultured for a further 12 hours. The cells were then washed with PBS, and then 
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incubated in DPBS containing either CMDCFDA (10μM) or C11 BODIPY (2μM) (both 
from Molecular Probes, ThermoFisher) for 30min. After this final incubation, cells 
were removed from culture plates by trypsinisation with 0.25% Trypsin-EDTA (Gibco, 
ThermoFisher), and then resuspended in PBS with 1% FBS. Cells were then 
analysed using an Attune NxT flow cytometer (ThermoFisher). Both dyes were 
excited using a blue 488nm laser and emission was measured on BL1 (530/30). 
Data was collected for a minimum of 5,000 cells per sample. 
2.7 GSH/GSSG quantification   
For the quantification of cellular reduced (GSH) and oxidised (GSSG) glutathione the 
method described by Rahman et al (Rahman et al., 2006) was used. This method 
depends on the reaction of GSH with 5,5′-Dithiobis (2-nitrobenzoic acid)(DTNB) to 
generate 5′-thio-2-nitrobenzoic acid (TNB), a chromophore whose concentration can 
be measured at 412nm (Tietze, 1969). 1x106 cells were plated in 6-well plates 
(Greiner) and cultured overnight. On the following day cell cultures were either 
treated with 200M of BSO, or had their media switched to cystine deficient media 
and then further cultured for 8h. Cells were then washed in cold PBS, trypsinised 
and resuspended in 0.2ml of ice-cold extraction buffer (0.1% Triton-X and 0.6% 
sulfosalicylic acid in 0.1 potassium phosphate buffer with 5 mM EDTA, pH 7.5 
(KPE)). The lysed cells were then subjected to 4 freeze-thaw cycles (liquid nitrogen - 
37°C water bath), and this was followed by centrifugation at 3000g for 5 min at 4 °C. 
Supernatants were collected, and the protein concentrations within were measured 
using a Bradford assay (Bradford, 1976) in order to express GSH and GSSG levels 
as nM/mg of total protein.  
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Total glutathione (Total[GSH] = [GSH] + 2 × [GSSG]) within the supernatants was 
determined by first reducing GSSG to GSH with the addition of glutathione reductase 
(GR, Sigma) and DTNB (Sigma) followed by addition of 240μM β-Nicotinamide 
adenine dinucleotide 2′-phosphate (β-NAPDH, Sigma) and the rate of TNB formation 
was calculated by measuring absorbance at 415nm in a Tecan Genios plate reader 
every 30sec. Total glutathione within cell lysates was quantitated against a standard 
curve generated using GSH standards of known concentration made from stock 
GSH (Sigma).  
For measurement of GSSG, 2-vinylpyridine (Aldrich) is added to cell lysates to a final 
concentration of 18.5mM, which were then incubated for 1h at RT. 2-vinylpyridine 
covalently binds to GSH to allow measurement of GSSG. Excess 2-vinylpyridine was 
neutralised with the addition of 75mM triethanolamine (Sigma) for 30 min (Griffith, 
1980). However, derivatisation of GSH with 2-vinylpyridine could have lead to 
overestimation of the GSSG content in these cells and therefore addition of N-
ethylmaleimide is suggested an approach that could yield more accurate 
measurements (McGill and Jaeschke, 2015) 
Following derivatisation, levels of GSSG were determined by first reducing it to GSH 
by addition of GR as described above, and then measuring the rate of TNB formation 
following the addition of DNTB. Reduced glutathione (GSH) in cell lysates could be 
then determined by this formula: (Total[GSH] = [GSH] + 2 × [GSSG]). All 
measurements were done in triplicate. Glutathione synthesis inhibitor buthionine 
sulfoximine (BSO, Santa Cruz Biotechnologies) was used at 200μM.  
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2.8 Western Blotting 
Cells were lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 1mM EGTA, 1 mM EDTA,  
1% Triton X-100, 1mM Na3VO4, 50 mM NaF, 50 mM β-glycerolphosphate, 0.27M 
sucrose, 0.1% beta-mercaptoethanol, Complete protease inhibitors (Roche)). Cell 
lysates were centrifuged at 10,000xg for 30min at 4C, and supernatants were taken 
for protein concentration determined by Bradford assay (Bradford, 1976) using 
Bradford reagent Biorad and measuring absorbance at 595nm using a SpectraMax 
Plus 384 Microplate Reader. 25 μg of total cellular protein was loaded per sample on 
to a SDS-PAGE gel, and proteins separated using 10% acrylamide gels. Separated 
proteins were electroblotted to PVDF membranes, which were then probed with the 
list of antibodies found in Table 2.4 
 
Table 2.3 List of antibodies used in this thesis 
2.9 In vivo mice models. 
NCI-H1650 tumours were allowed to form in 1:1 in Matrigel: PBS (100 mL) where 
250,000 cells were inoculated. Tumours were transferred to eight non-obese diabetic 
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(NOD) severe combined immunodeficiency (SCID) gamma male mice by 
subcutaneous injection. Prior to treatment, tumours were allowed to establish for 18 
days and were then administered interperitoneally with two different concentrations 
30 or 100 mg/kg cyst(e)inase (AECase) or PBS control for 20 days and left for 10 
more days without any treatment prior to necropsy. 
For WB and IHC samples derived from in vivo tumours, the tumors were allowed to 
engraft for 30 days (tumor volume averaged ~200 mm3) followed by intraperitoneal 
(i.p.) injection with 100 mg/kg cyst(e)inase or 100 mg/kg heatinactivated cyst(e)inase 
(n = 4 ea.) on day 30, with a second dose given on day 33. Mice were necropsied 24 
hr after the second dose. For determination of COX2 using immunohistochemistry 
(IHC),half of the excised tumors were preserved in 10% neutral buffered formalin, 
while the remaining half was frozen in liquid nitrogen and then pulverised with morter 
and pestle inside a classII biological safety hood.  The procedure of IHC was carried 
out and evaluated by Precision Pathology using an anti-COX2 antibody from Abcam 
(ab15191) with DAB detection.  
2.10 LC-MS for amino acid steady state levels 
For the measurement of steady state levels of amino acids within wild-type 
and HME-EGFR cells, 500,000 cells were seeded in 10cm dishes. The next day cells 
were washed 3 times using DPBS and switched to cystine lacking media, or 
complete The metabolites were extracted using  a polar solvent (50% methanol, 30% 
acetonitrile, 20% water) with 1ml used per 1,000,000 cells. Sample were then mixed 
first on arocking plate and then on Thermomixer (Thermomixer comfort, Eppendorf 
AG, Hamburg, Germany) and then centrifuged at 16,100 x g for 10 minutes, with all 
procedures taking place at 0-4°C. Hydrophilic Interaction Liquid Chromatography 
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was performed by Dr. Christiaan Labuschange using a Sequant ZIC-pHILIC column 
(2.1 × 150 mm, 5 μm) (Merck) to separate amino acids before detection with high-
resolution, accurate-mass (HR/AM) Mass Spectrometry using an Orbitrap Exactive in 
line with an Accela autosampler and an Accela 600 pump (Thermo Scientific). The 
elution buffers used to elute the analytes were Acetonitrile (ACN) for A and 20 mM 
(NH4)2CO3, 0.1% NH4OH in H2O for B. A linear gradient was programed starting 
from 80% A and ending at 20% A after 20 min at a flow rate of 200ul/min, followed 
by wash (20% A) and re-equilibration (80% A) steps at a flow rate of 400 μl/min. An 
Electrospray Ionization (ESI) probe was used to achieve ionization and the mass 
spectrometer operated in full-scan and polar-switching mode with the positive 
voltage at 4.5 kV and negative voltage at 3.5 kV. Metabolite identification and data 
analysis were done using TraceFinder TM software (Thermo Scientific).  
  
93 
3. CHAPTER 3. IDENTIFYING ONCOGENE-SELECTIVE DIFFERENTIAL 
EFFECTS OF SPECIFIC AMINO ACID DEPRIVATION IN HUMAN MAMMARY 
EPITHELIAL CELLS. 
3.1 Introduction 
The main aim of my study was to investigate whether the concept of synthetic 
lethality (Rehman et al., 2010) could be applied to the requirements of cancer cells 
harbouring specific oncogenic mutations for specific nutrient amino acids. To 
investigate this question, I performed a “drop-out” screen in which synthetic media 
were prepared that lacked each of the 20 amino acids found in DMEM media.  
The cell model I chose was a panel of hTERT-immortalised Human mammary 
epithelial (hTERT-HME1) cell lines that had been gene-edited to express five of the 
most common oncogenic mutations found in human tumours but present an 
otherwise isogenic genomic background. These cells have a normal diploid 
karyotype and were immortalised via retroviral transfection of human telomerase 
enzyme (Yi et al., 1999).  Gene editing of the parental wild-type hTERT-HME (HME) 
cell line was performed by adeno-associated-viral (AAV) mediated homologous 
recombination to introduce the following common oncogenic mutations: EGFR 
(delE746-A750) (HME-EGFR), KRAS (G13D) (HME-KRAS), BRAF (V600E) (HME-
BRAF), and PIK3CA (H1047R) (HME-PIK3CA) (Di Nicolantonio et al., 2008). Unlike 
tumour cell lines these cells have a normal genetic background and a diploid 
karyotype providing an excellent system to dissect the specific effects of the 
highlighted oncogenes (Di Nicolantonio et al., 2008). On the contrary, a model of 
isogenic cancer cell lines could potentially be more complex due to the presence of 
mutations accumulated during their oncogenic transformation. Moreover, these cell 
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lines, except for HME-BRAF, cannot grow in an anchorage-independent manner and 
none of them have tumorigenic properties (Di Nicolantonio et al., 2008). 
3.2 HME cells with activating EGFR and BRAF mutations require the nutrient 
amino acid cystine to maintain viability. 
3.2.1 Screen for oncogene-selective requirements of individual amino acids  
To define effects upon viability in wild-type and mutant hTERT-HME cells I 
firstly prepared DMEM media deficient in individual amino acid nutrients. This media 
was used to culture the above cells for 72h, after which viability was measured using 
Calcein-AM labelling. 
When cystine was omitted from the media, all cell lines demonstrated some 
loss of viability in the range of 40% to >80%. The cell lines that exhibited the highest 
loss in viability were those with a mutated allele for EGFR and BRAF where only 
<20% of the cells survived (Figure 3.1). However, some other differences were also 
observed. Thus, deprivation of Gln led to around 50% loss of viability for all cell lines 
irrespective of their mutational status. Similarly, Arg and Val deficiency also reduced 
the viability of cultured cells regardless of mutational status, but to a lesser extent 
than that found with deprivation of Gln. Finally, Met deficiency also caused some 
variable reduction in cell line viability. Deficiency of the other amino acids found in 
DMEM media did not markedly affect cell viability. 
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Figure 3.1 Cell survival assay for individual amino acid depletions in HME cell lines.  
Viability of each individual cell line was measured by fluorescence intensity from 
incorporated Calcein-AM used for labelling and was normalised to viability in complete 
media assigned an arbitrary value of 1. Each graph represents the average viability ± 
standard deviation (SD) of three biological replicates. Parts A – E indicate experiments 
performed on the indicated cell line (WT, wild-type HME cells). 
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3.2.2 HME-EGFR cells demonstrate the strongest requirement among the other 
cell lines for cystine. 
To further determine the specificity of the observed effect of cystine 
deprivation I assayed cells under different conditions of confluency. Wild-type HME 
cells along with HME-EGFR and HME-BRAF were plated in conditions that allowed 
them to reach complete (100%) or partial confluence (50%). All cell lines appeared 
partly sensitive under conditions of low confluency (Figure 3.2A). However, when 
allowed to reach complete confluency wild-type and HME-BRAF cells were protected 
from cystine deprivation-induced cell death, whereas cells with an activating EGFR 
mutation remained highly sensitive (Figure 3.2B). These observations demonstrate 
that cell-cell contact, for as yet unknown reasons, can partially overcome the death-
inducing effect of cystine depletion in wild-type and HME-BRAF cells, but not in 
HME-EGFR cells. This suggests greater dependence of the latter cells upon cystine, 
and allows the use of HME-EGFR cells to model the mechanism of cell death that is 
induced when cystine is depleted. From this point forward, all experiments were 
performed using confluent cell cultures. 
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Figure 3.2 Cell survival assay for deprivation of cystine under conditions of high and 
low confluence in wild-type HME (WT), HME-EGFR and HME-BRAF cell lines.  
Viability of each individual cell line was measured by luminescence using the Cell-titre Glo 
assay and was normalised to viability in complete media. Each graph represents the 
average viability ± standard deviation (SD) of three biological replicates. Panel A indicates 
viability under conditions of high confluence (~100%) whereas panel B displays the results 
obtained from lower confluence experiments (~50-70%).  
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3.2.3 HME-EGFR cells have an active requirement for L-cystine but not D-
cystine to maintain viability. 
To determine the minimum requirement of wild-type and EGFR-mutant cell 
lines for the presence of exogenous cystine, I next cultured confluent cells in a range 
of decreasing cystine concentrations. Two different media formulations were 
prepared, one including EGF and a second one where it was omitted. Under these 
conditions wild-type HME cells maintained their viability regardless of cystine 
concentration, the exception was when cystine was completely removed and cell 
viability of the EGF-cultured cells was reduced to around 80% (Figure 3.3A). In 
contrast, HME-EGFR cells exhibited a markedly elevated requirement for cystine, 
with loss of 50% viability (IC50) occurring at 2M concentration in the presence of 
EGF and 1M concentration when EGF was omitted (Figure 3.3A). These results 
suggest an active requirement for exogenous cystine by HME-EGFR cells.  
I next examined the possibility that supplementation of D-cystine (the 
enantiomer of L-cystine) could prevent cell death. Figure 3.3B shows that addition of 
D-cystine to either complete media or to media lacking L-cystine had no effect on the 
viability of wild-type HME or HME-EGFR cells. Importantly, there was no rescue from 
cell death of HME-EGFR cells when L-cystine was replaced with an equivalent 
concentration of D-cystine, indicating that the requirement of these cells is 
enantiomer specific, likely as a result of specificity the System Xc- for uptake of L- but 
not D-cystine (Patel et al., 2004).  
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Figure 3.3 HME-EGFR cells have an active requirement for exogenous L-, but not D-
cystine.  
A and B Cell viability assay for wild-type HME and HME-EGFR cell lines grown in media 
containing different concentrations of L-Cystine. Panel C Cell viability assay for wild-type and 
HME-EGFR cell lines cultured in complete or L-cystine-deprived media testing the effect of 
supplementation with (153M) D-Cystine. Viability of each individual cell line was measured 
by luminescence using the CellTitre-Glo assay and was normalised to viability in complete 
media. Each graph represents the average viability ± standard deviation (SD) of three 
biological replicates.  
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3.3 Deprivation of cystine leads to oxidative cell death and loss of the 
glutathione pool. 
3.3.1 Cystine withdrawal results in production of reactive oxygen species in 
HME-EGFR cells which lead to oxidative cell death. 
The majority of cystine in cells is used to produce glutathione, the most 
abundant antioxidant within cells (Lu, 2013). Given the importance of glutathione as 
a major antioxidant within cells, I next examined wild-type and HME-EGFR cells for 
evidence of oxidative stress during cystine deprivation. Figure 3.4A shows that total 
ROS increased in confluent cultures of HME-EGFR cells but not in cultures of wild-
type HME cells following 12h of cystine deprivation as detected using FACS analysis 
with the DCFDA probe. Further exploration of more specific indicators of ROS in 
cystine-deprived cell cultures revealed increased levels of lipid ROS within 
membranes of HME-EGFR cells compared with wild-type HME cells (Figure 3.4 B). 
Thus, cystine deprivation leads to increased levels of ROS in cultures of HME-
EGFR, but not wild-type HME cells. 
Next, I investigated the role of ROS in facilitating cell death in HME-EGFR 
cells. I treated HME-EGFR cells with two different ROS scavengers, idebenone and 
α-tocopherol. Idebenone is a short-chain benzoquinone, a synthetic analogue of 
coenzyme Q10, with antioxidant activity against a variety of different radical species 
(Mordente et al., 1998). Idebenone is less lipophilic than coenzyme Q10, making it 
more readily available by allowing for its localisation in the cytoplasm as well as 
inside mitochondria (Gueyen et al., 2015).  α-tocopherol is a naturally-occurring 
homologue of vitamin E, and acts as a potent lipophilic antioxidant within biological 
membranes (Brigelius-Flohe, 2009). Treatment with either of these antioxidants 
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rescued HME-EGFR cells from cystine deprivation-induced cell death (Figure 3.5). 
The differential mechanisms of how these compounds work to lower ROS indicates 
that rescue is not due to the individual properties of each compound, rather it is their 
collective ability to negate oxidative stress generated by cystine deprivation. 
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Figure 3.4 FACS analyses of total ROS and lipid peroxidation in wild-type and HME-
EGFR cell lines.  
Total ROS was measured using the DCFDA probe following 12h of cystine deprivation in 
wild-type (top left) and HME-EGFR (top right) and using FL1-H channel for detection. Lipid 
ROS was measured using the C11-BODIPY probe following 12h of cystine deprivation in 
wild-type (bottom left) and HME-EGFR (bottom right) and using FL1-H channel for detection. 
Each histogram shows the spread of a population of minimum 5000 events of cells in 
complete medium (dark graphs) or in medium lacking cystine (light outline). 
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Figure 3.5 Treatment with ROS scavengers protects HME-EGFR cells from oxidative 
cell death caused by cystine depletion.  
Confluent HME-EGFR cells were cultured in complete or cystine deprived media in the 
presence or absence of idebenone (1M) or α-tocopherol (30M) for 24h. A, viability assay 
using the Cell-titre Glo reagent. Viability of cells in cystine-deprived media was normalised to 
that of cells in complete media that was given the arbitrary value of 1. Statistical analysis 
was performed using a Kruskal Wallis non-parametric with Dunn’s post hoc test (p=0.0135). 
Each graph represents the average viability ± standard deviation (SD) of three biological 
replicates. B, 20X phase-contrast images depicting HME-EGFR cells cultured in complete 
media (top left), in cystine-deprived media (top right), in cystine-deprived media 
supplemented with 1μM idebenone (bottom left) and in cystine-deprived media 
supplemented with 30μM α-tocopherol (bottom right).  
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3.3.2 HME cells experience activation of a nutrient stress response and loss of 
intracellular cystine levels following deprivation of cystine.  
Having established that ROS was generated within confluent HME-EGFR 
cells when cystine is absent from the growth media, and was associated with the 
induced cell death, it was therefore important to determine if the intracellular levels of 
cystine corresponded to the deprivation of the nutrient from the growth media. To 
address this question, I deprived cells of cystine and performed an immunoblotting 
experiment to detect induction of GCN2 phosphorylation, a general sensor of amino 
acid depletion which becomes activated when phosphorylated (Hinnebusch, 2005). 
Both wild-type and EGFR mutant HME cells, demonstrated strong activation of 
GCN2 that peaked at 4h and remained high until after 20h later (Figure 3.6 A), 
indicating that the two cell lines responded to cystine deprivation in a similar way.  
In these experiments the steady state levels of cystine levels were also 
measured using liquid chromatography–mass spectrometry (LC-MS), showing that 
the basal levels of this amino acid within wild-type and EGFR mutant HME cells were 
similar and declined equivalently following extracellular cystine depletion (Figure 
3.6B).  
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Figure 3.6 Culture of HME cells in the absence of cystine stimulates GCN2 and results 
in loss of the intracellular cystine pool.  
A, immunoblot analysis of phosphorylated GCN2 in wild-type HME and HME-EGFR cells 
cultured in complete or cystine-deprived media for 1h, 4h and 20h, B, Amino acid analysis of 
steady-state levels of cystine, measured by LC-MS in wild-type and EGFR (delE746-A750) 
cells cultured in complete media (grey bars) or media lacking cystine (black bars) for 8 
hours. Bar plots represent the average values ± standard deviation (SD) of three biological 
replicates with the viability in complete media for wild-type HME cells assigned the arbitrary 
value of 1. Statistical analysis comparing differences between complete and cystine deficient 
media was performed using a student’s T-test. Amino acid analysis with LC-MS was 
performed by Dr Christiaan Labuschange. 
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3.3.3 Depletion of glutathione pools occurs due to cystine restriction. 
Having established that levels of cystine within cells decline in response to 
deprivation of cystine and that ROS accumulation occurs, it was therefore important 
to determine whether this was occurring as a result of decreased glutathione levels. 
To achieve this aim I examined the total levels of glutathione within cultures of wild-
type and HME-EGFR cell lines. Basal levels of total glutathione, and of both reduced 
(GSH) and oxidised glutathione (GSSG) were found to be higher in HME-EGFR cells 
compared to wild-type cells (Figure 3.6). Cystine deprivation however decreased the 
levels of glutathione to a similar degree in both cell types following 8h and 12h 
culture under these conditions. With respect to GSSG, while HME-EGFR cells 
initially had increased levels compared to wild-type HME cells, by 8h of culture in the 
absence of cystine the levels declined equivalently. Thus, decreased levels of 
glutathione are unlikely to be the cause of increased ROS production associated with 
cell death in HME-EGFR cells following cystine depletion. 
As a positive control to affect glutathione depletion, I treated cells with BSO a 
potent inhibitor of γ-glutamylcysteine synthetase (Griffith and Meister, 1979). 
Treatment of both cell types in complete media with BSO for 12 h decreased 
equivalently the levels of all glutathione pools to levels similar to those observed in 
cells cultured under conditions of cysteine deprivation (Figure 3.7). To investigate 
whether loss of the glutathione pools explained the cell death resulting from cystine 
depletion I assayed cell viability following BSO treatment. However, despite the 
similarity between BSO and cystine deprivation in affecting the levels of the 
glutathione pool (Figure 3.7), treatment with BSO failed to induce cell death of either 
wild-type or HME-EGFR cells after 24h of treatment (Figure 3.8, panel A).   
Moreover, BSO also failed to induce accumulation of total or lipid-associated ROS in 
  
108 
either cell type (Figure 3.8, panels B and C). These data therefore indicate that the 
effect of cystine deprivation on glutathione levels is unlikely to be the causative agent 
inducing cell death of HME-EGFR cells. 
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Figure 3.7 Cystine deprivation induces equivalent glutathione depletion in wild-type 
and HME-EGFR cells.  
Total, reduced and oxidised glutathione in confluent cultures of wild-type HME (WT, dark 
grey bars) and HME EGFR cells (black bars) investigating the effect of cystine deprivation. 
A, bar graph of total glutathione levels (GSH+2GSSG). B), bar graph of reduced glutathione 
(GSH) levels. C, bar graph of oxidised glutathione (GSSG) levels. Measurements were 
performed on cells cultured in complete media for 12 hours (Complete) or in media lacking 
cystine for 8 and 12 hours. As a positive control BSO (200M for 12h h) was added to cells 
cultured in complete media, and measurement of the glutathione pool performed. 
Measurements are mean ±SD of three biological replicates. Statistical analysis was 
performed using a two-way ANOVA with a Bonferroni post hoc test.  
  
110 
 
Figure 3.8 BSO treatment does not induce cell death nor induce total or lipid ROS, 
unlike deprivation of cystine. 
A, viability of wild-type HME cells (gray bars) and HME-EGFR cells (black bars). Viability of 
cells cultured for 24 hours in complete media (light bars), or media lacking cystine or 
complete media containing 200μM BSO (BSO) for 24 h with viability measured using 
CellTitre Glo. Bar plots represent the average values ± standard deviation (SD) of three 
biological replicates with the level in complete media assigned the arbitrary value of 1. B, 
FACS analyses of total ROS; and C, FACS analyses or lipid ROS in wild-type (left) and 
HME-EGFR (right) cells cultured in complete (black traces) or media lacking cystine for 12h 
(light grey) or complete media following treatment with BSO (dark grey).  
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3.4 Deprivation of cystine induces cell death by ferroptosis.  
3.4.1 Ferrostatin and Deferroxamine protect HME-EGFR cells from cystine 
deprivation-induced cell death unlike the pan-caspase inhibitor z-VAD-fmk. 
The requirement for cystine to regulate oxidative stress suggested that HME-
EGFR cells may undergo ferroptosis, an iron-dependent form of non-apoptotic cell 
death (Dixon et al., 2012). Ferroptosis is an oxidative type of cell death that occurs 
due to accumulation of lipid peroxides via a process that requires the presence of 
iron (Dixon et al., 2012). The significance of iron may be attributed to its role of in the 
Fenton reaction and its chelation is sufficient to prevent induction of lipid 
peroxidation(Yang and Stockwell, 2008). Additionally, an inhibitor of ferroptosis, Fer1 
has been developed (Dixon et al., 2012). Fer1 is a potent radical trapping antioxidant 
when present in phospholipid membranes that can react with and neutralise lipid 
peroxides, thereby acting as an inhibitor of ferroptosis (Zilka et al., 2017). This 
hypothesis is strengthened by observations that HME-EGFR cells accumulate lipid 
ROS following cystine deprivation (Figure 3.4).  
The notion that ferroptosis is the modality of cell death was tested by culturing 
HME-EGFR cells in the presence of the iron chelator Deferroxamine (DFO) or Fer1 
under conditions of cystine deprivation. The presence of these compounds fully 
rescued HME-EGFR cells from cystine deprivation-induced cell death (Figure 3.9 A). 
In contrast, treatment of HME-EGFR cells with Z-VAD-FMK, a broad-spectrum 
caspase inhibitor that can effectively inhibit apoptosis (Cain et al., 1996; Cohen, 
1997), had no effect on cell death induced by cystine deprivation. Importantly, 
treatment of HME-EGFR cells with Z-VAD-FMK rescued staurosporine (STS)-
induced apoptotic cell death (Figure 3.9 B). Next, I investigated the effects of DFO 
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and Fer1 on cysteine deprivation-associated lipid peroxidation. Figure 3.9 C shows 
that treatment of cells DFO and Fer1 blocks the formation of lipid ROS in HME-
EGFR cells under conditions of cystine deprivation. Taken together, rescue from cell 
death, and inhibition of lipid ROS accumulation by DFO and Fer1 treatment strongly 
suggests that cystine deprivation of these cells results in induction of ferroptosis. 
This phenomenon was not isolated to just HME-EGFR cells, but extended to the 
other hTERT-HME1 cell lines used in this study as Fer1 also provided protection 
against the variable loss of viability resulting from cystine deprivation of these cells 
(Figure 3.10). 
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Figure 3.9 DFO and Fer1 protect HME-EGFR cells from cell death and generation of 
lipid ROS.  
A, viability of HME-EGFR cells. Bar plots are average viability ± SD cells cultured in 
complete media (grey bars, DMSO assigned an arbitrary value of 1) or media lacking cystine 
for 24 hr (black bars) in the presence of DMSO as a control or DFO (100µM), Fer1 (2µM), or 
z-VAD-FMK (50µM). Statistical analysis was performed using a two-way ANOVA with a 
Bonferroni post hoc test. n = 3 per each group. B, viability of HME-EGFR cells. Bar plots are 
average viability ± SD cells cultured in control media with DMSO as a positive control (black 
bar, assigned an arbitrary value of 1) or 1μΜ of STS in untreated or pre-treated cells with 
50μM z-VAD-FMK. Statistical analysis was performed using a Kruskal Wallis non-parametric 
test with a Dunn’s post hoc test. n = 3 per each group. C, lipid ROS in HME-EGFR cells. Left 
histogram shows an overlay of cells cultured in complete (black) or media lacking cystine 
(grey) for 12 hr. On the right histogram all cells were grown in media lacking cystine in the 
absence (grey) or presence of DFO (100µM, red line) or Fer1 (2µM, blue line) for 12 hr. 
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Figure 3.10 The variable loss of viability in HME cell lines following cystine depletion 
occurs by ferroptosis.  
Cell viability of all HME1 cell lines in complete or cystine depleted media in the presence or 
absence of Fer1. Bar plot represents the average viability ± SD of cells normalised to the 
average viability of each cell line in complete media being 1. Viability was measured using 
the CellTitre-Glo assay. 
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3.4.2 Treatment with Erastin induces a similar differential loss of viability in 
HME-EGFR cells as cystine deprivation. 
  Erastin is a small molecule inhibitor that has been shown to induce ferroptosis 
in RAS mutant cell lines (Dixon et al., 2012). Despite being originally identified as an 
inhibitor of VDAC2 and VDAC3 (Yagoda et al., 2007), erastin is now thought to act 
primarily by inhibiting cystine uptake via the Xc system, a cystine/glutamate-
antiporter (Dixon et al., 2012). Thus, I reasoned that erastin treatment should act 
equivalently to artificial removal of cystine from the cell culture media and lead to 
selective loss of viability of HME-EGFR cells. I treated both wild-type HME and HME-
EGFR cells with erastin in normal media and measured cell viability. Erastin 
treatment led to a greater than 70% loss of viability in HME-EGFR cells, but did not 
cause any loss of viability in wild-type HME cells (Fig 3.11A). Moreover, HME-EGFR 
cells could be protected from loss of viability following either cystine deprivation and 
erastin treatment when supplemented with Fer1 (Figure 3.11). Thus, either blockade 
of cystine import or depletion of cystine from the cell culture media leads to a 
selective loss of viability of HME-EGFR cells. 
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Figure 3.11 Erastin induces a differential ferroptotic response in HME-EGFR cells.  
A, viability of wild-type HME (WT, gray bars) or HME-EGFR (black bars) cells. Bar plots 
represent the average viability ± SD cells cultured in normal media, media lacking cystine or 
normal media with Erastin (2.5μg/ml) for 24 hr in the presence or absence of Fer1. Viability 
was measured using the CellTitre-Glo assay and viability was normalised to the average 
viability of cells in complete media. Statistical analysis was performed using a two-way 
ANOVA with a Bonferroni post hoc test. n = 3 per each group. B, 20X phase-contrast images 
depicting wild-type (left) and HME-EGFR cells (right) cultured in complete media, in cystine-
deprived media or normal media with Erastin for 24 hr in the presence or absence of Fer1. 
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3.4.3 Loss of intracellular cysteine leads to ferroptosis  
 The previous section showed that inhibition of Xc- system-mediated uptake of 
cystine using erastin generates a similar effect to deprivation of cystine from the 
growth media, with marked ferroptosis being observed in cultures of HME-EGFR 
cells. Although intracellular cystine is required for GSH synthesis, lack of GSH is not 
the cause of ferroptosis in these cells as shown in Figure 3.8. Nevertheless, cystine 
deprivation does cause reduction in intracellular cystine levels (Figure 3.6B), 
suggesting that cystine itself is required to prevent ROS formation, and that cysteine, 
generated by thioredoxin (TRX)-mediated reduction of cystine (Mandal et al., 2010a), 
is responsible for mediating this prevention. To test this hypothesis, I used auranofin, 
an inhibitor of TRX reductase (Gromer et al., 1998). Treatment of HME-EGFR cells 
with 1μΜ auranofin or 200M BSO had no effect on cell viability or induction of lipid 
peroxidation (Figure 3.12). However,  when combined, these two compounds 
induced ferroptosis in HME-EGFR cells to a similar extent as is observed under 
conditions of cystine deprivation, with viability of cells being reduced and 
accumulation of lipid peroxides being evident (Figure 3.12)  The next experiment 
involved pre-treatment of HME-EGFR cells with BSO to effectively diminish GSH 
levels, then adding either Erastin or S-4-PG, two inhibitors of the Xc- system, or 
culturing the cells under conditions of cystine deprivation. In all cases, prior inhibition 
of GSH synthesis with BSO resulted in accelerated cell death (Figure 3.13). Taken 
together, these data demonstrate the central importance of cysteine within cells, 
acting to counteract either directly or as a precursor to GSH synthesis the formation 
of lipid peroxides that cause ferroptosis.  
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Figure 3.12 BSO and auranofin act synergistically to induce loss of reductive cysteine 
and lead to ferroptosis. 
 A, viability of HME-EGFR cells following 18h of DMSO (grey bars) or BSO (200μM, black 
bars). Bar plots represent the average viability ± SD cells cultured in complete media, media 
lacking cystine for 24h and complete media with auranofin (1μM) for 24 hr. Viability was 
measured using the CellTitre-Glo assay and normalised to the average viability of cells in 
complete untreated media. Statistical analysis was performed using a two-way ANOVA with 
a Bonferroni post hoc test. n = 3 per group. B, corresponding lipid ROS in HME-EGFR cells 
with the same treatments. Panels 1-3 show histograms of complete media (black) overlaid 
against cystine deprived media (gray) or single treatment histograms of BSO-treated cells 
(green) or auranofin-treated cells (blue). Panel 4 show a histogram overlay between mono-
treatment of cells with auranofin (blue) or double-treatment with BSO and auranofin together 
(red). 
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Figure 3.13 HME-EGFR cells undergo rapid ferroptosis after deprivation of cystine or 
inhibition of XC- mediated cystine uptake when glutathione is diminished.  
A, viability of HME-EGFR cells following pre-treatment with DMSO (grey bars) or 200μM 
BSO (black bars) for 24h. Bar plots represent the average viability ± SD cells cultured in 
complete media, media lacking cystine for 36h or 12h and complete media with Erastin 
(2.5μg/ml) or S4PG (100μM) for 12 hr. Viability was measured using the CellTitre-Glo assay 
and viability was normalised to the average viability of cells in complete untreated media. 
Statistical analysis was performed using a two-way ANOVA with a Bonferroni post hoc test. 
n = 3 per each group. 
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3.4.4 Glutaminolysis is not involved in ferroptosis occurring in HME-EGFR  
Previous reports have indicated an important role for Gln and glutaminolysis 
in the process of ferroptosis  (Gao et al., 2015). Measurement of glutamine and 
glutamate in order to determine if glutaminolysis was contributing to the induction of 
cystine deprivation cell death as is reported(Gao et al., 2015) showed that 
intracellular levels of the former were equivalent and unaffected by deprivation of 
cystine, whereas levels of the latter seemed to increase under these conditions 
(Figure 3.14).  This increase in glutamate is likely due to the inhibitory effects that 
cystine deprivation has on the Xc- (Bannai, 1984). Taken together, these data 
indicate that glutaminolysis is not affected by cystine deprivation in the HME-EGFR 
cells used and is therefore unlikely to contribute to ferroptosis. Instead, a rapid loss 
of intracellular cystine is observed and is responsible for the induction of the ISR 
through GCN2 activation.  
 
  
122 
 
Figure 3.14 Steady state levels of Gln and Glu do not suggest involvement of 
glutaminolysis in modulation of ferroptosis in HME cells.  
Amino acid analysis of steady-state levels of glutamine (A) and glutamate (B) measured by 
LC-MS in wild-type HME and EGFR (delE746-A750) cells cultured in complete media (grey 
bars) or media lacking cystine (black bars) for 8 hours. Bar plots represent the average 
values ± standard deviation (SD) of three biological replicates with the viability in complete 
media for wild-type HME cells assigned the arbitrary value of 1. Statistical analysis 
comparing differences between complete and cystine deficient media was performed using a 
Student’s T-test. Amino acid analysis with LC-MS was performed by Dr Christiaan 
Labuschange. 
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3.5 Conclusions 
This chapter reports the finding that cystine is essential for survival of HME 
cells with an activating EGFR mutation. This finding is the result of a viability screen 
whereby wild-type HME or EGFR-, BRAF-, KRAS- and PI3K-mutant HME cells were 
grown in media lacking individual amino acids. All of the cell lines used 
demonstrated some loss of viability following removal of cystine from growth media, 
but the cell lines containing EGFR and BRAF mutations were most sensitive to this 
condition. However, when allowed to grow to confluence, only the EGFR mutant 
HME cells remained fully sensitive to cystine deprivation. 
Confirmation of the essential requirement of HME- EGFR- cells for cystine 
was achieved in experiments titrating the addition of this amino acid to growth media. 
These experiments showed a requirement for a minimal concentration of 2M L-
cystine that could not be rescued with the D-cystine. This result shows that HME-
EGFR cells have a specific requirement for L-cystine. This is likely due to the 
stereoselectivity of the Xc- system transporter for L-cystine and not its enantiomer, D-
cystine. 
Cystine taken up by cells is reduced to cysteine for biosynthetic purposes 
(Bannai and Kitamura, 1980). To determine if the ISR is induced following restriction 
of cystine I measured the phosphorylation of GCN2, the EIF2AK4 that senses loss of 
individual amino acids and activates phosphorylation of eIF2α (Hinnebusch, 2005), 
and found that both cell lines experience similar levels of kinase activation and 
thereby presumably similar levels of intracellular cystine depletion. This conclusion 
was further strengthened using LC-MS to quantify the intracellular levels of cystine, 
which did not differ significantly and declined equivalently after deprivation of cystine.  
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The majority of intracellular cysteine is utilised by cells primarily for 
glutathione synthesis, and only a smaller proportion is incorporated into proteins (Lu, 
2013). To address if the differential response observed in EGFR-HME1 cells is due 
to lower levels of glutathione following cystine deprivation, I measured the levels of 
reduced and oxidised glutathione. My results demonstrate that wild-type and EGFR-
HME1 cells experience a similar decrease in their total levels of glutathione when 
they are cultured in the absence of cystine. However, induction of cell death in HME-
EGFR cells is not the result of reduced glutathione levels alone because 
pharmacological inhibition of glutathione synthesis (with BSO) was ineffective in 
killing cells despite inducing loss of the glutathione pool. These results suggest that 
HME-EGFR cells require cysteine/cystine to compensate for loss of glutathione in 
the maintenance of their survival.  
Glutathione in cells is responsible for opposing ROS (Lu, 2013). Thus, cell 
lines generating increased levels of ROS will be sensitive to decreased glutathione 
levels. Analysis of wild-type HME and HME-EGFR cells showed increased 
comparative levels of total ROS as well as lipid peroxides, a secondary product of 
ROS that affects membrane lipids, in the latter. The probable role of ROS in the loss 
of viability induced in EGFR-HME1 cells by cystine deprivation was confirmed in 
experiments where addition of ROS scavengers, compounds that neutralise 
produced oxygen radicals, protected the cells from the death response. Taken 
together, these observations indicate that uncontrolled oxidative stress is the 
underlying cause of loss of viability.  
Ferroptosis is an iron-dependent regulated form of necrotic cell death that 
results from the accumulation of lipid peroxidation in cell membranes. Characteristic 
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features of this mechanism of cell death are a requirement for cystine and a 
phenotype of lipid ROS accumulation. HME-EGFR cells cultured in the absence of 
cystine show evidence of oxidative stress, suggesting that they undergo ferroptosis. 
To confirm this hypothesis experiments were carried out testing the effects of the 
ferroptosis-selective inhibitor Fer1 and the iron chelator DFO. Culture of HME-EGFR 
cells with these inhibitors protected them from accumulation of lipid peroxides and 
subsequent loss of viability under conditions of cystine deprivation, whereas 
treatment with z-VAD-fmk, an inhibitor of caspase-mediated apoptosis had no effect. 
Further evidence of ferroptosis was provided using Erastin, a compound that 
effectively blocks the Xc- system, a cystine-glutamate antiporter that transfers cystine 
inside cells in exchange for intracellular glutamate. (Dixon et al., 2012). Treatment of 
wild-type and HME-EGFR cells with Erastin induced a selective cell death response 
undistinguishable from that observed under conditions of cystine deprivation. Finally, 
I confirmed that cystine itself is the important component that protects cell from 
ferroptosis acting either as a precursor of GSH or in combination with thioredoxin 
when GSH synthesis is impaired. Moreover, measuring intracellular levels of 
glutamine and glutamate that again did not differ between the two cells lines I was 
able to rule out any possible involvement of glutaminolysis in ferroptosis as other 
reports had suggested (Gao et al., 2015).   
In summary, the results presented in this chapter indicate that loss of cystine 
induces a ferroptotic cell death response in HME-EGFR cells. This observation could 
be extended to the other hTERT-HME1 cell lines to different degrees because Fer1 
treatment also inhibited the variable loss of viability under cystine deprivation 
conditions in all HME cell lines tested. The striking feature of my findings is the 
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exquisite sensitivity of HME-EGFR cells to cystine deprivation, suggesting that the 
constitutive signals generated by the mutant EGFR (delE746-A750) endow a 
selective requirement for cystine. The next chapter of this thesis investigates the 
elements of this signalling pathway with the aim of determining why HME-EGFR cell 
survival depends upon cystine.  
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4. CHAPTER 4: EGFR SIGNALLING SENSITISES CELLS TO FERROPTOSIS. 
4.1 Introduction 
In the previous chapter I identified an active requirement for the amino acid 
cystine in maintaining viability of hTERT-immortalised HME cells expressing a 
mutationally-active EGFR oncoprotein. The EGFR protein is member of a receptor 
tyrosine kinase (RTK) protein family that transduces extracellular signals resulting in 
intracellular responses of cells (Pines et al., 2010). Activation of EGFR under 
physiological conditions is dependent upon the presence of ligands such as EGF or 
TGF-α. Ligand binding leads to receptor dimerization allowing cross-phosphorylation 
of tyrosine residues within the EGFR intracellular domains (Seshacharyulu et al., 
2012). Activated receptors then trigger multiple downstream signalling cascades 
including activation of the MAPK and PI3K-AKT pathways (Figure 4.1) (Raymond et 
al., 2000).  
In the cell system studied in this thesis, the mutation that was introduced in 
the EGFR gene is deletion of exon 19, which is the most common EGFR mutation 
found in NSCLC, followed by an exon 21 mutation, L858R (Shigematsu and Gazdar, 
2006). Both mutations lead to an active protein kinase that is not strictly dependent 
upon ligand binding for activity, although retaining some responsiveness to EGF 
binding (Greulich et al., 2005). Response to EGFR signalling inhibition in cell lines of 
NSCLC origin is dependent on activation of MAPK and AKT pathways highlighting 
their importance in EGFR-driven oncogenesis (Ono et al., 2004).  
Since the presence of a mutant EGFR allele sensitises HME cells to 
ferroptosis it became pertinent to inhibit EGFR and its downstream targets and 
determine whether this response was strictly dependent upon EGFR activation. Such 
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an approach would allow me to determine the mechanism through which the 
presence of an EGFR mutation determines sensitivity to ferroptosis. To block EGFR 
signalling I used gefitinib, an FDA-approved EGFR-inhibitor for the management of 
NSCLC (Baselga and Averbuch, 2000). Gefitinib can inhibit both wild-type and 
mutant (delE746-A750 and L858R) EGFR by binding to the ATP-binding cleft (Yun et 
al., 2007). Gefitinib has demonstrated clinical efficacy in the treatment of NSCLC 
with EGFR mutations, particularly those patients with EGFR deletions of exon 19 
(Paez et al., 2004; Riely et al., 2006).  
To determine if the signals that confer sensitivity are mediated through the 
MAPK signalling cascade I selected selumetinib, an allosteric ATP-non-competitive 
MEK inhibitor that blocks downstream activation of ERK (Yeh et al., 2007). To inhibit 
activation of PI3K I employed wortmannin an inhibitor that acts by covalently binding 
to the active site of the catalytic subunit of PI3K (Arcaro and Wymann, 1993; 
Wymann et al., 1996).  
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Figure 4.1 Schematic representation of EGFR pathway and its downstream pathways 
PI3K and MAPK pathway.  
Following interaction with its ligand, EGF, the EGFR dimerises facilitating cross-
phosphorylation of specific tyrosine residues within the intracellular domain. Activated EGFR 
signalling can lead to activation of the MAPK pathway via the signalling cascade of RAS-
RAF-MEK-ERK, or activation of the AKT pathway through activation of PI3K. To identify the 
downstream components of this signalling pathway that confer sensitivity to ferroptotic cell 
death three different inhibitors were used. Gefitinib (Iressa) which inhibits the kinase activity 
of the EGFR itself; selumetinib which inhibits the MAPK pathway via inhibition of MEK, and 
wortmannin which inhibits activation of the AKT pathway by blocking the catalytic activity of 
PI3K. 
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4.2 Inhibition of EGFR-mediated MAPK activation rescues cells from 
ferroptosis. 
The first step in understanding the mechanism whereby constitutively active 
EGFR signalling drives sensitivity to ferroptosis was through inhibition of the 
downstream signalling pathways. To determine the effectiveness of gefitinib, 
selumetinib and wortmannin, respective inhibitors of EGFR, MEK and PI3K within 
the EGFR-induced signalling pathway, an immunoblotting experiment was performed 
after treatment of HME-EGFR cells. Treatment of HME-EGFR cells with 1M 
gefitinib for 30 hours effectively blocked phosphorylation of EGFR and downstream 
phosphorylation of ERK1/2 (Fig. 4.2A). Surprisingly, phosphorylation of AKT was 
unaffected by treatment of the cells with gefitinib but was blocked when cells were 
treated with 1μM wortmannin suggesting that AKT activation in HME-EGFR cells is 
independent of EGFR activity. Finally, treatment of HME-EGFR cells with 5μM 
selumetinib effectively inhibited ERK1/2 phosphorylation. Similar results were 
obtained when HME-EGFR cells were cultured in the absence of cystine for 12h, 
with the exception that ERK1/2 phosphorylation was enhanced following deprivation 
of cystine. Taken together, these data demonstrate that gefitinib, selumetinib and 
wortmannin are effective inhibitors of their respective targets within HME-EGFR 
cells. 
These inhibitors were then tested to investigate their effect upon cystine 
deprivation-induced ferroptosis. Ferroptosis of HME-EGFR cells was reversed when 
the cells were pre-treated with gefitinib and, to a lesser extent, selumetinib for a total 
of 30 hours (Figure 4.2 B). In contrast, the PI3K inhibitor wortmannin did not inhibit 
ferroptosis, following cystine deprivation (Figure 4.2 B). Taken together with 
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observations showing that HME-EGFR cells are particularly sensitive to cystine 
deprivation compared to wild-type HME cells, these observations indicate that 
constitutive signals from EGFR to the MAPK pathway play a critical role in 
ferroptosis when the availability of cystine is restricted. In contrast, the PI3K pathway 
appears not to be involved in promoting sensitivity to ferroptosis in these cells.  
The rescuing effect following sustained gefitinib or selumetinib treatment was 
also observed in control of cellular morphology. By phase-contrast microscopy HME-
EGFR cells pre-treated with the EGFR or MEK inhibitors appeared flattened and 
demonstrated more well-defined cell-cell borders (Fig. 4.3). Following deprivation of 
cystine cells treated with DMSO and wortmannin demonstrated features of 
ferroptosis as observed previously, with swollen plasma membranes and condensed 
nuclei. In contrast, cells in which the MAPK pathway was inhibited by prior treatment 
with selumetinib did not undergo ferroptosis and cells remained flattened with well-
defined cell-cell borders as observed by phase-contrast microscopy (Fig. 4.3, bottom 
right panel).  
In Chapter 3 I showed that cystine deprivation increased ROS levels within 
cells, particularly lipid ROS. To investigate the role of MAPK pathway in generating 
ROS a flow cytometry experiment was performed. Pre-treatment of HME-EGFR cells 
with gefitinib and selumetinib blocked the formation of total ROS (Figure 4.4) and 
lipid ROS (Figure 4.5) in cells cultured under conditions of cystine deprivation in 
HME-EGFR cells. In contrast, inhibition of PI3K with wortmannin had no effect on 
induction of total ROS or lipid ROS in HME-EGFR cells. These results suggest a 
critical role for the MAPK pathway in generating ROS involved in the process of 
ferroptosis in these cells.  
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Figure 4.2  Inhibition of EGFR signalling in HME-EGFR cells.  
HME-EGFR cells were cultured in complete media (Complete) or media lacking cystine (-
Cys) for 12h in the presence of DMSO, 1μM Gefitinib, 1μM Wortmannin, or 5μM Selumetinib 
added for a total of 30h. A, immunoblot analysis of HME-EGFR cell lysates probed to detect 
phosphorylated EGFR, AKT, and ERK. B, viability assay examining the effect of the 
indicated inhibitors following deprivation of cystine for 24h. Each bar represents mean ± SD 
of three biological replicates of cells cultured in complete media (grey bars) or media lacking 
cystine for 24 hr (black bars). All measurements are expressed relative to the viability of 
HME-EGFR cells grown in complete media (assigned the arbitrary value of 1). Statistical 
analysis was performed using a 2-way ANOVA test with a Bonferroni’s post hoc comparing 
each treatment effect following cystine deprivation with the DMSO treated control. 
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Figure 4.3 Inhibition of EGFR and MAPK signalling in HME-EGFR cells protects cells 
from ferroptosis and induces morphological changes.  
20X phase-contrast images showing HME-EGFR cells cultured in complete media 
(Complete, left panels) or media lacking cystine for 24 hr (No Cys, right panels) following 
treatment with DMSO control or inhibitors 1μM Gefitinib, 1μM Wortmannin, or 5μM 
Selumetinib for a total of 30h. 
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Figure 4.4 Accumulation of reactive oxygen species is reversed following EGFR and 
MEK inhibition in protects cells from ferroptosis cells.  
FACS analyses of total ROS for HME-EGFR cells cultured in the presence or absence of 
inhibitors (DMSO as control, 1μM Gefitinib, 1μM Wortmannin, 5μM Selumetinib, with cells 
treated for a total of 30h using the DCFDA probe (10μM) and detected using the BL1 
channel. Each histogram shows the spread of a population of minimum 5000 events of cells 
cultured in complete medium (black graphs) or in medium lacking cystine (grey outline) for 
12h. 
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Figure 4.5 Lipid ROS is attenuated following treatment of cells with Gefitinib and 
Selumetinib.  
FACS analyses of lipid peroxides in HME-EGFR cells cultured for 12h in complete medium 
(black graphs) or in medium lacking cystine (grey outline) prior to using the C11 probe (2μM) 
and flow cytometry to detect lipid peroxides. Each panel represents overlaid histogram plots 
to show the effects of treatment with DMSO, 1μM Gefitinib, 1μM Wortmannin and 5μM 
Selumetinib for a total of 30h. 
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To further substantiate the association between inhibition of MAPK signalling 
and resistance to ferroptosis three additional MEK inhibitors (U0126, PD184352, 
PD0325901) and two inhibitors of ERK1/2 (GDC-0994, SCH772984) were also 
tested for their effect on rescuing cell viability and inhibiting ROS accumulation 
following cystine deprivation of HME-EGFR cells. The effectiveness of these 
inhibitors was first evaluated by Western blot analysis using phosphorylation of RSK 
as a readout, as RSK is a known downstream target of ERK1/2 (Yoon and Seger, 
2006). All the inhibitors tested, including gefitinib and selumetinib, effectively blocked 
phosphorylation of RSK by ERK1/2 (Figure 4.6 A). Next, I used these inhibitors in 
cell viability assays. All inhibitors of MEK or ERK1/2 effectively inhibited ferroptotic 
cell death following cystine deprivation in HME-EGFR cells (Figure 4.6 B, C). These 
inhibitors also blocked both total (Figure 4.7) and lipid ROS (Figure 4.8) following 
cystine deprivation. Taken together, these results point to a critical role of active 
MAPK kinase pathway signalling in the cell death mechanism induced in HME-EGFR 
cells when cells are deprived of cystine. 
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Figure 4.6 Inhibition of MEK and ERK signalling HME-EGFR cells.  
HME-EGFR cells were cultured in normal media or media lacking cystine (No Cys) in the 
presence of inhibitors (DMSO as control, 1μM Gefitinib, 5μM Selumetinib, 10μM U0126, 
10μM PD184352, 1μM PD0325901, 5μM GDC-0994, 5μM SCH77294) for a total of 30h A, 
immunoblot analysis of HME-EGFR cell lysates probed to detect phosphorylated RSK with 
total RSK detected as a loading control. B, viability assay examining the effect of the 
indicated inhibitors using the Cell-titre Glo assay. Each bar represents mean ± SD of three 
biological replicates of cells cultured in complete media (grey bars) or media lacking cystine 
for 24 hr (black bars). All measurements are expressed relative to the viability of HME-EGFR 
cells grown in complete media (assigned the arbitrary value of 1). Statistical analysis was 
performed using a 2-way ANOVA test with a Bonferroni’s post hoc C, 20X phase-contrast 
images showing HME-EGFR cells cultured in normal media (Complete, left panels) or media 
lacking cystine for 24 hr (no Cys, right panels) following treatment with the indicated 
inhibitors. 
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Figure 4.7 Accumulation of reactive oxygen species is reversed following MEK and 
ERK1/2 inhibition in HME-EGFR cells.  
FACS analyses of total ROS for HME- EGFR cells cultured in the presence or absence of 
inhibitors (DMSO as control, 10μM U0126, 10μM PD184352, 1μM PD0325901, 5μM GDC-
0994, 5μM SCH77294) for a total of 30h using the DCFDA probe (10μM) and detected using 
the BL1 channel. Each histogram shows the spread of a population of minimum 5000 events 
of cells in complete medium (black graphs) or in medium lacking cystine (grey outline) for 
12h. 
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Figure 4.8 Lipid peroxidation is attenuated following incubation of HME-EGFR cells 
with MEK and ERK1/2 inhibitors.  
FACS analyses of lipid peroxides for HME- EGFR cells cultured in the presence of inhibitors 
(DMSO as control, 10μM U0126, 10μM PD184352, 1μM PD0325901, 5μM GDC-0994, 5μM 
SCH77294) for a total of 30h, measured using the C11 probe (2μM) and detected using the 
BL1 channel. Each histogram shows the spread of a population of minimum 5000 events of 
cells in complete medium (black graphs) or in medium lacking cystine (grey outline) for 12h. 
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4.3 GPX4 modulates sensitivity to ferroptosis following cystine depletion. 
4.3.1 EGFR-mutant cells have impaired oxidation of glutathione  
The results from Chapter 3 suggest that HME-EGFR cells utilise GSH and 
cystine to oppose the effects of increased ROS, a conclusion that is supported by 
data showing that HME-EGFR cells cultured in complete media have higher levels of 
oxidised GSH (GSSG) than do wild-type HME cells (Figure 3.7). Considering the role 
of MAPK pathway signals in generating ROS in HME-EGFR cells, it was necessary 
to investigate how this pathway affected glutathione levels.  Measurement of the 
ratio of GSSG/total GSH showed that oxidation of GSH to GSSG occurred faster in 
EGFR cells treated with gefitinib than in cells treated with DMSO control (Figure 4.9). 
This result suggests that MAPK pathway inhibition in HME-EGFR cells led to a more 
efficient oxidation of GSH, which would presumably facilitate increased neutralisation 
of ROS. Therefore, subsequent experiments focused on determining the 
mechanism(s) regulating GSH oxidation. 
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Figure 4.9 Inhibition of EGFR signalling improves oxidation of glutathione.  
HME-EGFR cells in the absence (black, DMSO) or presence (grey) of gefitinib (1μM) for a 
total of 30h were grown in complete media (time 0h) followed by culture in media lacking 
cystine for 4 or 8 hours. Each point represents the mean percentage of oxidised glutathione 
± standard deviation (SD) of three biological replicates.   
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4.3.2 GPX4 expression is downregulated in HME-EGFR cells by active MAPK 
signalling 
Glutathione peroxidases are a family of enzymes that utilise available GSH to 
neutralise ROS, and therefore might potentially play roles in protecting cells from 
ferroptosis (Brigelius-Flohe and Maiorino, 2013). To investigate any role of these 
enzymes in our system, I performed immunoblotting experiments to assess the level 
of expression of the 4 main members of this family (GPX1 – 4) in wild-type and 
HME-EGFR cells (Figure 4.10). Neither cell line expressed detectable GPX2 or 
GPX3. Expression levels of GPX1 were similar between wild-type and HME-EGFR 
cells. However wild-type HME cells expressed around 2.5-fold higher levels of GPX4 
than HME-EGFR cells (Figure 4.10 A). To determine whether reduced GPX4 
expression was a result of elevated EGFR-MAPK signalling I again utilised EGFR 
and MAPK inhibitors. Treatment of HME-EGFR cells with the previously used 
inhibitors showed that GPX4 levels could be restored to levels comparable to those 
detected in wild-type HME cells following gefitinib or selumetinib treatment, but not 
following treatment with wortmannin (Figure 4.10 A). Importantly, such inhibitor 
treatments had no effect on expression of GPX1, whose expression remained 
constant in wild-type and HME-EGFR cells regardless of the inhibitor treatment 
used. Similar restoration of GPX4 expression was also observed when HME-EGFR 
cells were treated with other MAPK (MEK or ERK) inhibitors (Figure 4.10 B). These 
results, together with those generated using gefitinib and selumetinib, suggest that 
activation of the MAPK pathway suppresses the expression of GPX4. 
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Figure 4.10 Inhibition of MAPK pathway increases GPX4 expression.  
A, immunoblot analysis of wild-type HME (WT) and HME-EGFR cells cultured in the 
presence of inhibitors (DMSO as control, 1μM Gefitinib, 1μM Wortmannin, 5μM Selumetinib) 
for a total of 30h. Cell lysates were probed for GPX1, GPX2 and GPX4. ERK1/2 was used 
as a loading control and a mouse liver sample as a positive control.  B, immunoblot analysis 
of HME-EGFR cell lysates probed for GPX4 in HME-EGFR cells the presence or absence of 
inhibitors (DMSO as control, 1μM Gefitinib, 5μM Selumetinib, 10μM U0126, 10μM 
PD184352, 1μM PD0325901, 5μM GDC-0994, 5μM SCH77294) for a total of 30h. ERK1/2 
was used as a loading control. Quantification for both panels was performed using Image J 
and the ratio of GPX to HME-EGFR cells treated with DMSO was taken as an arbitrary value 
of 1. Immunoblot experiment in panel A was performed by Ms. Xiaomeng Wang.  
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4.3.3 Suppression of GPX4 expression reverses the protective effects of EGFR 
signalling inhibition on viability following cystine deprivation. 
That GPX4 expression is negatively regulated by EGFR-MAPK-driven 
signalling is significant because this enzyme is thought to be the only member of the 
GPX family able to detoxify lipid ROS using GSH (Brigelius-Flohe and Maiorino, 
2013). To determine the role of GPX4 within the mechanism protecting wild-type and 
inhibitor-treated HME-EGFR cells from cell death under conditions of cystine 
deprivation, I used siRNA to suppress GPX4 expression. For these experiments 
siRNAs targeting all four GPX proteins were employed, and immunoblotting first 
used to confirm knockdown of the respective GPX proteins. Expression of GPX1 and 
GPX4 were both effectively reduced following transfection of their respective siRNAs 
(Figure 4.11 A). Knockdown of GPX2 and GPX3 could not be measured in HME cell 
lysates because GPX2 is not expressed in these cells, and GPX3 is a secreted 
protein. It is noteworthy that GPX2 siRNA partially reduced expression levels of 
GPX1, presumably due to the high sequence similarity of these two proteins 
(Brigelius-Flohe and Maiorino, 2013). Moreover, downregulation of GPX4, but not 
GPX1, induced accumulation of total and lipid ROS following deprivation of cystine 
(Figure 4.11 B, C). 
Next I used siRNA-treated HME cells in functional experiments measuring cell 
viability. Targeted reduction in expression of GPX enzymes 1-3 did not alter the 
viability of wild-type HME cells following deprivation of cystine (Figure 4.12).  In 
contrast, knockdown of GPX4 in wild-type HME cells sensitised these cells to 
deprivation of cystine, inducing formation of lipid ROS (Figure 4.12 A) resulting in 
loss of viability (Figure 4.12 B). Knockdown of GPX4 also affected HME-EGFR cells 
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cultured under conditions of cystine deprivation that had been previously treated with 
gefintinib (Figure 4.13). These data demonstrate a key role for GPX4 in regulating 
sensitivity of wild-type HME cells to cystine deprivation, where expression of this 
glutathione peroxidase is downregulated through activation of MAPK pathway 
resulting from the constitutively-active mutant EGFR. This conclusion was further 
supported by experiments whereby GPX4 was ectopically overexpressed in HME-
EGFR cells (Figure 4.14). HME-EGFR cells were transfected with a tagged GPX4 or 
control vector and subjected to cystine deprivation. GPX4-transfected cells were less 
sensitive than HME-EGFR cells transfected with an empty vector to cystine 
deprivation, and displayed a response similar to wild-type HME cells (Figure 4.14). 
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Figure 4.11 Knockdown of GPX family members in wild-type HME cells.  
Wild-type HME were analysed 72h after transfection with control non-targeting siRNA (siCtrl) 
or siRNA Smartpools targeting each of the individual GPX proteins (siGPX1-4). A, 
immunoblot analysis of GPX1 and GPX4 after siRNA transfection targeting indicated 
proteins. ERK1/2 was used as a loading control. B, C FACS analyses of total ROS (B) and 
lipid ROS (C) for wild-type HME cells transfected with indicated siRNAs and measured using 
the DCFDA (10μM) and C11 probe (2μM) respectively, detected using the BL1 channel. 
Each histogram shows the spread of a population of minimum 5000 cells in complete 
medium (black) or in medium lacking cystine (grey) for 14h. 
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Figure 4.12 Knockdown of GPX family members in wild-type HME cells.  
A, viability assay for wild-type HME cells following mock transfection or transfection with 
control non-targeting siRNA (siCtrl) or siRNAs targeting each individual of the 4 GPX 
proteins (siGPX1-4) for 72h followed by culture in normal media or media lacking cystine for 
24 hr. Viability of each individual cell line was measured using the Cell-titre Glo assay.  
Results were expressed for each condition separately, with viability in normal media 
assigned the arbitrary value of 1. Each graph represents the average viability ± standard 
deviation (SD) of three biological replicates. B, 20X Phase-contrast micrographs of wild-type 
HME cells following transfection for 72h and culture in media lacking cystine for 24 hr. 
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Figure 4.13 Knockdown of GPX4 in gefitinib-treated HME-EGFR cells induces 
sensitivity to ferroptosis.  
A, viability assay for HME-EGFR cells following mock transfection or transfection with control 
non-targeting siRNA (siCtrl) or siRNAs targeting each individual of the 4 GPX proteins 
(siGPX1-4) for 72h followed by culture in normal media or media lacking cystine for 24 hr. 
Cells were treated with gefitinib (1μM) 24h after transfection. Viability of each individual cell 
line was measured using the Cell-titre Glo assay.  Results were expressed for each 
condition separately, with viability in normal media assigned the arbitrary value of 1. Each 
graph represents the average viability ± standard deviation (SD) of three biological 
replicates. B, 20X phase-contrast micrographs of gefitinib-treated HME-EGFR cells following 
transfection for 72h and culture in media lacking cystine for 24 hr. 
  
150 
 
Figure 4.14 Overexpression of GPX4 in HME-EGFR cells rescues viability.  
A, viability assay for wild-type and HME-EGFR cells transfected with eGFP as a control or 
FSH-GPX4, followed by culture in normal media or media lacking cystine for 24 hr. Viability 
of each individual cell line was measured using the Cell-titre Glo assay.  Results were 
expressed for each condition separately, with viability in normal media assigned the arbitrary 
value of 1. Each graph represents the average viability ± standard deviation (SD) of three 
biological replicates. B, 20X Phase-contrast micrographs of cells cultured in normal media or 
media lacking cystine for 24 hr. Scale bar represents 200μm distance. 
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4.4 Responses of a Non-Small Cell Lung Cancer cell line panel to cystine 
deprivation indicate a general MAPK-driven sensitivity to ferroptosis. 
The cell system used in this study to identify differential response of cells to 
deprivation of individual amino acid nutrients comes with certain limitations. hTERT-
HME cells are diploid immortalised cells and even with an activating mutation in 
EGFR these cells are not oncogenic unlike bone fide cancer cells (Di Nicolantonio et 
al., 2008). It therefore became pertinent to test whether such responses could be 
replicated in cancer cell lines in order to potentially test the efficacy of cystine 
limitation as an anti-cancer therapy. A panel of nine Non-Small Cell Lung Cancer 
(NSCLC) cell lines were selected to further clarify correspondences between EGFR, 
MAPK and sensitivity to ferroptosis due to the presence of EGFR mutations in some 
fraction of NSCLC tumours and cell lines (Shigematsu and Gazdar, 2006) (Table 
4.1).  
Deprivation of cystine appeared to have distinct effects in the cell lines utilised 
(Figure 4.15 A).  The viability of three of the cell lines (Calu-6, H1650, H3255) was 
significantly compromised following cystine depletion, to an extent similar to that 
observed in HME-EGFR cells (Figure 4.15 B). The H1650 and H3255 cell lines both 
have an activating mutation in the EGFR gene, with H1650 having the exon 19 
deletion similar to HME-EGFR cells, and H3255 expressing an exon 20 L858R 
mutant EGFR. On the contrary Calu 6, are wild-type for EGFR but have an activating 
mutation Q61K in the KRAS gene promoting activation of the MAPK pathway (Bos, 
1989). I next sought to investigate the potential biomarkers of sensitivity in these 
NSCLC cell lines. The first rational target to investigate as responsible for the 
observed sensitivity was expression of GPX4. However, lower expression of GPX4 
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in NSCLC cell lines did not appear to correspond to higher sensitivity to cystine 
deprivation (Figure 4.15 C). However, activation of the MAPK pathway, as measured 
by the ratio of ppERK/ERK, did correspond to sensitivity to ferroptosis, and was 
highly elevated in the three most sensitive NSCLC cell lines as well as HME-EGFR 
cells and lower in the most resistant cells (Figure 4.15 C).  
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Table 4.1 List of NSCLC cell lines and their mutational profile and their 
sensitivity to cystine deprivation.  
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Figure 4.15 NSCLC cell lines with elevated MAPK activation are sensitive to 
ferroptosis following deprivation of cystine.  
A, viability assay for indicated NSCLC cell lines cultured in normal media (grey bars) or 
media lacking cystine (black bars) for 48 hr. Viability of each individual cell line was 
measured using the Cell-titre Glo assay.  Results were expressed for each cell line 
separately, with viability in normal media assigned the arbitrary value of 1. Each graph 
represents the average viability ± standard deviation (SD) of three biological replicates. B, 
20X phase-contrast micrographs of responding cell lines Calu6, H1650 and H3255 cultured 
in normal media (Complete, top panels) or media lacking cystine (No Cys, bottom panels) for 
48 hr. C, immunoblot analysis of NSCLC cell lines to detect ERK phosphorylation. Total 
ERK1/2 were detected as a loading control. Ms. Xiaomeng Wang has assisted with the 
immunoblot experiment 
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Given the strong association observed between sensitivity to ferroptosis and 
activation of the MAPK pathway observed in the responding NSCLC cell lines I 
investigated whether treatment with MAPK inhibitors could similarly protect NSCLC 
cells from ferroptosis following cystine depletion. In Calu6 cells which express a 
mutant KRAS oncoprotein I observed significant protection from cell death when 
cells were treated with either MEK and ERK inhibitors, whilst gefitinib treatment was 
without effect (Figure 4.16 A). In H3255 cells however, which express an activating 
L858R mutation in exon 20 of EGFR, viability was strongly protected by both MEK 
inhibitors (U0126 and PD0325901) and gefitinib (Figure 4.16 B). Taken together 
these data indicate that EGFR-MAPK signalling in NSCLC cells can sensitise cells to 
ferroptosis.  
The EGFR-mutant cell lines H1650 that harbours the same EGFR mutation as 
found in HME-EGFR cells (deletion of exon 19) was found to be one of the most 
sensitive NSCLC lines to ferroptosis and additionally displayed the highest MAPK 
activation amongst the NSCLC cell lines tested. H1650 was therefore selected as a 
good candidate to study the effects of EGFR signalling in a cancerous cell line. To 
clarify whether cell death observed in H1650 occurred by ferroptosis, I treated these 
cells alongside HME-EGFR cells with Fer1, an antioxidant inhibitor of ferroptosis 
(Dixon et al., 2012) as well as with a known ROS antioxidant, α-tocopherol. Both 
antioxidants suppressed cell death following cystine depletion, indicating that H1650 
cells, like HME-EGFR cells, underwent ferroptosis following cystine depletion (Figure 
4.17). 
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Figure 4.16 MAPK pathway inhibition reverses ferroptosis in ferroptosis-sensitive 
NSCLC cell lines.  
Viability assays of Calu6 (A), H1650 and H3255 (B) cultured in complete media (grey bars) 
or media lacking cystine for 48 hr (black bars) in the presence or absence of MAPK pathway 
inhibitors (DMSO as control, 1μM Gefitinib, 5μM Selumetinib, 10μM U0126, 10μM 
PD184352, 1μM PD0325901, 5μM GDC-0994, 5μM SCH77294). Each bar plot represents 
mean ± SD of cell viability measured using Cell-titre Glo. Results were expressed for each 
condition separately, with viability in normal media assigned the arbitrary value of 1. 
Statistical analysis was performed using a 2-way ANOVA test and a Bonferroni post hoc test 
between different media of the same inhibitor treatment. 
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Figure 4.17 H1650 response to cystine deprivation is reversed by Fer1 and antioxidant 
α-tocopherol.  
Cell viability assays of HME-EGFR (A) and H1650 (B) following treatment with Fer1 or a-
tocopherol. Each bar plot represents mean ± SD of cells cultured in complete media (grey 
bars) or media lacking cystine in the absence or presence of tocopherol (30μM) and Fer1 
(2μM). All measurements are expressed relative to the viability of HME-EGFR cells grown in 
complete media (assigned the arbitrary value of 1). Statistical analysis was performed using 
a Kruskal Wallis non-parametric test with a Dunn’s post hoc test. 
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4.4.1 The enzymatic degradation of cystine in cell culture media mimics 
cystine depletion and results in ferroptosis.  
A recent paper has described the mutational modification of a human enzyme, 
cystathionine-γ-lyase to create a cysteinase (AECase), an enzyme that can degrade 
and therefore deplete both cysteine and cystine (Cramer et al., 2017). We therefore 
wished to determine whether AECase treatment of cells also resulted in ferroptosis. 
Indeed, treatment of HME-EGFR cells or H1650 cells with AECase, but not its heat-
inactivated form, efficiently killed the majority of both cell lines (by >90%) in a 
manner similar to deprivation of cystine, which was inhibited in the presence of Fer1, 
indicating that cell death occurred by ferroptosis (Figures 4.18 and 4.19). Following 
depletion of cystine, or following addition of AECase, nuclear accumulation of a 
marker of loss of membrane impermeability, Sytox Green, was evident within cell 
nuclei, whilst treatment with the heat-inactivated AECase was without effect (Figure 
4.20).  
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Figure 4.18 AECase induces ferroptosis in HME-EGFR cells.  
A, viability assay for HME-EGFR cells following treatment with AECase. Each bar plot 
represents mean ± SD of cells cultured in complete media or media lacking cystine or media 
containing active or heat-inactivated AECase (125nM) in the absence or presence of Fer1 
(2μM). All measurements are expressed relative to the viability of HME-EGFR cells grown in 
complete media (assigned the arbitrary value of 1). Statistical analysis was performed using 
a Kruskal Wallis non-parametric test with a Dunn’s post hoc test. B, 20X phase-contrast 
micrographs of HME-EGFR cells following culture in complete media or media lacking 
cystine or media containing active or heat-inactivated AECase (125nM) for 24 hr. 
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Figure 4.19 AECase also induces ferroptosis in H1650 cells.  
A, viability assay for H1650 cells following AECase treatment. Each bar represents mean ± 
SD of cells cultured in complete media, media lacking cystine, or normal media containing 
active or heat-inactivated AECase (125nM) in the absence or presence of Fer1 (2μM). All 
measurements are expressed relative to the viability of H1650 cells grown in complete 
media (assigned the arbitrary value of 1). Statistical analysis was performed using a Kruskal 
Wallis non-parametric test with a Dunn’s post hoc test. B, 20X phase-contrast micrographs 
of H1650 cells following culture in complete media or media lacking cystine or media 
containing active or heat-inactivated AECase (125nM) for 24 hr. 
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Figure 4.20 Ferroptosis in H1650 cells leads to loss of plasma membrane integrity.  
Time-lapse 20X phase contrast photographs (Phase) together with epifluorescence capture 
of the non-permeable green fluorescent nuclear dye Sytox Green in H1650 cells cultured in 
media lacking cystine or media containing active or heat-inactivated formulations of AECase 
(125nM) at the indicated times following cystine depletion or enzyme addition.  
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4.4.2 Treatment of a mouse xenograft model with AECase indicates reduction 
of tumour growth associated with ferroptosis 
In order to study the response of tumours in vivo to systemic cystine depletion 
elicited by AECase treatment we employed a mouse xenograft model using 
engrafted ferroptosis-sensitive H1650 cells. Immunocompromised mice were 
inoculated with H1650 cells to form xenograft tumours. Tumours were allowed to 
grow for 18 days prior to treament with two different concentrations of AECase or 
control for 20 days. Tumour growth was found to be significantly retarded in mice 
administered with the AECase enzyme, which also prolonged overall survival of the 
AECase-treated mice (Figure 4.21). To determine if ferroptosis was occuring within 
tumours from the AECase-treated mice, tumour sections were stained for COX2 a 
suggested indicator of ferroptosis (Yang et al., 2014) whilst tumour lysates were 
immunoblotted for COX2. Upregulation of COX2 expression was observed by IHC as 
well as by immunoblotting in AECase-treated tumours (Figure 4.22). These results 
taken together indicate that tumours sensitive to ferroptosis could potentially be 
targeted by modulation of plasma cystine levels using AECase.  
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Figure 4.21 Cyst(e)inase (AECase) administration inhibits tumour growth in a NCI-
NH1650 xenograft mouse model.  
A, increase in tumour volume following i.p. administration of PBS control (dark circles) or 30 
mg/kg (dark squares) or 100 mg/kg (light triangles) AECase. Start and end of treatment 
times are also shown. B, Kaplan-Meier plots of median survival times of PBS- or AECase-
treated tumour-bearing mice. All animal experiments were performed by Ms. Shira L. Cramer 
and Ms. Kendra Triplett in The University of Texas at Austin, TX, USA. 
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Figure 4.22 Induction of COX2 in H1650 xenograft tumours following treatment with 
AECase indicates ferroptosis.  
A, immunoblot analysis of lysates from control (lanes 1–4) or AECase-treated (lanes 5–8) 
H1650 xenograft tumours probed to detect COX2. ERK1/2 was used as a loading control.  B, 
quantification of relative COX2/ERK in control or AECase-treated groups. p = 0.0286; n = 4 
using a student’s t test. C, Images of IHC staining for COX2 in sections from control and 
AECase-treated tumours. Staining was performed and evaluated by Precision Pathology. Ms 
Xiaomeng Wang has assisted with the immunoblot experiment. 
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4.4 Conclusions 
The results presented in this chapter provide an insight on the mechanisms 
through which activation of EGFR and subsequently MAPK pathway sensitises cells 
to ferroptosis. Inhibition of constitutive EGFR signalling using gefitinib was shown to 
be effective in reversing ferroptosis in HME-EGFR cells and blocked the formation of 
lipid ROS. Dissecting the downstream pathways active in the presence of the mutant 
EGFR, I demonstrated that sensitivity to ferroptosis was mediated by activation of 
the MAPK pathway through the RAS-RAF-MEK cascade. In contrast, activation of 
PI3K and its downstream effector AKT was independent of EGFR signalling, and 
appeared irrelevant to ferroptosis sensitivity. Further interrogation of the MAPK 
pathway using distinct MEK and ERK inhibitors yielded similar results and blocked 
cell death and ROS accumulation following deprivation of cystine.  
An increased rate of glutathione oxidation was observed in wild-type HME 
cells and gefitinib-treated HME-EGFR cells that led me to investigate the role of the 
GPX family of enzymes in modulation of glutathione oxidation. Expression of GPX4 
was found to be downregulated in HME-EGFR cells, an effect reversible upon 
inhibition of EGFR and downstream MAPK signalling. Inhibition of expression of 
GPX4 using an siRNA transient knockdown approach effectively sensitised both 
wild-type and gefitinib-treated HME-EGFR cells to deprivation of cystine to a degree 
comparable to untreated HME-EGFR cells. Inhibition of GPX4 expression was also 
shown to induce accumulation of lipid ROS in wild-type HME cells. Finally using a 
reconstitution approach, ectopic expression of GPX4 in HME-EGFR cells increased 
their resistance to ferroptosis following cystine depletion.  
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To establish the potential of nutrient modulation to induce ferroptosis in 
cancer cells I expanded my study to a panel of NSCLC cell lines. In these cells 
sensitivity to ferroptosis did not appear to strictly correlate with the levels of GPX4 
but did show that MAPK activation determined sensitivity to ferroptosis. Inhibition of 
MAPK pathway in two of these cell lines correlated with restoration of cell viability. 
The H1650 cell line, which shares the same mutation as the one found in HME-
EGFR cells, was shown to be sensitive to deprivation of cystine, inducing ferroptosis, 
which could be reversed following addition of Fer1 or tocopherol. 
I have additionally shown that using an enzymatic approach to decrease the 
extracellular levels of cystine successfully induced ferroptosis in both HME-EGFR 
and H1650 cells, cell lines that share the same activating EGFR mutation (exon 19 
deletion). This observation was supported by the ability of AECase to induce cell 
death that was reversible by treatment with a ferroptosis-specific antioxidant Fer1 
and by α-tocopherol. Moreover, incubation of H1650 cells in cystine-deprived media 
or following treatment AECase compromised the integrity of the cell membrane. 
Finally, utilising an in vivo xenograft model provided evidence that cystine depletion 
in vivo could potentially provide a therapeutic benefit in some NSCLC tumours 
sensitive to ferroptosis. Given the previous observations on the importance of MAPK 
activation in determining sensitivity to ferroptosis, my results suggest that tumours 
with a high level of MAPK activation may be particularly good candidates to effect 
cystine depletion in a therapeutic setting.  
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5. CHAPTER 5. STUDYING THE PROPAGATION OF FERROPTOSIS IN HUMAN 
MAMMARY EPITHELIAL CELLS.  
5.1 Introduction 
The initial screen of amino acid sensitivity performed in Chapter 3 established 
that the requirement for cystine varies depending on the mutational status of each 
HME cell line used (Figure 3.1). Interestingly, cell confluence appeared to play an 
important role in rescue from ferroptosis; whereas sub confluent cultures of wild-type 
HME and HME-BRAF cells were as sensitive to cystine deprivation as were HME-
EGFR cells, confluent cell cultures of the former cell types were significantly less so 
(Figure 3.2).  These observations suggested that cell-cell contact may protect 
against ferroptosis in wild-type HME and HME- BRAF cells in a way that it did not in 
HME-EGFR cells.  
These cells take on a characteristic balloon-like morphology during ferroptosis 
that was particularly apparent in confluent cultures of HME-EGFR cells where more 
than 90% of the cells took on this morphology. In contrast, confluent monolayers of 
wild-type HME cells largely appear normal in morphology and only a small proportion 
of dead cells were seen that appeared to accumulate in sporadic foci (see Section 
5.2).   
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5.2 Ferroptosis occurs in a wave like manner. 
Typical representations of the cell death occurring in confluent cultures of 
cystine-deprived wild-type HME and HME-EGFR cells are shown in Figure 5.1A. 
Cells that had undergone ferroptosis exhibit a characteristic balloon-like morphology 
(as indicated by red arrows in both images). Cultures of HME-EGFR cells displayed 
wide-spread cell death, whereas wild-type HME cultures showed more limited 
ferroptosis that seemed to accumulate in specific foci (indicated by the red border) 
that was surrounded by otherwise healthy cells.  
The balloon-like morphology of cells that have undergone ferroptosis 
suggested a loss of plasma membrane integrity. This hypothesis was tested using 
Sytox Green staining. Sytox Green is a membrane impermeable nuclear cell dye that 
indicates cells in which the integrity of the plasma membrane is compromised. Sytox 
Green uptake is a widely used tool to indicate cell death by necrosis using time-lapse 
microscopy (Forcina et al., 2017; Wallberg et al., 2016). Figure 5.1B shows that 
cultures of wild-type HME cells developed sporadic foci of Sytox Green-positive cells 
when deprived of cystine for 72h.  Time-lapse microscopic observation of wild-type 
HME cells showed that foci of Sytox Green-positive cells grew in size with time, with 
increasing numbers of cells adjacent to Sytox Green-positive cells losing membrane 
integrity in an apparent wave-like manner (Figure 5.2). Additionally, cells on the 
wave-front appeared to lose contact both with neighbouring cells and with the 
substratum prior to uptake of Sytox Green (Figure 5.3). Taken together, these data 
suggest that in wild-type HME cells, ferroptosis resulting from cystine deprivation 
occurs sporadically within the monolayer and progresses which is then propagated 
from cell to cell in a progressive, wave-like, manner. 
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Figure 5.1 Ferroptosis initiated in confluent cultures of wild-type HME cells by cystine 
deprivation occurs in sporadic foci.  
A, 20x phase-contrast image of confluent wild-type HME and HME-EGFR cells following 
culture in media lacking cystine for 24h. Area bounded in red is a necrotic foci, and arrows 
indicate characteristic balloon-like cells that have undergone ferroptosis. B, 4x phase-
contrast (top panels) and green fluorescence (Sytox Green, bottom panels) images of 
confluent wild-type HME cells following culture in normal media (left panels) or media lacking 
cystine for 72h (right panels). 
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Figure 5.2 Ferroptosis is propagated in a wave-like manner in wild-type HME cells 
following cystine deprivation.  
Wild-type HME cells were cultured in the absence of cystine for 24h and then observed by 
video time-lapse photography (20x magnification) for 5 hours following observation of 
initiation of a focus of ferroptotic cells using Sytox Green uptake as a marker. Phase-contrast 
and green fluorescence images of cultured cells were superimposed, the wave-front is 
highlighted by a red arrowed line to demonstrate the boundary between Sytox Green-
positive (dead), and Sytox Green-negative (live) cells. White arrow indicates the direction of 
the wave of Sytox Green positivity.   
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Figure 5.3 Cell detachment appears to precede loss of membrane integrity in wild-type 
HME cells cultured in the absence of cystine.  
A, wild-type HME cells were cultured for 24h in the absence of cystine, then stained with 
Sytox green. Video time-lapse microscopy was performed and phase contrast/fluorescence 
images (20x magnification) recorded over a period of 90 minutes. The white arrow indicates 
the direction of the wave progression while the red arrow indicates a cell, proximal to 
neighbouring Sytox Green-positive cell (in green) and presented images track loss of cell-
cell (yellow arrows) and cell-substratum contact prior to uptake of Sytox Green at 20, 60 and 
90min.  
.  
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5.3 Release of soluble H2O2 and involvement of NOX enzymes in ferroptosis.  
In Chapter 3 I demonstrated that HME-EGFR cells cultured in the absence of 
cystine have higher levels of ROS than do wild-type HME cells, and that ferroptosis 
of the former cells is associated with accumulation of lipid peroxides.  In Chapter 4 I 
demonstrated that lipid peroxide generation in HME-EGFR cells results from MAPK 
pathway-driven suppression of GPX4 expression and partly explains the rapid 
induction of ferroptosis in these cells. NADPH oxidase (NOX) enzymes may also 
promote ferroptosis because of their role in regulating ROS levels in cells (Dixon et 
al., 2012; Linkermann et al., 2014) through the production of hydrogen peroxide  
(H2O2) (Kamata, 2009). In this regard, NOX4 is of particular interest because of its 
role in direct generation of hydrogen peroxide (Takac et al., 2011) and because 
expression of this enzyme is known to be positively regulated by the MAPK pathway 
(Kodama et al., 2013; Ogrunc et al., 2014). Moreover, previous reports have 
indicated EGFR signalling promotes the accumulation of hydrogen peroxide (Bae et 
al., 1997).   
To determine whether hydrogen peroxide and NOX1/4 have a role to play in 
the mechanism regulating ferroptosis of HME-EGFR cells, I added to cell culture 
media soluble catalase, an enzyme that breaks down H2O2 (Aebi, 1984) and 
GKT136901, an inhibitor of NADPH-oxidases 4 (NOX4) (Laleu et al., 2010). Both 
treatments protected HME-EGFR cells from ferroptosis following cystine deprivation 
(Figure 5.4 A), with the presence of GKT136901 additionally attenuating the 
formation of lipid ROS (Figure 5.4 B). These observations indicate that both 
generation and release of H2O2 contribute to ferroptosis following deprivation of 
cystine in HME-EGFR cells.  
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Figure 5.4 Involvement of hydrogen peroxide in ferroptosis in HME-EGFR cells.  
A, viability assay for HME-EGFR cells cultured in complete media or media lacking cystine in 
the presence or absence of catalase (1000kU/ml) or NOX4 inhibitor, GKT136901 (20μM) for 
24h. B, analyses of lipid ROS by FACS analysis in HME-EGFR cells cultured in complete 
media or media lacking cystine in the presence or absence of GKT136901 (20μM) using the 
C11 probe (2μM) detected using the BL1 channel. Each histogram shows the spread of a 
population of minimum 5000 events of cells in complete medium (black graphs) or in 
medium lacking cystine (grey outline) for 12h. 
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5.4 Cell-cell contact protects cells from ferroptosis. 
5.4.1 The formation of well-defined adherence junctions protects cells from 
ferroptosis and is suppressed by activation of MAPK signalling. 
Observations that wild-type HME cells are less sensitive to deprivation of 
cystine when confluent (Figure 3.2), that cell-cell contact is lost during ferroptosis 
propagation and a report that E-cadherin:β-catenin complexes that form adherens 
junctions (AJ) between cells are degraded in ischemic epithelia (Bush et al., 2000) all 
suggested an important role for cell-cell contact in regulating induction of ferroptosis. 
I next explored this possibility by examining AJs between cells in cultures of wild-
type HME and HME-EGFR cells. Figure 5.5 shows confocal microscope images of 
wild-type HME and HME-EGFR cells stained with -catenin to observe AJs. 
Examination of wild-type HME cells showed characteristic features of epithelial cells 
with distinct borders and linear AJs. In contrast, HME-EGFR cells stained for -
catenin exhibited inconsistent cell-cell borders, broken AJ and obvious spaces 
between cells. The role of EGFR-MAPK signalling in AJ disruption was tested next 
using inhibitors of EGFR (gefitinib) and MEK (selumetinib). Treatment of HME-EGFR 
cultures with these compounds (for 30 h) restored AJ connections to generate a 
staining pattern similar to that observed in cultures of wild-type HME cells. In 
contrast, inhibition of PI3K signalling in HME-EGFR cultures by treatment with 
wortmannin was without obvious effect on AJ straining. Together these data suggest 
a role for increased MAPK signalling in disruption of AJs in cultures of HME-EGFR 
cells. Considering that MAPK signals are responsible for sensitivity to ferroptosis 
(Figures 4.2-4.5), it seems probable that the protective effect of cell-cell contact in 
wild-type HME cells may be the result of reduced MAPK activation resulting in 
increased AJ formation. 
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Figure 5.5 Wild-type and EGFR-mutant HME cells display differential distribution of 
intercellular AJ.  
Confocal laser scanning microscope images of β-catenin immunofluorescent staining in wild-
type HME and HME-EGFR cells. Wild-type cells were only treated with DMSO control (left 
panel) and HME-EGFR cells (right panels) were treated with either DMSO, 1μM Gefitinib, 
1μM Wortmannin or 5μM Selumetinib for a total of 30h. Yellow arrows point to consistent 
linear β-catenin staining at adherens junctions (A, C and E) whereas white arrows are used 
to indicate discontinuous adherens junctions between cells (B and D). Experiment was 
performed by Mr Thomas Crighton.  
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5.4.2 Cell contact facilitates the formation of Gap junctional communication 
channels that have a protective effect in wild-type cells. 
Following the observation that establishment of AJ was associated with a 
protective effect in cells from ferroptosis I next examined the role of Gap junctions 
(GJ). GJ are intercellular channels formed between cells that allow exchange of 
small molecules such as metabolites and enzyme cofactors (Nielsen et al., 2012). 
GJs can be found colocalised with AJs on cell borders, due to the instructive role that 
AJs have in the formation of GJs (Shaw et al., 2007). Moreover, both type of 
junctions have been found disrupted in ischemic models suggesting a potential role 
in regulation of subsequent cell death. To test whether GJs are important for the 
propagation of ferroptosis I initially employed carbenoxolone (CBX), an inhibitor of 
GJ intercellular communication (GJIC) (Davidson and Baumgarten, 1988). Notably, 
treatment of wild-type HME cells with CBX increased cell death in cystine-deprived 
cultures (Figure 5.6).  
However, CBX is widely considered as a pharmacological agent with limited 
specificity (Connors, 2012) .To determine if the previously observed effect of CBX to 
accelerate ferroptosis in wild-type HME cells was dependent on GJIC I next 
examined GJIC in cultures of wild-type HME, while also examining GJIC in HME-
EGFR cells. For this purpose, we used an assay that measures the transfer of 
Lucifer yellow dye from cells scrape loaded following monolayer wounding (Figure 
5.7). This assay showed that CBX blocked GJIC in cultures of both wild-type HME 
and HME-EGFR cells. Quantitative comparison of Lucifer yellow dye transfer in 
cultures of wild-type HME and HME-EGFR cells showed reduced GJIC in HME-
EGFR cells. I next investigated the role of MAPK signalling in impaired GJIC in HME-
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EGFR cells. As with AJ formation, treatment of HME-EGFR cells with gefitinib (to 
inhibit EGFR) or selumetinib (to inhibit MEK signalling) for 30h restored GJIC to 
levels comparable to those observed in wild-type cells (Figure 5.7). These 
experiments therefore suggest that the MAPK pathway resulting from increased 
EGFR signalling plays a role in inhibiting GJIC formation, and that GJ are important 
in protecting wild-type HME cells from induction of ferroptosis. A potential 
mechanism could be hypothesised by the ability of GJIC to dilute the NOX-generated 
hydrogen peroxide in order to prevent its accumulation within a single cell which 
could be responsible for induction of ferroptosis.  
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Figure 5.6 Inhibition of GJIC using carbenoxolone sensitises wild-type HME cells to 
ferroptosis.  
A, 4x phase contrast (top panels) and green fluorescence (Sytox Green, bottom panels) of 
confluent wild-type HME cells taken 24h after change of media to either complete synthetic 
HME media or media deficient in cysteine with or without CBX (100μM). B, Graph shows 
quantification of total necrotic area observed in cells cultured for 24h in complete media, 
cystine-deficient media or cystine-deficient media with CBX (n=3). Results are typical of 
three independent experiments. Experiment was performed by Mr Thomas Crighton. 
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Figure 5.7 HME-EGFR cells demonstrate lower levels of GJIC that can be restored 
following MAPK inhibition.  
A, 20x green fluorescence micrographs of lucifer yellow transfer in wild-type HME and HME-
EGFR cells treated with DMSO control,  Gefitinib (1μm) or  Selumetinib (5μM) for a total of 
30h in the presence or absence of CBX (100μM). B, Bar graph representing quantification of 
GJIC. Grey bars indicate DMSO-treated or drug-treated cells and black bars indicate CBX 
treated cells. For each condition 18 different fields in three biological replicates were 
analysed with the values shown representing the mean and SD and expressed relative to 
GJIC in wild-type HME cells assigned an arbitrary value of 1. Experiment was performed by 
Mr Thomas Crighton. 
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5.5 Ferroptotic cell spread occurs through extracellular products of lipid 
peroxidation. 
My previous results suggest that ferroptosis within cultures of wild-type HME 
cells occurs in a wave-like manner, spreading from dead Sytox Green-positive cells 
to their neighbouring Sytox Green-negative cells in a way reminiscent of the 
synchronous pattern of necrotic spread previously reported in ischemic renal tubules 
undergoing ferroptosis (Linkermann et al., 2014). My results also show that GJIC 
protects HME cells against ferroptosis, but once this process is initiated it appears 
that proximity to Sytox Green-positive ferroptotic cells affects neighbouring cells 
firstly to disrupt their cell-cell and cell-matrix contacts and secondly to induce 
membrane permeabilization and cell death. This poses the question of whether a 
paracrine factor is responsible for the propagation of ferroptosis.  
I first investigated whether the spread of ferroptosis was associated with 
generation of reactive oxygen species. Treatment with antioxidants Fer1, α-
tocopherol (vitamin E) or Trolox [a water-soluble form of vitamin E (Davies et al., 
1988) inhibited cell death propagation as measured by quantification of rate of 
increase of area of Sytox-Green-positivity determined by fluorescence time-lapse 
microscopy (Figure 5.8). Given the effectiveness of catalase in inhibiting ferroptosis 
in HME-EGFR cells following cystine deprivation, I next examined whether soluble 
H2O2 could be responsible for the propagation of ferroptosis in cultures of wild-type 
HME cells deprived of cystine.  However, propagation of cell death was unaffected 
by the presence of soluble catalase (Figure 5.9) suggesting that local extracellular 
release of H2O2 was not responsible for the cell-cell spread of cell death. In contrast, 
addition of the NOX4 inhibitor GKT136901, involved in direct intracellular synthesis 
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of H2O2 effectively blocked ferroptosis propagation. Addition of BSA in similar 
quantity to the enzyme catalase was used as a positive control to exclude any 
possible effects of protein macropinocytosis and did not generate any effect on cell 
death transmission (Figure 5.9). Thus, H2O2, plays an important role in the 
propagation of ferroptosis but is unlikely to be the paracrine factor involved in cell-
cell spread. Instead, a possible scenario is that hydrogen peroxide is responsible for 
the appearance of lipid peroxides through the Fenton reaction that is mediated by 
iron (Winterbourn, 1995). 
To test whether soluble lipid peroxides were involved in ferroptotic spread I 
employed addition of recombinant GPX4, a GPX enzyme that can specifically 
neutralise lipid peroxides. Addition of soluble GPX4 to cultures of wild-type HME 
cells following initiation of ferroptosis significantly inhibited subsequent spread of 
ferroptosis (Figure 5.10). Next, I tested whether end-products of lipid peroxidation, 
such as 4HNE, were involved in ferroptotic spread. To detoxify 4HNE I employed a 
GST, recombinant GST4-4, which is known to detoxify 4HNE (Awasthi et al., 2004). 
Treatment with GST4-4 similarly inhibited spread of ferroptosis. 4HNE is known to 
react primarily with reactive cysteines within proteins (LoPachin et al., 2009). To 
further investigate the role of such lipid peroxidation-induced protein modifications in 
cell-cell spread of ferroptosis we utilised a linoleamide alkyne (LAA) assay which 
detects lipid peroxidation-induced protein modifications (Gong et al., 2016). Addition 
of Cumene hydroperoxide (CuOOH) to wild-type HNE cells was used as a positive 
control for such protein modifications due to its ability to generate lipid peroxides 
(Vanderkraaij et al., 1990). This experiment showed that strong DAPI-positive 
adherent cells proximal to morphologically distinct weak DAPI-positive cells that had 
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undergone ferroptosis exhibited strong LAA signals following deprivation of cystine 
(Figure 5.11) that diminished with distance. Thus, lipid peroxide-associated protein 
adducts, likely derived primarily from 4HNE, appear to be a likely promoter of cell-
cell propagation of ferroptosis.  
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Figure 5.8 Propagation of ferroptosis can be inhibited by antioxidants and Fer1.  
A, Dual phase-contrast/fluorescence images of Sytox Green stained cells captured by video 
time-lapse for 5 hours following culture in media lacking cystine for 24h hours in the 
presence of BSA, Fer-1 or antioxidants Trolox and α-tocopherol. Area of Sytox Green 
positivity is bounded in red. B, Quantification of the rate of increase of Sytox Green positivity 
in the presence of BSA (control), Trolox (1μM), Fer-1 (2μM) or α-tocopherol (30μM). For 
each condition four 10X fields were analysed and the values shown represent the mean and 
SEM relative to BSA supplemented media assigned an arbitrary value of 1. Statistical 
analysis was performed using ANOVA with a Bonferroni post hoc test. Mr Thomas Crighton 
has assisted in this experiment. 
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Figure 5.9 Inhibition of hydrogen peroxide generation, but not extracellular 
release, restricts propagation of ferroptosis. 
A, Dual phase contrast/fluorescence images of video time-lapse for 10 hours following 
culture in media lacking cystine for 24h hours in the presence of BSA, antioxidant Trolox, 
catalase or the NOX4 inhibitor GKT136901. Area of Sytox Green positivity is bounded in red. 
B, Quantification of the rate of progression of ferroptosis (increase in Sytox Green positivity) 
in the presence of Trolox (5μM) or in the presence of BSA (0.3mg/ml), catalase 
(1000kU/ml) or NOX4 inhibitor GKT136901 (20μM). For each condition three 10X fields 
were analysed. Values shown represent the mean and SEM and rate of ferroptosis in BSA 
supplemented media assigned an arbitrary value of 1. Statistical analysis was performed 
using an ANOVA with a Bonferroni post hoc test. Mr Thomas Crighton has assisted in this 
experiment. 
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Figure 5.10 Detoxification of lipid peroxides or 4HNE inhibits ferroptotic spread.  
A, dual phase contrast/fluorescence images of video time-lapse for 10 hours following 
culture in media lacking cystine for 24h hours in the presence of BSA, GSH alone or in the 
presence of GPX4 or hGSTA4-4. Area of Sytox Green positivity is bounded in red. B, 
quantification of the rate of progression of ferroptosis in the presence of BSA (10μg/ml), 
GSH (20μM) alone or in the presence of GSTA4-4 (10μg/ml enzyme /20μM GSH) or GPX4 
(10μg/ml enzyme /20μM GSH). For each condition three 10X fields were analysed with and 
values shown represent the mean and SEM with the rate of ferroptosis in BSA 
supplemented media assigned the arbitrary value of 1. Statistical analysis was performed 
using an ANOVA with a Bonferroni post hoc test. Mr Thomas Crighton has assisted in this 
experiment. 
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Figure 5.11  Lipid peroxidation-associated protein modification is detected adjacent to 
ferroptotic cells.  
Confocal laser scanning microscope images of cells stained with LAA-azide and DAPI. Cells 
were treated with complete media as a negative control (left), or in complete media with 
addition of CuOOH (100μM, middle) as a positive control to induce lipid peroxidation or with 
media lacking cystine for 24h (right). White arrows point to necrotic cells that have 
undergone ferroptosis and yellow arrows indicate cells that are still adherent but with 
significant levels of lipid peroxidation. Red line indicates the borders of the wave front. 
Experiment was performed by Mr Thomas Crighton. 
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5.6 Conclusions 
This chapter describes the cell-cell transmission and expansion of area of cell 
death by ferroptosis within epithelial cell monolayers of HME cells. Early 
observations of cell morphology following oxidative stress elicited by deprivation of 
cystine had previously revealed a distinctive necrotic phenotype, with the 
appearance of ruptured cells exhibiting a balloon-like appearance. In wild-type HME 
cells cell death following cystine deprivation occurred heterogeneously within 
discrete foci within the monolayer and was significantly slower than in HME-EGFR 
cells, where cell death was rapid and synchronous. Cells that had undergone 
ferroptosis could be distinguished from cells that had not by virtue of becoming 
permeable to membrane-impermeant nuclear die Sytox Green which allowed 
visualization of cell-cell transmission of ferroptosis and allowed me to quantify the 
rate of spread of cell death with time. Sytox Green-positive foci were observed to 
grow in size over time in a manner reminiscent of a wave, with Sytox Green positive 
cells inducing loss of cell-cell and cell-substratum contacts prior to attaining Sytox-
Green positivity.  
Two previous reports have highlighted the role of the NOX enzymes, that 
generate superoxide radicals and hydrogen peroxide, in the induction of ferroptosis 
(Dixon et al., 2012; Linkermann et al., 2014). In the cell system studied here, NOX4 
inhibition using GKT136901 and extracellular addition of catalase to degrade 
extracellular hydrogen peroxide equally rescued the most-sensitive HME-EGFR cells 
from ferroptosis. It would be therefore possible that hydrogen peroxide acted as a 
paracrine factor inducing ferroptosis in cells adjacent to the focus margin. 
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Since loss of cell-cell contact of Sytox Green-negative cells was observed by 
fluorescence video time-lapse microscopy to be associated with proximity to Sytox 
Green-positive cells and subsequent death, I examined two distinct types of cell-cell 
junctions in wild-type and EGFR-mutant HME cells. In wild-type HME cells typical 
linear continuous adherens junctions detected by β-catenin staining were observed 
associated with robust gap junctional communication, determined by Lucifer Yellow 
dye transfer.  In contrast, in HME-EGFR cells AJs were smaller and discontinuous, 
and gap junctional communication was weak relative to wild-type HME cells. To 
determine whether these features were dependent upon EGFR-MAPK signalling I 
again used small molecule inhibitors of these pathways. Inhibition of MAPK 
signalling effectively restored both AJ and GJ in HME-EGFR cells to levels similar to 
wild-type cells, corresponding with decreased sensitivity to ferroptosis. Thus, these 
observations indicate that differences in cell-cell contact and in cell-cell 
communication can influence sensitivity to ferroptosis. Given the role of AJ’s in 
influencing GJIC (Shaw et al., 2007), one possibility is that robust GJIC is important 
in preventing local accumulation of hydrogen peroxide and other radicals within 
individual cells, thereby slowing the rate of progression of cell death by ferroptosis.  
Addition of ferroptosis inhibitor Fer1 and antioxidants, trolox and α-tocopherol 
effectively inhibited death propagation in wild-type HME cells indicating that death 
spread is ROS-dependent. To determine the role of hydrogen peroxide in this 
process I used the NOX4 inhibitor GKT136901 to block hydrogen peroxide 
generation and addition of soluble catalase to cell culture media to break down 
extracellular hydrogen peroxide. Addition of the former effectively inhibited 
propagation of ferroptosis but catalase alone did not. Therefore, despite the critical 
  
189 
role that hydrogen peroxide generation plays in determining sensitivity to ferroptosis, 
it is unlikely to act as the paracrine factor that propagates ferroptosis within wild-type 
HME monolayers. Since lipid peroxidation is the distinctive feature of cell death by 
ferroptosis I determined whether extracellular lipid peroxides, or a major by-product 
of lipid peroxidation 4HNE, mediated ferroptosis propagation. To assess this 
possibility, I utilised addition to culture media of recombinant GPX4 or GST4-4, 
enzymes that detoxify lipid peroxides and 4HNE, respectively. Both enzymes 
effectively inhibited ferroptotic propagation, indicating that both lipid peroxidation and 
the generation of 4HNE are involved in spread of ferroptosis.  
Together these observations indicate a previously undiscovered process of 
cell death spread that can occur in epithelial monolayers in which ferroptosis has 
been initiated. This process can be partially resisted by cell-cell contact, with cells 
that form better junctions more resistant to ferroptosis. Understanding of such 
mechanisms could potentially provide insight on how disease associated with 
ferroptosis affects healthy epithelial tissues, and how such processes might be 
modulated.  
.  
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6. CHAPTER 6: GENERAL DISCUSSION 
The results presented in this thesis demonstrate that HME cells require the 
amino acid cystine to prevent cell death by ferroptosis. Deprivation of cystine 
induces the accumulation of ROS and oxidative stress leading eventually to 
ferroptosis, a non-apoptotic necrotic cell death. Cystine deprivation-induced 
ferroptosis occurs to different extents and in different ways in the HME cell line 
series tested in this thesis (wild type HME cells and with those activating mutations 
in EGFR, BRAF, KRAS and PIK3CA). HME-EGFR cells demonstrated the highest 
dependence upon cystine to maintain cell viability through mechanisms involving 
MAPK pathway-driven changes in gene expression and increased sensitivity to 
ROS.  
In wild type HME cells induction of ferroptosis once initiated was found to 
spread in a novel manner from the initiating cell to those in close proximity, leading 
to a “wave” of necrotic cell death within the epithelial monolayer (Section 5.2). 
Sensitivity of these cells to ferroptosis was also found to be associated with cell-cell 
contact and the establishment of strong adherens and gap junctions between cells. 
Finally, both ferroptosis initiation and subsequent spread and was found to be 
dependent upon hydrogen peroxide generation, likely due to its intracellular role in 
generating lipid peroxides. The results presented in this thesis further suggest that 
induction of ferroptosis may be exploitable as a therapeutic tool against MAPK-
driven cancers. Indeed, experiments to degrade cystine using a recombinant 
cyst(e)inase effectively reduced the viability of EGFR-driven cancer cells in vitro and 
inhibited tumour growth in vivo, inducing ferroptosis in both cases. 
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6.1 Nutrient amino acid requirement screen for cells bearing oncogenic 
mutations.  
The Chapter 3 of this thesis identifies cystine as an amino acid critically 
important for the survival of HME cells. This was determined using an amino acid 
dependency screen in HME cells (Figure 3.1) and is similar in principle to other 
studies using similar screens of nutrient dependency in cancer cells (Maddocks et 
al., 2013; Sheen et al., 2011). The initial aim of this work was a comparison of 
individual amino acid requirements between wild type HME cells and HME cells 
bearing activating mutations in the driver oncogenes EGFR, KRAS, BRAF and 
PIK3CA. I found that restriction of most amino acids generates small changes to the 
viability of the explored cell lines, consistent with a slowing of cell cycle progression 
in the absence of cell death (Figure 3.1). An exception is glutamine whose 
deprivation induced a strong loss of viability amongst all HME cell lines (Figure 3.1), 
consistent with previous findings (Wise and Thompson, 2010).  The other notable 
exception was cystine where it was observed that cells with an activating mutation in 
EGFR or BRAF were particularly sensitive to removal of this amino acid (Figure 3.1).  
Conditions of higher confluency were also found to exert a protective effect upon cell 
viability in wild type HME and HME-BRAF, but not HME-EGFR cells (Figure 3.2). 
Overall these results indicate that the presence of an activating oncogene can alter a 
cell’s nutrient requirements and their sensitivity to cell death by ferroptosis. 
Titration experiments showed that HME-EGFR cells minimally require around 
2μM of cystine in their growth media to ensure protection from ferroptosis (Figure 
3.3). Moreover, HME-EGFR cells have an active requirement specifically for L-
cystine because the presence of its enantiomer D-cystine did not protect HME-EGFR 
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cells from L-cystine deprivation-induced cell death (Figure 3.3). The enantiomer-
specific selectivity of these cells for L- but not D-cystine may be attributed to the 
selectivity of the Xc− system transporter which actively transfers the former but is 
inhibited by the latter (Patel et al., 2004).  
A major question arising from my observations is why is cystine so critical as 
an amino acid nutrient to prevent cell death by ferroptosis? The requirement of some 
cultured cells for cystine, despite the ability to synthesise it from methionine, was 
initially observed in the early 1960s (Eagle et al., 1961). Later studies demonstrated 
that leukemic cells were auxotrophic for cystine, and therefore sensitive to 
deprivation of this amino acid (Foley et al., 1969; Iglehart et al., 1977; Ohnuma et al., 
1971). Early attempts to take advantage of this requirement involved the 
administration of either rat cystathionine γ-lyase or cysteine desulfhydrase to lower 
the serum levels of cystine and cysteine in mice engrafted with L1210 leukemic cells 
to limit growth of the tumour (Uren and Lazarus, 1979; Uren et al., 1978). A more 
recent approach has proposed the use of recombinant human cystathionine γ-lyase 
enzyme that has been genetically engineered to degrade both cystine and cysteine 
(Cramer et al., 2017). Intermittent peritoneal injection of this recombinant cysteinase 
in mice with xenograft tumours of prostate and breast cancer origin, as well as in 
Tcl1-transgenic mice- which model human chronic lymphocytic leukaemia- was 
observed to inhibit tumour growth through induction of ROS and oxidative stress 
(Cramer et al., 2017). 
Following uptake via the Xc− system, cells need to reduce cystine to cysteine 
for further use in biosynthesis (Mandal et al., 2010a). Only a small fraction of 
intracellular cysteine is thought to be used in protein synthesis, with most of it is 
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utilised for the synthesis of the antioxidant glutathione (Lu, 2013). Glutathione is the 
major antioxidant defence of eukaryotic cells due to its capacity to neutralise ROS, 
and is found in high concentrations both intracellularly and in the extracellular milieu 
(Lu, 2013). Why then are HME-EGFR cells particularly sensitive to cystine-
deprivation induced ferroptosis? Deprivation of cystine induces the accumulation of 
total ROS as well as lipid peroxidation, indicating that the cell death observed might 
be attributed to oxidative stress (Figure 3.4). Consistent with this notion, my 
experiments show that addition of ROS scavengers idebenone and α-tocopherol to 
cultures of cystine-deprived HME-EGFR cells rescues them from induction of cell 
death (Figure 3.5). Measurement of glutathione levels in wild type HME and HME-
EGFR cells shows the latter have higher basal levels of both reduced (GSH) and 
oxidised (GSSG) glutathione (Figure 3.7). The similarity in glutathione depletion in 
both HME cell lines following deprivation of cystine is suggestive of a higher basal 
generation of ROS in HME-EGFR cells, and indeed activation of EGFR following 
ligand interaction had been previously shown to promote ROS induction (Bae et al., 
1997). It would therefore not have been surprising that exposure to a basally higher 
ROS burden even in normal media was the underlying reason for the higher basal 
levels of glutathione in HME-EGFR cells. Why then did only HME-EGFR cells 
accumulate ROS when depleted of cystine and die by ferroptosis, whilst wild type 
cells did not?  My studies point strongly to a failure of HME-EGFR cells to efficiently 
detoxify ROS, due in large part to a MAPK-driven programme, that leads to an 
increased sensitivity to ferroptosis following limitation of cystine. It seems to me a 
likely possibility that this could be a natural tumour suppressive mechanism that 
prevents cancer cells with elevated MAPK signalling from thriving under conditions of 
nutrient limitation.   
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This conclusion- that MAPK-activated cells are particularly ROS-sensitive and 
therefore susceptible to a form of death associated with damage to membranes- is 
supported by a number of my observations. Firstly, I could rule out any differences in 
intracellular cystine levels themselves as responsible for the differential increase in 
ROS and cell death. Thus, both wild type HME and HME-EGFR cells were found to 
respond to cystine deprivation with similar kinetics of activation of GCN2, a sensor 
for amino acid deficiency (Figure 3.6). Similarly, intracellular levels of cystine were 
found to diminish equivalently following cystine depletion in ferroptosis-sensitive or -
resistant HME cells, as determined by LC-MS (Figure 3.6). This equivalent loss of 
intracellular cystine was associated with an equivalent reduction in levels of reduced 
and oxidised glutathione in wild type HME and HME-EGFR cells regardless of their 
basal levels in complete media (Figure 3.7). Thus, both cell lines require cystine to 
maintain levels of glutathione, and it is unlikely that cystine is preferentially 
maintained in ferroptosis-resistant wild type HME cells, for example via increased 
levels of transulfuration, a compensatory pathway that can synthesise cysteine from 
methionine (Stipanuk, 2004). Moreover, my results surprisingly indicate that 
intracellular cystine through reduction to cysteine, not only acts as an antioxidant by 
providing a component of the major cellular antioxidant glutathione, but also as an 
alternative antioxidant that can to some degree compensate for transient reductions 
in the glutathione pool. Thus, inhibition of glutathione synthesis following BSO 
treatment induced a similar reduction in glutathione levels as cystine depletion, but 
failed to induce cell death or accumulation of ROS or lipid peroxidation unless 
cysteine was co-depleted (Figure 3.8).  
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6.2 Ferroptosis is the modality of cell death in HME cells following deprivation 
of cystine.  
 How do EGFR-mutant HME cells die once ROS is generated to high levels 
during cystine depletion? Microscopically these cells appeared ruptured and burst, 
which suggested membrane damage was the main cause of death. By a variety of 
criteria the mechanism of the cell death that occurs in HME-EGFR cells, and to a 
lesser extent the other HME cell lines used in this thesis is indistinguishable from 
ferroptosis a form of cell death associated with lipid damage by ROS.  
Previously it had been shown that ferroptosis was associated with the 
accumulation of lipid peroxides within cell membranes, and such ROS could be 
inhibited by chelation of iron using DFO (Yang and Stockwell, 2008). Ferroptosis has 
also been found to be inhibited by a lipophilic antioxidant, Fer1, a small lipophilic 
antioxidant that appears to specifically inhibit ferroptosis (Dixon 2012). Similarly, my 
data shows that both DFO and Fer1 also inhibit cystine-deprivation induced cell 
death in HME-EGFR cells (Figures 3.9 and 3.10).  
The term “Ferroptosis” was first used to describe a non-apoptotic form of cell 
death resembling necrosis in a study where RAS-lethal small molecules were 
screened against cell lines with an activating RAS mutation (Yagoda et al., 2007). 
One such  ferroptosis-inducing small molecule, erastin, was initially thought to target 
mitochondrial VDAC2/3 proteins (Yagoda et al., 2007), but was eventually shown to 
inhibit the XC− system and thereby prevent uptake of cystine (Dixon 2012). In the 
HME cell system treatment with erastin generated responses that were similar to 
cystine deprivation. Thus, ferroptosis was observed to occur in cultures of HME-
EGFR treated with this compound and not in wild type HME cells (Figure 3.11).  
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A recent report has similarly demonstrated a requirement for cystine, but 
described necroptosis as the modality of cell death in cultures of renal cell carcinoma 
cells in response to cystine deprivation. However, in that setting the effect was 
dependent on loss of von Hippel-Lindau gene expression/function which enhanced 
TNFα signalling and induced RIPK1-mediated formation of the necrosome (Tang et 
al., 2016).  
In the HME cell system I used cystine was found to be more important in 
preventing ferroptosis than simply providing substrates for glutathione synthesis.  
Reduction in glutathione levels following treatment with BSO was found to occur to 
the same extent to that elicited by cystine depletion, but failed to induce ferroptosis. 
Another report has found different results and demonstrated that BSO treatment, and 
subsequent inhibition of glutathione synthesis, can in some cells be sufficient to 
induce ferroptosis (Yang et al., 2014).  However, my work confirms a previous study 
showing that cysteine can also function as an alternative antioxidant during 
glutathione deficiency (Mandal et al., 2010a). Such a role for cysteine requires the 
presence of both thioredoxin, which reduces intracellular cystine to cysteine, and 
upregulated expression and function of the Xc− cystine transporter to facilitate 
increased cystine uptake. In my experiments individual treatments of HME-EGFR 
cells with BSO, to reduce total levels of GSH (Figure 3.8), or with auranofin, an 
inhibitor of thioredoxin reductase to limit the recycling of thioredoxin (Arner and 
Holmgren, 2000) induced neither cell death nor accumulation of lipid peroxides. 
However, the combination of both treatments in HME-EGFR induced both lipid 
peroxidation and ferroptosis (Figure 3.12). Moreover, prior glutathione depletion in 
HME-EGFR cells by BSO treatment sensitised these cells to cystine limitation 
  
197 
elicited by inhibition of Xc− transporter using erastin or S4PG to more rapidly induce 
ferroptosis (Figure 3.13). Together, these results highlight the importance of 
cystine/cysteine as an alternative antioxidant to glutathione in HME-EGFR cells.   
Insight from a previous study has suggested a role for transferrin and 
glutamine in the induction of ferroptosis within nutrient-starved mouse embryonic 
stem cells (Gao et al., 2015). This study demonstrated that the process of 
glutaminolysis, a process that generates glutamate from glutamine to be used in 
downstream metabolic pathways, is key for ferroptosis to occur in these cells, and 
that its inhibition was sufficient to restrict ferroptosis in an ex vivo model of ischemic 
heart injury (Gao et al., 2015). However, measurements of Gln and Glu steady state 
levels before and after cystine deprivation did not demonstrate any discernible 
alteration suggesting that glutaminolysis was not required for ferroptosis in the 
context of HME cells.  
 
6.3 EGFR mediated activation of MAPK pathway is responsible for conferring 
sensitivity to cystine-deprivation induced ferroptosis through downregulation 
of GPX4 expression 
Chapter 4 of this thesis is concerned with the elucidation of the mechanistic 
underpinnings of EGFR signalling that confer sensitivity of HME-EGFR cells to 
ferroptosis.  I found that sustained inhibition of EGFR or MAPK was sufficient to 
block generation of ROS and thereby block ferroptosis. One underlying mechanism 
for this phenomenon is the role of MAPK signalling in downregulating GPX4 
expression, an enzyme which specifically detoxifies lipid peroxides (Brigelius-Flohe 
and Maiorino, 2013; Yang et al., 2014).  
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The potential therapeutic benefit that cystine restriction might confer in a 
cancer treatment setting was examined using the NSCLC cell line H1650. In a 
xenograft mouse model systemic depletion of cystine, using an enzyme that 
specifically degrades cystine, reduced tumour cell growth (Section.4.4), suggesting 
that induction of ferroptosis through enzymatic depletion of cystine could be 
exploited therapeutically to target tumours with elevated MAPK signalling. 
The mutation present within the EGFR gene engineered by gene editing in 
HME-EGFR cells was a deletion of exon 19 which leads to the generation of a 
protein which is ligand independent for activation of the EGFR signalling pathway 
(Greulich et al., 2005; Raymond et al., 2000). HME-EGFR cells were found to exhibit 
high levels of pAKT and ppERK (Figure 4.2), and treatment of these cells with 
gefitinib (EGFR inhibitor) or selumetinib (a MEK inhibitor) lowered ppERK levels, 
demonstrating the role of active EGFR in stimulating MAPK pathway activation. 
Interestingly, pAKT levels could only be lowered by treating HME-EGFR cells with 
wortmannin not gefitinib, indicating that PI3K activation of AKT was independent of 
EGFR in these cells (Figure 4.2). Importantly, activation of the MAPK pathway was 
responsible for the over-accumulation of ROS and lipid peroxidation I had previously 
observed in HME-EGFR cells following cysteine deprivation (Figures 4.4-4.8). Thus, 
MAPK pathway activation by active EGFR can be correlated with cell sensitivity to 
ferroptosis during conditions of cystine deprivation, and observation that agrees with 
previous work (Yagoda et al., 2007). 
My observation that the rate of glutathione oxidation in HME-EGFR cells was 
enhanced following inhibition of EGFR signalling (Figure 4.9) indicated possible 
alterations in the activity of antioxidant enzymes, or generators of ROS, in HME-
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EGFR cells that could account for ROS over-accumulation during cystine depletion. 
This difference could in part be attributed to reduced expression of the lipid ROS 
detoxification enzyme GPX4 in HME-ERGR cells, which, following inhibition of 
MAPK was found to be restored to levels found in wild type HME cells (Figure 4.10). 
Indeed, knock-down of GPX4 utilising an siRNA approach sensitised both wild-type 
HME and gefitinib-treated HME-EGFR cells to ferroptosis following cystine 
deprivation (Figure 4.11-4.13), whereas ectopic GPX4 overexpression in HME EGFR 
cells exerted a protective effect towards ferroptosis (Figure 4.14). Taken together, 
these results demonstrate a clear role for GPX4 in regulating ferroptosis in HME 
cells. This finding agrees with previous research highlighting the importance of GPX4 
in ferroptosis (Friedmann Angeli et al., 2014; Yang et al., 2014). In particular, 
inhibition of GPX4 can induce ferroptosis independently of cystine sufficiency (Yang 
et al., 2014). Moreover, in some cells it is known that MAPK activation affects GPX4 
expression. Thus, treatment of melanoma cells expressing mutant BRAF (V600E) 
with the BRAF inhibitor vemurafenib, which inhibits MAPK activation, had been found 
previously to increase GPX4 mRNA abundance (Parmenter et al., 2014). Thus, the 
findings of this thesis, combined with those of others, support a conclusion that 
MAPK pathway activation in HME-EGFR cells suppresses expression of GPX4 and 
thereby increases the accumulation of lipid ROS following cystine deprivation, 
leading ultimately to the loss of membrane integrity characteristic of cell death by 
ferroptosis.  
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6.4 Enzymatic induction of ferroptosis in lung cancer cell line models as a 
therapeutic approach. 
 The pro-ferroptotic effect of cystine deprivation on HME-EGFR cells was 
replicated in other NSCLC tumour cell lines. Of nine lines tested, three (Calu-6, 
H1650, H3255) were found to demonstrate marked sensitivity to ferroptosis when 
deprived of cystine. Two of these cell lines had activating mutations on EGFR 
(H1650, H3255) and one was mutant KRAS-driven (Calu-6). In contrast to my 
findings in HME cells, the levels of GPX4 expression within Calu-6, H1650, H3255 
cells did not appear to predict sensitivity in these cells, indicating that despite the 
demonstrated role of this enzyme in protecting HME cells, it cannot generally be 
used a marker of sensitivity to ferroptosis (Figure 4.15). Nevertheless, inhibition of 
the MAPK pathway also protected against cystine-induced ferroptosis in NSCLC 
lines, further highlighting the general role of this pathway in determining sensitivity to 
ferroptosis (Figure 4.15) and implying the existence of alternative mediators of 
sensitivity downstream of MAPK.  
Limitation of an individual amino acid or protein in general is possible through 
implementation of a isocaloric diet that provides all the required nutrients except 
those of interest (Horvath et al., 1996; Kalhan and Marczewski, 2012; Wu et al., 
1999). While such an approach is feasible in mice, its application to human subjects 
would likely be problematic. An alternative approach to generate cystine depletion, or 
depletion of other amino acids in man is the use of genetically-modified enzymes 
that specifically degrade the amino acid nutrient of interest systemically. Such 
approaches have been used for the restriction of several amino acids such as 
arginine, glutamine and asparagine (Fernandes et al., 2017). Tumour-specific 
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targeting of such enzymes if it could be achieved, could conceivably also allow the 
effects of cystine depletion to be restricted to the tumour microenvironment, 
preventing potentially deleterious side-effects of systemic cystine depletion on 
normal tissues.  
With respect to cystine, an enzyme that specifically degrades cystine and 
cysteine (AECase) was described and demonstrated to lower the systematic levels 
of cystine and cysteine in animals following intraperitoneal administration during the 
work presented in this thesis (Cramer et al., 2017). To test this approach, I first 
performed proof-of-principle experiments and showed that HME-EGFR cultures 
grown in complete media underwent ferroptosis following addition of AECase (Figure 
4.20). In a similar manner the NSCLC cell line H1650 was found to be equally as 
sensitive to AECase treatment as cystine depletion (Figure 4.21). Importantly, the 
effects of AECase on HME-EGFR and H1650 cells were also reversible by Fer1 
supplementation (Figure 4.21 and 4.22), indicating that the AECase-mediated cell 
death in these cultures was via ferroptosis. A model where immunocompromised 
mice were engrafted with H1650 cells was then used to test whether cystine 
restriction had therapeutic utility. Intermittent treatment of these mice in a xenograft 
therapeutic regime with AECase markedly decreased subsequent tumour growth 
and increased overall survival of tumour-bearing mice (Figure 4.23). In line with my 
observations of HME-EGFR and H1650 cells made in vitro, ferroptosis appeared to 
be occurring within the tumour xenografts as COX2 - which has been described as a 
marker of ferroptosis in vivo (Yang et al., 2014) was found to be upregulated 
following AECase treatment (Figure 4.24). Taken together, these observations 
indicate that implementation of cystine restriction in patients with NSCLC tumours 
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with activating EGFR mutations could potentially be therapeutically beneficial 
through induction of ferroptosis. 
6.5 Wave-like propagation of ferroptotic cell death in wild type HME cells.  
Chapter 5 of this thesis focused on the study of ferroptosis propagation in 
cultures of wild type HME cells. Ferroptosis in these cells initiated in foci and 
contained cells with a characteristic balloon-like morphology that stained positive 
with Sytox Green, a marker of loss of membrane integrity. By video time-lapse 
microscopy ferroptosis could be observed to spread from Sytox Green-positive to 
nearby Sytox Green-negative cells in an apparent wave-like manner.  
Μy results show that cell-cell contact has a significant effect in conferring 
resistance to ferroptosis in wild type HME cells. In wild type HME cells I observed 
more mature AJ and a higher level of GJIC than in HME-EGFR cells. Both of these 
weakened junctional effects in HME-EGFR cells could be reversed by MAPK 
inhibition (Section 5.3). I also found that the generation of extracellular hydrogen 
peroxide, possibly through NOX4 activity, was important for mediating synchronous 
cell death in cultures of cystine-deprived HME-EGFR cells because addition of 
catalase or the NOX4 inhibitor GKT136901 (Laleu et al., 2010) prevented ferroptosis. 
However, extracellular hydrogen peroxide was not responsible for the wave of 
ferroptosis in cultures of cystine-deprived wild type HME cells as addition of catalase 
did not prevent propagation of ferroptosis (Section 5.5).  
Despite being more resistant to ferroptosis than HME-EGFR cells, wild type 
HME cells demonstrated low levels of ferroptotic cell death when deprived of cystine 
(Figure 5.1). Dead cells in such cultures had a characteristic balloon-like morphology 
with loss of plasma membrane integrity, and these cells appeared to initiate 
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ferroptosis randomly and then expand in size over time (Figure 5.1). Once these foci 
formed, I found that the adjacent healthy cells very quickly lost cell and substratum 
adhesion prior to loss of membrane integrity, generating a domino-like spread of cell 
death (Figures 5.2 and 5.3). It seems possible that this wave phenomenon could be 
representative of the type of death observed when some normal epithelia experience 
extreme oxidative stress, as is the case during ischemic injury (Conrad et al., 2016).  
Inhibition of ferroptosis spread was also achieved by the use of a NOX4 
inhibitor, GKT136901. This inhibitor, along with extracellular catalase, were both 
found to be effective in protecting HME-EGFR cells from ferroptosis when added 
immediately with deprivation of cystine (Figure 5.7). This observation indicates the 
involvement of hydrogen peroxide in the process of ferroptosis. However, when 
assayed for their ability to inhibit the spread of cell death in wild-type HME cells, the 
NOX4 inhibitor GKT136901 prevented cell-cell spread of ferroptosis whereas 
catalase addition failed to (Figure 5.9). This difference may be attributed to the ability 
of catalase to neutralise extracellular hydrogen peroxide but not affect the 
intracellular formation of lipid peroxides. Hydrogen peroxide is known to have an 
important role in the Fenton reaction involving iron and the production of more 
damaging ROS species and therefore its accumulation could contribute to the 
accumulation of lipid peroxides typical of ferroptosis (Winterbourn, 1995). The ability 
of the NOX4 inhibitor to equally block initiation of ferroptosis and cell death spread 
indicates that the generation of hydrogen peroxide is also important for ferroptosis 
propagation. However, a recent report has indicated that this NOX4 inhibitor could 
potentially act as a scavenger of peroxynitrite, a radical that is formed by superoxide 
and nitric oxide (Schildknecht et al., 2014). Therefore, further studies are required to 
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determine if the observed protective effect of NOX4 inhibition is completely 
attributable to its ability to inhibit NOX4. Moreover, recent insights into the 
mechanisms of ferroptosis indicate the involvement of additional oxidising enzymes 
other than NOX4. Such an example is lipoxygenase (LOX) whose function is 
responsible for direct oxidation of phospholipids, and recent reports demonstrate that 
LOX-driven lipid oxidation can also contribute to induction of ferroptosis (Kagan et 
al., 2017; Yuan et al., 2016)  
In my experiments cell-cell contact was also found to modulate induction of 
ferroptosis because confluent wild type HME and HME-BRAF cells maintained 
higher viability when deprived of cystine than did culture at lower density (Figure 
3.2). My results suggest that this modulation may be due to the formation of strong 
AJ and GJIC between wild type HME cells as they reach confluence. Such 
connection did not occur between HME-EGFR cells regardless of the state of 
confluence unless the cells were treated with EGFR or MAPK inhibitors (Figure 5.4). 
GJIC was particularly important because inhibition of these channels in cultures of 
cystine-deprived wild type HME cells induced ferroptosis that was similar in extent 
and rapidity as was observed in similar cultures of HME-EGFR cells (Figure 5.5). 
Higher levels of GJIC could be restored in HME-EGFR cells following treatment with 
EGFR and MAPK inhibitors (Figure 5.6), suggesting that cell-cell adhesion and GJIC 
are impaired by oncogenic EGFR signalling. That AJ and GJ are important in my cell 
system is supported by evidence found in ischemic models where AJs are disrupted 
and the corresponding GJ are found mislocalised (Matsushita et al., 1999). The 
observation that ferroptosis is accelerated rather than inhibited by inhibition of GJIC 
presumably suggests that cell-cell spread of ferroptosis is not mediated by the so-
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called “bystander effect”, a phenomenon describing toxic effects on cell viability of 
neighbouring cells, mediated partly through the function of GJs(Nagasawa and Little, 
1992). However, a protective effect of GJIC had been previously identified in a 
glutamate-induced cell death that resembled ferroptosis in neuronal cells during 
ischemia (Nakase et al., 2003; Naus et al., 2001). These findings, along with my 
results, indicate the importance of GJIC not only as an additional line of defence 
against oxidative stress. Moreover, previous research highlights the regulation of 
GJIC by activation of EGFR and downstream MAPK signals in agreement with the 
changes we observed in our studies (Kanemitsu and Lau, 1993). Further research is 
need however to clarify how GJIC protects against ferroptosis in this system. This 
could be attributed for example to either an increased ability to share nutrients 
(Alexander and Goldberg, 2003), such as cystine or glutathione within the 
monolayer, thereby protecting individual cells from experiencing excessive ROS   or 
in providing a buffering capacity against over-accumulation of ROS species such as 
hydrogen peroxide (Decrock et al., 2009; Kirchhoff et al., 2001). 
I further observed that the propagation of ferroptotic cell death was inhibited 
by antioxidants, including Fer1 (Figure 5.8). Ferroptosis inhibitors Ferrostatin1 (Fer1) 
and Liproxstatin1 (Lip1) were discovered with the help of high-throughput screening 
(Dixon et al., 2012; Friedmann Angeli et al., 2014). Both compounds can act as 
radical trapping antioxidants and neutralise lipid peroxides within biological 
membranes (Skouta et al., 2014). Outside lipid membranes the ability of these 
compounds to counteract peroxyl radicals is not as potent as that of α-tocopherol. 
However, when these molecules operate within lipid membranes, their potency is 
higher due to the lipophilic nature of these compounds (Zilka et al., 2017). Lipid 
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peroxidation is thought to occur via a chain reaction, termed autoxidation, where lipid 
peroxides can interact with other lipids to generate further lipid radicals in the 
presence of molecular oxygen. Fer1 and Lip1 inhibit the autoxidation chain reaction 
as they neutralise the lipid radicals and inhibit further oxidative damage (Zilka et al., 
2017). Such a phenomenon could potentially explain the ferroptosis wave spread, as 
lipid peroxidation is a continuous reaction that can be further propagated (Yin et al., 
2011).  Administration of these antioxidant molecules in in vivo models of renal and 
hepatic IRI has demonstrated protective effects from ferroptosis, indicating a future 
clinical potential (Friedmann Angeli et al., 2014; Linkermann et al., 2014). 
The importance of GPX4 function as a critical regulator of ferroptosis indicates 
that excessive lipid peroxidation has a likely causative role in induction of ferroptosis 
(Yang et al., 2014). Increased levels of lipid peroxides in biological membranes 
induce loss of membrane bilayer stability and loss of water impermeability (Lis et al., 
2011; Wong-Ekkabut et al., 2007). Such an effect could additionally explain the 
characteristic balloon phenotype of ferroptotic cells. It was therefore important to 
investigate if lipid peroxidation and its downstream by-products played a role in 
propagating cell death and affecting the viability of nearby cells. Accumulation of lipid 
peroxides is accompanied by the formation of other reactive electrophiles such as 
malondialdehyde (MDA) and 4HNE, which can create protein and DNA adducts and 
induce cell death (Awasthi et al., 2017; Del Rio et al., 2005). Addition of either 
recombinant GPX4 or recombinant GST4-4 both effectively inhibited death 
propagation, indicating that neutralisation of either lipid peroxides or 4HNE inhibits 
cell death propagation (Figure 5.10). Further indication of lipid peroxidation 
associated damage was supported from the accumulation of LAA staining in cells 
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adjacent to the wave front where lipid peroxidation by-product adducts were formed 
(Figure 5.11). Previous research on 4HNE has indicated a role in disruption of 
formed junctions as well as junctional communication (Radu and Moldovan, 1991; 
Usatyuk et al., 2006). Such evidence indicates a possible role for 4HNE as an 
important mediator in ischemic death spread where cell junctions are disrupted prior 
to ferroptotic cell death by accumulation of lipid peroxidation. If indeed 4HNE was 
released locally from cells that had undergone ferroptosis and inhibited GJIC in 
adjacent cells, one could envisage a scenario whereby those cells with impaired 
GJIC then fail to adequately buffer ROS species with neighbouring cells, thereby 
accelerating their accumulation of ROS damage and demise by ferroptosis. 
As mentioned previously, ferroptosis is an oxidative type of cell death where 
generation and accumulation of ROS, particularly lipid peroxides, catalyse cell 
necrosis in an iron-dependent manner (Dixon et al., 2012). Lipid peroxidation has 
been previously implicated in a variety of human diseases, including neurological 
conditions, possibly due to the lipid content of neurons and high oxygen consumption 
(Gaschler and Stockwell, 2017). It is therefore possible that inhibition of ferroptosis 
might have a clinical potential and alleviate some neuronal diseases. In the context 
of acute kidney injury renal tubules appear also to die in a synchronous manner, with 
necrotic cell death spread within the kidney tubule (Linkermann et al., 2014). 
Similarly in an animal model of myocardial ischemia-reperfusion injury an analogous 
spreading wave front phenomenon of cell death has been observed that correlates 
with ischemia duration and increase in size of adjacent necrotic areas (Reimer et al., 
1977). Therefore, the work I present in this Chapter may be important in designing 
novel ways of inhibiting myocardial cell death during ischemia-reperfusion injury. 
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What then might be released from cells that have undergone ferroptosis and lost 
membrane integrity that might mediate cell-cell spread of ferroptosis? My results 
suggest that both lipid peroxides and their by-products, such a 4HNE, generated 
within cystine-deprived wild type HME cells play a significant role in propagating 
death stimuli between cells.  
6.6 Proposed model for ferroptosis progression 
The first requirement to model the progression of ferroptosis in tissues is the 
generation of increased ROS. In our system this was generated by cystine depletion. 
In wild type HME cells it appears that with time some cells may generate sufficient 
ROS during cystine deprivation to induce ferroptosis sporadically. However in other 
situations this could be due to alterations in activity of enzymes that generate ROS 
such as NOX or LOX (Dixon et al., 2012; Kagan et al., 2017; Linkermann et al., 
2014), depletion of glutathione as occurs during acetaminophen poisoning (Lorincz 
et al., 2015) or the high ROS accumulation that occurs following ischemia 
reperfusion (Conrad et al., 2016). Over-accumulation of ROS could then induce lipid 
peroxidation. Accumulation of lipid peroxidation may then be amplified through the 
autoxidation of lipids (Skouta et al., 2014; Zilka et al., 2017) until a critical threshold 
of lipid damage is reached and the permeability of the cell is compromised (Lis et al., 
2011; Wong-Ekkabut et al., 2007) leading to ferroptosis. In a tissue such a process 
may then lead to a local increase in the levels of lipid peroxides or peroxidation by-
products such as 4HNE. 4HNE may then promote propagation of ferroptosis through 
effects on junctional formation and communication (Radu and Moldovan, 1991; 
Usatyuk et al., 2006), which may accelerate ferroptosis in adjacent cells Such a 
cascade would then further propagate in a positive-feedback manner, inducing the 
wave expansion of cell death by ferroptosis I have characterised here (Figure 6.1).  
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Figure 6.1 Model of ferroptosis progression. 
Loss of antioxidant capacity induces a state of high oxidative stress. Ferroptosis initiation 
releases 4HNE and a local increase in the content of lipid peroxidation. Neighbouring cells 
are affected by 4HNE through disruption of adhesion and interruption of GJIC while the 
increase in lipid peroxidation promotes further oxidative stress. As a result, their threshold is 
surpassed, and adjacent cells die by ferroptosis affecting their own neighbours and 
promoting further cell death.  
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6.7 Future work and perspectives 
 The insights that my studies have provided as to the mechanisms controlling 
sensitivity to ferroptosis could be useful in understanding further the mechanisms 
and mediators of ferroptosis. Such knowledge could ultimately allow control over this 
process, whether that is inhibitory to prevent damage to normal tissues or stimulatory 
to kill tumour cells via systemic depletion of cystine. Moreover, overall knowledge 
over the field of ferroptosis has expanded significantly since its initial 
characterisation. Induction of this process is multifactorial and the mechanisms that 
mediate sensitivity are incompletely understood. The specific cellular and disease 
contexts in which ferroptosis operates in vivo constitute an emerging and expanding 
field. Understanding how ferroptosis is propagated from cell to cell, and whether this 
propagation also occurs in vivo, remain future avenues for further research. 
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